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The advent of powerful information technology and the increasing availability of so-
called ‘Big Data’, in a multitude of forms, has had revolutionary impact on many 
aspects of society, such as commerce and communication. Within healthcare broadly 
and mental health research specifically, however, the progress of these techniques 
is considered relatively nascent. This is paradoxical, as the complexity and multi-
factorial nature of mental health conditions, such as major depression and self-harm, 
makes them particularly tractable for more sophisticated data-driven approaches.  
 
In this thesis I will apply the transformative potential of data science applications 
related to record-linkage for mental health research. I will demonstrate that record-
linkage of cohort studies to administrative health data enables:   
 
(i) improved signal and power for discoveries and the reduction of false 
associations  
(ii) validation of research data and the identification of inaccuracies  
(iii) transformation of cross-sectional studies into longitudinal studies; and 
(iv) identification of new phenotypes for study.  
 
Chapters 1, 2 and 3 provide an introductory overview. In Chapter 1, I will survey the 
current state of psychiatric research in major depressive disorder (MDD), 
antidepressant pharmacoepidemiology, self-harm and suicidal ideation. These inter-
related aspects of mental illness are common, highly complex and place a high 
burden on society. They are thus particularly appropriate for the research methods I 
shall employ herein.  In Chapter 2 I will discuss the evolution of data sciences 
approaches within psychiatry, and specifically of record-linkage techniques and their 
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application in medical epidemiology. In Chapter 3 I will also review the demographics 
and characteristics of the datasets used in this thesis, namely Generation Scotland 
(GS:SFHS), UK Biobank (UKB), the Scottish Morbidity Records (SMR) and the 
Prescribing Information System (PIS) of NHS Scotland.  
 
Chapter 4 demonstrates the application of record-linkage to administrative health 
data for validation in psychiatric research. Using national prescribing data in PIS as 
the ‘gold standard’, I compare the accuracy of GS:SFHS cohort self-reported 
psychiatric drug use, which is often thought to be relatively under-reported for reasons 
such as self-stigma, compared to other commonly prescribed medications. Our study 
finds that under-reporting is not found for all psychiatric medications, indeed 
antidepressants show very good agreement between self-report and prescribing data 
(k=0.85,(95% Confidence Interval(CI)0.84-0.87)), similar to antihypertensives 
(k=0.90, (CI 0.89-0.91)) which are another commonly prescribed medicine. However, 
for mood stabilizers the agreement is relatively poor (k=0.42, CI 0.33-0.50). A number 
of medication-related and patient-level factors are analysed, with relevant past 
medical history being the strongest predictor of self-report sensitivity. By contrast, 
general intelligence is not found to be predictive. The chapter concludes that there is 
no simple relationship between psychiatric medication use and medication under-
reporting. In addition, that no patient-level factor produces greater accuracy of self-
report across all medications studied, although history of indicated illness – where 
this could be defined - predicted more accurate self-report.  
 
In Chapter 5 the potential of record-linkage to transform cross-sectional research 
studies into longitudinal studies, is investigated using the problem of quantifying 
antidepressant prevalence. Antidepressants are the most commonly prescribed 
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psychiatric medication, but concerns have been raised about significant increases in 
their usage. By linking PIS prescribing data with the phenotypic data in a subset of 
GS:SFHS, the study is able to determine new measures of antidepressant 
prevalence, incidence, adherence, prescribing patterns with other medications, and 
patient-level predictors of usage. An antidepressant prevalence of almost one third of 
the cohort (28%, 95% CI 26.9-29.1), defined as dispensing of at least one PIS 
antidepressant prescription in the five-year period 2012-16, is described. This is a 
36.2% increase in annual prevalence between 2010 and 2016. Incidence is 
calculated as 2.4(2.1-2.7)% per year, which is not significantly changed from previous 
estimates. The majority of antidepressant episodes (57.6%) are found to be greater 
than 9 months duration and adherence, using the Proportion of Days Covered (PDC) 
measure, is found to be generally high(69%). In time-to-antidepressant-use Cox 
regression analysis of the 5 years following individual GS:SFHS enrolment, predictors 
of new antidepressant use included: history of affective disorder; being female; 
physical comorbidities; higher neuroticism scores; and lower cognitive function 
scores.  The chapter finds that this research supports the hypothesis that increased 
long-term use among existing (and returning) users, along with wider range of 
indications of antidepressants, has significantly increased the prevalence of these 
medications.  
 
In Chapter 6 the potential of record-linkage to identify new phenotypes for study within 
psychiatric cohorts is examined using the example of self-harm. Self-harm is a 
common and debilitating behaviour but often difficult to research as there may be 
unwillingness in sufferers to disclose. Using record-linkage to hospital morbidity 
data(SMR), I identified individuals with hospital-treated self-harm in GS:SFHS and 
compared these to a replication cohort drawn from UK Biobank, with self-reported 
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hospital-treated self-harm. I further demonstrated that neuroticism, a stable 
personality trait associated with depression, is independently positively associated 
with self-harm (per Eysenck Personality Questionnaire Short-Form(EPQ-SF) unit 
Odds Ratio 1.2 95% Credible Interval 1.1-1.2, PFDR <0.001), even when adjusted for 
a range of relevant covariates. I further replicated this finding in UK Biobank (per 
EPQ-SF unit Odds Ratio 1.1, 1.1-1.2, pFDR <0.001). In a follow-up recontact study of 
GS:SFHS, STRADL, where self-reported suicidal ideation was recorded, I find that 
neuroticism, and the neuroticism-correlated coping style, emotion-oriented coping 
(EoC), were also associated with suicidal ideation in multivariable models. Therefore 
the chapter concludes that neuroticism is an independent predictor of hospital-treated 
self-harm risk, and is therefore independent of major depressive disorder in this 
respect, and is also (along with emotion-oriented coping), an independent predictor 
of suicidal ideation.  
 
Chapter 7 summarises the empirical findings presented in Chapters 4 to 6. The 
Chapter will also recapitulate the strengths and limitations of the record-linkage 
approaches used in this thesis. Finally, suggestions for future research avenues for 
record-linkage studies using psychiatric cohorts, and psychiatric data science as an 






We know that modern computer technology has changed many aspects of how we 
work, learn, communicate and trade. It also has enormous potential to improve how 
we understand our health, in particular research into the complex world of our mental 
health (how we think, feel, behave and relate to each other). We have learned a lot 
from previous studies of mental health, which often involve recruiting large groups of 
volunteers followed by collecting detailed health-related information and performing 
tests. However, these studies often have problems, such as not having enough 
information about the volunteers to make robust conclusions about the topics being 
studied; or only having information from a particular point in time rather than a broader 
view across many years; or by the fact that people may be understandably unwilling 
to talk about some personal aspects of their mental health. A new computer 
technology called ‘record-linkage’, which enables the connecting of willing research 
volunteers with information stored about them in other places, such as in hospital 
records, in an anonymous and confidential way, has great potential to help. This PhD 
thesis demonstrates how record-linkage can improve research into mental health, in 
particular addressing questions central to research in major depressive disorder 
(MDD).  
 
In the first research chapter (Chapter 4) I will investigate the accuracy of people’s 
recollection and reporting of the medications they are using.  In particular, whether 
those who are on psychiatric medications are less likely to self-report accurately, due 
to factors such as feeling stigmatised. This is done by comparing NHS prescriptions 
data (collected by pharmacies) as a trusted gold standard with the self-report of 
participants in the Generation Scotland cohort(GS:SFHS). What I will show is that 
accuracy of self-report is high across most of the medicines studied (psychiatric and 
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non-psychiatric), thus drugs for depression (antidepressants) are roughly as 
accurately self-reported as drugs for blood pressure (antihypertensives). However, I 
also find that self-report for another psychiatric drug group (mood stabilisers) is much 
less accurate and discuss potential reasons for this including that many patients may 
be confused at what ‘mood stabilisers’ means. I consider various factors that may 
lead to more accurate self-report and find that the strongest is having a history of an 
illness related to the medication in question. 
 
In Chapter 5, I explore how commonly people are using antidepressants (drugs for 
depression) which has become an important question as prescribing rates of 
antidepressants has reached unprecedented levels in the UK. I use record-linkage to 
prescribing data to try to provide reliable figures for which groups of people use 
antidepressants most frequently, how regularly they are taking them, how many new 
people are starting them, and what other medications they might be taking. I 
demonstrate that antidepressant exposure is indeed significantly higher in the 
Generation Scotland cohort than previous reports would indicate. Indeed, almost one 
third of the cohort had been dispensed at least one antidepressant prescription in the 
five years studied (2012-16). However, I also show that the number of new users 
(incidence) has not significantly increased. This suggests that antidepressant use has 
risen mainly because of longer periods of usage, better compliance with 
antidepressant treatment and previous users returning to use. I also determine a 
number of predictors of antidepressant use, including history of depressive illness, 





Finally, the last research chapter(Chapter 6) looks at a very important aspect of 
mental health and depressive illness that people are often unwilling to discuss with 
clinical and research professionals: self-harm and thoughts of suicide. I show that 
record-linkage can help identify sufferers of these conditions in an anonymous and 
confidential way, by linking Generation Scotland with the NHS hospital records 
(Scottish Morbidity Records). Having defined those who have a history of self-harm, 
I am able to demonstrate that those who tend to find the world more stressful and 
threatening (high neuroticism) are at particular risk of self-harm. I am able to repeat 
this finding using another large cohort study (UK Biobank). In the second part of the 
study I examine a smaller subgroup of Generation Scotland(STRADL) who were re-
contacted some years after their original enrolment and completed a questionnaire 
on the coping skills they use in response to stressful events. I find that those who 
tend to cope with problems through their emotions are more likely to have ideas of 
suicide. This chapter concludes that neuroticism is an important predictor of self-harm 
risk which is associated with, but independent of, major depressive disorder. This 
research can potentially help us improve access to care for these individuals who 
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Chapter 1 : Introduction  
 
A leitmotiv of this thesis is the transformative potential of record-linkage to 
administrative health data in addressing some of the most important issues in mental 
health research. In particular, I will assess the ways in which record-linkage 
(introduced and discussed in detail in the next Chapter) can provide phenotyping 
information that is often missing, unvalidated or incomplete in conventional cohort 
studies. In the chapters that follow I shall look in particular at research pertinent to 
major depressive disorder, which is the most common mood disorder in the UK and 
USA (Hillhouse and Porter, 2015). In particular, this thesis will examine two 
psychiatric topics – antidepressant use and self-harming behaviour - which are 
closely entwined with MDD research, but which have in the past generated concerns 
about methodological issues including (a)unreliable self-report, (b) potentially 
untrustworthy prevalences, and (c)non-representativeness of the research 
populations previously studied compared to real world experience.  
 
In the research chapters that follow, three specific research objectives will be 
addressed. These are to provide answers to the following questions:  
1. Are users of psychiatric medications less likely to accurately self-report their 
usage in research studies compared to users of other medications?  
2. Has exposure to antidepressant medications significantly increased in recent 
years and, if so, is this due to a change in how antidepressants are used ?  
3. Is the psychological trait of neuroticism an independent risk factor for the 




In this introductory chapter, I will introduce the reader to the main topic area of this 
thesis, Major Depressive Disorder (MDD), before providing a brief introduction to 
antidepressant and self-harm research. Due to the wide range of content to be 
discussed, including epidemiology, pathophysiology, genetics, diagnostic sub-
categorisations and treatment of depressive illness; the psychological trait of 
neuroticism; and self-harm and suicidality; the approach taken here is, of necessity, 
that of a narrative review rather than a systematic literature review. Major reviews are 
however cited and can be found in the Bibliography and References.  
 
 
1.1 Major Depressive Disorder  
 
Major depressive disorder (MDD) is a highly debilitating syndrome characterised by 
persistent low mood and anhedonia (reduced enjoyment in activities previously found 
pleasurable) as well as a number of cognitive, psychological and physiological 
symptoms. A diagnosis of MDD is based on a number of potential symptom clusters 
which differ to an extent with individual presentations (see Table 1.1), but a central 
characteristic of major depression is its persistence, pervasiveness and pathological 
extent (McIntosh et al., 2019). 
 
Major depression is a leading cause of global disability, accounting for more than 4% 
of all years lived with disability (Vos et al., 2017). Depression occupies a higher rank 
over time in the global burden of disease than many conditions which receive much 
greater levels of research funding (McIntosh et al., 2019; Woelbert et al., 2019). Major 
depression is associated with social disadvantage, physical morbidity and mortality 




1.2  Epidemiology of MDD 
Studies originating in the United States have found that the reported annual 
population prevalence of depression has increased (probably reflecting improved 
reporting and diagnosis) from 3.33% (1991-92) to 7.06%(2001-02)(Compton et al., 
2006), to 8.3% in 2011 (Kessler and Bromet, 2013; Bromet et al., 2011). The lifetime 
prevalence of depression in the United States, in a study published in 2011, was 
found to be 19.2% (Kessler and Bromet, 2013; Bromet et al., 2011). The prevalence 
of depression in females is fairly consistently found to be approximately double that 
of males (Gelder et al., 2012). Median age of onset, symptomatology, disorder 
severity and sociodemographic profiles of depression are mostly comparable across 
countries and cultures (Kendler et al., 2015), although there are variations in 
depression annual prevalence (or presentation) between countries, varying from 
2.2% in Japan to 10.4% in Brazil (Kessler and Bromet, 2013).  
 
Depression tends to first occur between later adolescence and the early 40s, with a 
median age of onset of major depressive disorder of 25 years (Bromet et al., 2011). 
While overall depression prevalence rates are thought to be broadly comparable 
between high-income and lower-income countries, only an estimated 10% of 
sufferers receive treatment for depression in lower-income countries compared to 
60% for higher-income countries (Wang et al., 2007). 
 
The disorder is associated with a number of biological, psychological and socio-
demographic risk factors. In one landmark study using the Virginia Twin Registry, 
Kendler (Kendler et al., 2002) was able to predict over 50% of the variance in the 
liability to develop major depression in the proceeding 12 months (in females). The 
strongest predictors for depression were (1) stressful life events (2) genetic factors, 
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both direct and indirect (3) previous history of major depression and (4) the 
psychological trait of neuroticism. Depression is also associated with other factors 
including childhood adversity, sexual abuse, marital discord, unemployment, physical 
illness, and is comorbid with a number of mental and physical health problems, 
especially anxiety disorder, substance abuse disorders and personality disorders 
(Gelder et al., 2012). 
 
 
1.3  Pathophysiology and Genetics of Major Depression  
 
The pathophysiological basis of the majority of cases of major depression remains 
unknown. As discussed below, the accidentally discovered antidepressant action of 
drugs promoting monoamine transmission led to the development of a ‘monoamine 
hypothesis’, relating depression to deficiencies in monoamine networks in the brain 
(Bunney and Davis, 1965). There is some evidence that stress and hypothalamus-
pituitary-adrenal (HPA) axis activation can induce reduction in monoamine levels and 
is associated with depression onset (Cowen, 2002). Stress has also been implicated 
with decreases in neuronal growth and survival, such as that mediated by brain-
derived neurotrophic factor (BDNF) (Belmaker and Agam, 2008). There is some 
evidence that synaptogenesis can be upregulated, and stress-induced neuronal 
atrophy counteracted, by glutamate NMDA-receptor antagonists, leading to an 
interest in ketamine as a potential antidepressant (Duman and Li, 2012).  
 
Another major theoretical framework for understanding depression is as a 
neuroinflammatory process (Maes et al., 1990; Bullmore, 2018). MDD has well 
established comorbidities with a variety of inflammatory diseases (Graff et al., 2009; 
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Carney et al., 1988) and chronic stress can induce cytokine dysregulation leading to 
chronic neuroinflammation (Kim et al., 2016). Intriguingly, interferons – a superfamily 
of proinflammatory cytokines used in the treatment of a variety of autoimmune 
conditions – have been found to induce depression in up to a third of those treated 
(Bullmore, 2018). This has also led to recent interest in anti-inflammatory medications 
as potential antidepressants.  
 
Early twin heritability studies of major depression estimated a genetic heritability of 
between 31 and 42% (Sullivan et al., 2000). To date, linkage analysis, candidate gene 
studies and re-sequencing studies have not produced robust, replicable findings 
regarding the underlying genetic basis for depression (McIntosh et al., 2019).  
 
Another approach is to use haplotype analysis (based on a group of genes inherited 
together from a single parent), which has recently identified a haplotype in 6q21 (a 
region previously associated with bipolar disorder) in Generation Scotland 
(GS:SFHS, n=18,773) which also replicates (P<0.05) in UK Biobank (UKB, n=25,035) 
(Howard et al., 2017). This study is significant within the context of this research 
thesis, as it employed record-linkage techniques (including work by the present 
author) to link GS:SFHS to administrative health data in the Scottish Morbidity Record 
to screen the case and control group, identifying false positives (cases of MDD that 
had other significant diagnoses such as bipolar disorder and schizophrenia) and false 
negatives (members of the control group with diagnoses of MDD). This is an example 
of record-linkage being used to improve signal and power for discoveries and reduce 
false associations, as will be discussed further in the following chapters.  
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The implication of linkage, candidate gene and genome-wide association studies 
(GWAS) performed to date are that the underlying liability depression is polygenic 
and no loci of major effect exist (Ripke et al., 2013). A recent large-scale meta-
analysis performed on 246,363 cases and 561,190 controls from the three largest 
genome-wide association studies of depression to date and replicated into an 
independent sample of 414,055 cases and 892,299 controls (Howard et al., 2019), 
identified 102 independent variants (87 replicated) and a heritability of major 
depression of 8.9% (95% Confidence Interval 8.3-9.5%). Larger sample sizes with 
denser imputation, plus greater use of next-generation/whole-genome sequencing 
technology, are awaited to uncover more of the genetic component of major 
depression indicated by the twin heritability studies.   
 
 
1.4  Historical Overview of Depression Diagnosis in Research and Clinical 
Practice 
 
Depressed mood is a common psychological symptom and part of the normal range 
of normal human emotional experience. While depressed mood is often transient and 
non-pathological, this symptom can/may be sustained, severely and adversely 
impacting many areas of functioning. The Greek physician Hippocrates (460-377 BC) 
recognised a condition of unremitting and persistent “fear or sadness” and described 
associated symptoms including aversion to food, insomnia, psychomotor 
restlessness, irritability and hopelessness or despondency. This was termed 
melancholia. Additional insight was provided by Galen (131-201 AD) who made the 
important point that melancholia, ascribed to an excess of ‘black bile’, produced 
symptoms that were prolonged and disproportionate to any external circumstances 
that may have affected the sufferer.  
 35 
 
In The Anatomy of Melancholy (1621) (Burton, 1621), the Oxford University scholar 
Robert Burton described melancholia as a “sorrow…without any evident cause” and 
which consisted of mood, cognitive and physical components. During the 19th century, 
with the development of psychiatry as a distinct medical discipline, Emil Kraepelin 
(1856-1926) identified melancholia as consisting of “morbid emotions [that] are 
distinguished from healthy emotions chiefly through the lack of a sufficient cause, as 
well as by their intensity and persistence” (Kraepelin, 1915). Having differentiated 
schizophrenia (dementia praecox) from manic-depressive insanity, Kraepelin initially 
defined melancholia as a separate disorder but was later persuaded that melancholia 
and manic-depressive insanity has the “same morbid process” (Kraepelin, 1921).  
 
While Kraepelin’s insights mostly evolved from work within asylums, the work of 
(principally) outpatient neurologists and psychiatrists, especially Jean-Martin Charcot 
(1825-1893) and Sigmund Freud (1856-1939) led to the development of an 
alternative understanding of depression. Freud’s background was in neurology, 
where a differentiation was made between neuroses, afflictions of the nerves without 
an obvious neuropathology, and neuritis where inflammation or other pathological 
processes were observable (e.g. via microscopy). The neuroses included a variety of 
conditions seen by outpatient clinicians (tending to an, often, wealthy clientele), 
including hysteria (conversion disorder, somatization, fugue and amnesia), phobias 
and anxieties, obsessions and depressed mood. In Freudian psychiatry, neuroses 
began to be understood as being more psychological than neurological in basis, 
reflecting defence mechanisms against anxiety, the manifestation of unconscious 
processes and desires, and the products of psychosocial adversities such as loss of 
a love object. 
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Thus by the turn of the 20th century, depression was often conceptualised as two 
distinct conditions (Shorter, 2007). Melancholia (often understood as part of manic-
depressive insanity) was characterised by mental anguish, hopelessness, 
joylessness, stupor and often suicidal thoughts or actions. It was typically chronic and 
recurrent and often treated by alienists. Neurosis, by contrast, encompassed anxiety, 
fatigue, somatic preoccupations, obsessions and low mood. It was more likely to be 
treated by outpatient neurologists and spa doctors. In 1920 Kurt Schneider formalised 
this distinction by differentiation of endogenous depression (evolved from 
melancholia) from reactive depression (evolved from neurosis).  
 
The experience of the First and Second World Wars had a profound effect on 
psychiatry, which had to respond to epidemics of ‘shell shock’ and ‘combat fatigue’. 
This led to greater professionalism within psychiatry, greater pragmatism regarding 
treatments, and a greater public understanding of the existence of mental illness and 
the requirement for treatment (Gelder et al., 2012). This was further informed by the 
emergence of the first antipsychotic and antidepressant treatments in the 1950s and 
the rise of ‘biological psychiatry’ with its emphasis on neuropathological processes in 
mental illness such as disruption of neurotransmitter systems.  
 
The first edition of the  Diagnostic and Statistical Manual of the American Psychiatric 
Association (American Psychiatric Association, 1952) grouped melancholia and 
‘manic-depressive reaction’ with psychotic disorders (schizophrenic and paranoid 
reactions), while grouping neurotic depression with anxiety disorders. DSM-II 
(American Psychiatric Association, 1968) maintained the distinction between ‘manic-
depressive illness’ and psychoneurotic disorders. By the 1970s, there were a wide 
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range of depressions treated within both the psychodynamic and biological 
psychiatric traditions, and were surveyed in a landmark paper by Kendell (Kendell, 
1976) as including psychotic and nonpsychotic, endogenous versus reactive, 
melancholic versus psychoneurotic and (following the work of Karl Kleist), bipolar 
versus unipolar.  
 
Meanwhile, the Freudian concept of neurosis was adapted and transformed by the 
work of Hans Eysenck (Eysenck, 1967) and his developing taxonomy of personality.  
The modern concept of neuroticism (not to be confused with neurotic depression) 
came to be seen as a trait of emotionality, in particularly a tendency to arouse quickly 
when stimulated, and to inhibit emotions slowly, with a propensity to experience 
negative emotions (Ormel et al., 2013).  As such neuroticism came to be regarded as 
one of the ‘Big Five’ personality traits, along with extraversion, agreeableness, 
conscientiousness and openness to experience. As will be demonstrated in the 
research chapters to follow, neuroticism is conceptually distinct from major 
depression but is closely associated with it.  
 
1.5 Diagnosis of Major Depression in Research Studies  
 
The foundational basis of the diagnosis of depression in current clinical and research 
practice is the operationalised definitions of mental illness adopted in DSM-III 
(American Psychiatric Association, 1980) and ICD-10 (World Health Organisation, 
2017). This approach is most closely associated with Robert Spitzer (1932-2015), a 
highly influential psychiatrist of the latter 20th century, and influenced by a number of 
studies which called the credibility and consistency of psychiatric diagnosis into 
question (Rosenhan, 1973; US-UK Cross-National Project, 1974).  
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Operationalism is a philosophical tradition whereby a concept can only be understood 
if there is an appropriate means of measurement of it, subserved by a set of 
operations. Developed from conceptual work in the field of physics (Bridgman, 1927), 
operationalism was developed within psychology and psychiatry by the logical 
positivist philosopher Hempel (1966). In Hempel’s model a mental state could be 
observed by an assessor, leading to a totalising of a symptom list, which is compared 
to specified duration and severity criteria, and also to specified exclusion, sub-type 
and other multi-axial dimensional criteria. One of the first attempts to make psychiatric 
diagnosis operationalised was the “St Louis Classification” of Washington University 
(Feighner et al., 1972). 
 
The Research Diagnostic Criteria (Spitzer et al., 1975) separated ‘major depression’ 
which had many subtypes including endogenous depression, from ‘minor depression’ 
– a lesser form of depression which occurred with or without anxiety, and these were 
also distinguished from bipolar disorder. This provided the basis of DSM-III (American 
Psychiatric Association, 1980) which formally separated bipolar disorder and major 
depression (on the basis of presence or absence of manic symptoms) and replaced 
the concept of ‘minor depression’ with dysthymic disorder (or depressive neurosis, 
understood to be a persistent low grade depressive condition recurring throughout 
life). Melancholic depression and endogenous depression were removed as concepts 
and, despite some later efforts to resurrect them, Major Depressive Disorder has 
persisted since as a unitary concept describing a clinically heterogenous condition 
(Table 1.1), although melancholia can theoretically (along with psychotic and atypical 
depression) be sub-classified.   
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Table 1.1 – Diagnostic Criteria for Major Depressive Disorder in DSM-5 and ICD-
10, Adapted from McIntosh et al. (2019) 
DSM-V Major Depressive Disorder ICD-10 ‘Moderate Depressive Episode’ 
Five or more symptoms, at least one of 
which must come from the “A” criteria.  
Two or more symptoms from the following : 
“A” criteria  
1. Depressed mood 1. Depressed mood 
2. Markedly diminished interest or pleasure 
in almost all activities  
2. Loss of interest and enjoyment  
 3. Reduced energy leading to increased 
fatigability and diminished activity  
“B” criteria Three or more typical symptoms from the 
following:  
1. Significant weight loss/gain or 
decrease/increase in appetite  
1. Reduced concentration and attention  
2. Insomnia or excessive sleep  2. Reduced self-esteem and self-confidence  
3. Psychomotor agitation or retardation  3. Ideas of guilt and unworthiness (even in 
mild type of episode) 
4. Fatigue or loss of energy  4. Bleak and pessimistic views of the future  
5. Feelings of worthlessness or 
excessive/inappropriate guilt 
5. Ideas or acts of self-harm or suicide  
6. Diminished concentration or 
indecisiveness 
6. Disturbed sleep  
7. Recurrent thoughts of death, suicidal 
ideation, plans or an attempt 
7. Diminished appetite  
Both sets of criteria require a minimum symptom duration of 2 weeks, significant functional impairment and for the disorder 
to not be better accounted for by another medical/psychiatric condition.  
 
1.6 Alternative Research Definitions of Depression  
 
In a recent literature review aimed at understanding the phenomenology of major 
depression and the representativeness of DSM criteria, Kendler (2016) has argued 
that current diagnostic criteria place heavy emphasis on neurovegetative features of 
depression at the expense of changes in cognitive functioning, attitudinal change and 
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somatic symptoms  previously understood to be important features of depression. 
Kendler cautions against the ‘category mistake’ of conflating DSM criteria with the 
syndrome of depression as one and the same, given that the ICD/DSM will of their 
nature select criteria that require lesser levels of inference (to improve reliability), 
hence emphasis on readily quantifiable symptoms like weight, appetite and sleep.  
 
In 2013, Thomas R. Insel, Director of the US National Institute of Mental Health 
(NIMH), stated that the agency would be “re-orienting its research away from DSM 
categories” (Insel, 2013), citing a lack of validity given that, unlike diseases like 
ischaemic heart disease, there are no objective laboratory measures yet developed 
for major depression and schizophrenia. Insel proposed the development of 
Research Domain Criteria (RDoC) to be used by future research projects, that would 
incorporate genetics, imaging, cognitive science and other sources of objective data. 
While this is an aspiration for the future, such criteria are not yet in common use in 
research studies.  
 
A further recent development in depression diagnosis within psychiatric research has 
been the increased use of self-reported depression, outside of operationalised clinical 
diagnostic systems. Partly, this has been the result of the creation of very large study 
samples and biobanks enabling, for example, massive genome-wide association 
studies, which may not have access to formal DSM/ICD diagnostic evaluation. The 
company 23andMe recently provided a sample of in excess of one million individuals 
self-reporting the presence or absence of a depression diagnosis made by a 
healthcare individual (Howard et al., 2019). This leads to uncertainty about whether 
the full DSM or ICD criteria have been met in these cases, to which end the 
Psychiatric Genomics Consortium (PGC) have developed the concept of “Major 
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Depression” (MD) to include more ‘minimally phenotyped’ samples (McIntosh et al., 
2019).  
 
MD cases include those who self-declare diagnosis of depression by a healthcare 
professional or who meet research diagnostic criteria, or both. For example, in UK 
Biobank depression like traits can be broadly defined by questions such as ‘Have you 
seen a doctor (GP) for nerves, anxiety, tension or depression’ (UKB Data-Field 2090) 
and ‘Have you seen a psychiatrist for nerves, anxiety, tension or depression’  (UKB 
Data-Field 2100). This can lead to debate as to the extent to which MD and MDD 
describe the same condition, which is further complicated as many with MDD do not 
present to a healthcare professional for diagnosis (a necessary condition for MD that 
has not been ascertained by diagnostic criteria), and many individuals with anxiety 
disorders are not depressed. Nevertheless, two recent studies have identified high 
correlation at the genetic level between self-declared depression and DSM-
diagnosed depression (Zeng et al., 2016; Howard et al., 2018) , although a further 
(pre-print) study suggests that the relationship may be more nuanced between 
minimal phenotyping GWAS hits and specificity for major depression (Cai et al., 
2018).  
 
In addition to large-scale genetic and biobank studies which have led to the 
development of minimally phenotyped MD as a research diagnosis, another 
significant factor for depression phenotyping is increased access to record-linkage of 
administrative health and prescribing data (McIntosh et al., 2019). This enables other 
means of phenotyping depression cases, such as record-linkage to DSM/ICD 
diagnostic codes within health data (Davis et al., 2018), neuro-linguistic programming 
based text mining of health data for depression related keywords (Smoller, 2018) and 
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identifying depression cases through analysis of antidepressant users in prescribing 
records (Wigmore et al., 2019) (Table 1.2). An advantage of using record-linkage to 
administrative health data to identify cases is that it is well known that sufferers from 
depression may forget or fail to report past depressive episodes in self-report (recall 
bias) (Gelder et al., 2012). 
 
Table 1.2 : Methods of Phenotyping Depression in Research Studies, Adapted 
From McIntosh et al.  (2019) 
 DATA SOURCE   
 Self-rated Electronic Health 
Records 
Trained interview e.g. 
research nurse 
Diagnostic Standard Self-report 
questionnaire  
e.g. CIDI-SF used in 
STRADL 
Recorded diagnostic 
codes e.g. ICD-10 in 
Scottish Morbidity 
Records / NHS data 
Structured diagnostic 
interview e.g. SCID 
used in GS:SFHS 
Single item  
(sub-diagnostic) 
Single question self-
report e.g. ‘have you 








Evoked recollection of 
previous history of 
depression  
Multiple item  
(sub-diagnostic) 
Multiple item self-
report e.g. UKB self-
reported depression  
Multiple search term 





scale of psychological 






1.7 Neuroticism and Major Depression  
As we have seen, neuroticism is a stable personality trait described by Eysenck and 
characterised by negative emotional response and stress sensitivity. Numerous 
studies have demonstrated an association between neuroticism and major 
depression (Chan et al., 2007; Kendler et al., 2006) and a large meta-analysis has 
demonstrated this relationship between neuroticism and depressed mood or 
dysthymia (Kotov et al., 2010). However, much of the research linking neuroticism 
and major depression is cross-sectional, and thus it is difficult to discriminate 
associative relationships from causal ones. Furthermore, there is debate as to the 
extent to which neuroticism plays a mediating role between adversity and mental 
health outcomes (Lardinois et al., 2011). Thus it has been argued that negative life 
events in childhood promote the development of neuroticism, which then increases 
the vulnerability to major depression (Roy, 2002).  
 
Neuroticism is itself a partially heritable trait, and twin studies have suggested a 
genetic correlation between neuroticism and major depressive disorder of between 
0.43 and 0.69 (Kendler et al., 2006; Kendler and Myers, 2010; Hettema et al., 2006). 
A recent large neuroticism GWAS has identified four loci are also of nominal 
significance in a GWAS of MDD (Okbay et al., 2016). In summary, neuroticism and 
major depression appear to be genetically and phenotypically distinct, although with 
significantly overlapping and intertwined underlying architecture at the gene and 




1.8 Antidepressants  
 
There are a number of treatment options for MDD, including pharmacological, 
psychological (e.g. cognitive behavioural therapy), electroconvulsive therapy, 
exercise and occupational therapies. The majority of moderate to severe MDD cases 
are treated by antidepressants (Donoghue, 2019). For most patients there is a 
delayed onset of efficacy of antidepressant therapy before adequate remission of 
symptoms is achieved (Uher et al., 2011). Nevertheless, it is estimated that some 34-
46% of MDD patients do not adequately respond to treatment (Fava et al., 2005).  
 
Imipramine, the first antidepressant, was discovered serendipitously by Roland Kuhn 
in 1957 (Kuhn, 1958). At the time Kuhn was researching antipsychotics (Healy, 1998). 
Imipramine was the first of a new class of tricyclic antidepressants (TCAs), many of 
which are molecularly modified from the classic antihistamine chemical structure. In 
that same year, while researching anti-tuberculosis compounds, Nathan Kline 
discovered the first of the monoamine oxidase inhibitor class (MAOI) of 
antidepressants, iproniazid (Loomer et al., 1957). In 1965, in one of the first 
randomised controlled trials, the Medical Research Council demonstrated that, in 
treatment of depression, imipramine and electro-convulsive therapy (ECT) were 
superior to placebo (and phenelzine) (Thiery, 1965). Interestingly, further clinical 
experience and research demonstrated that while many responded to imipramine, 
many did not, and some of those who were treatment resistant to imipramine did 
respond to iproniazid (Healy, 2016).  
 
In the early 1960s it was discovered that tricyclic antidepressants exerted their action 
by blocking the reuptake of monoamines, principally noradrenaline and serotonin. 
The monoamines (dopamine, noradrenaline and serotonin) are neurotransmitters in 
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the central nervous system (CNS) which are involved in neural networks subsuming 
a variety of functions, including emotion, arousal, movement and some types of 
memory.  The ‘monoamine hypothesis’ postulates that the pathophysiology of 
depression relates to diminished concentrations of monoamines within the brain 
(Bunney and Davis, 1965). In addition to the monoaminergic-related (putative) action 
of antidepressants, the monoamine hypothesis noted that medications that deplete 
serotonin and catecholamines (such as the early antihypertensive drug reserpine), 
precipitate depression in some patients (Hillhouse and Porter, 2015).  
 
In the 1970s Arvid Carlsson developed zimelidine, the first antidepressant which 
(relatively) selectively blocked serotonin reuptake (Carlsson and Wong, 1997). 
Zimelidine and fluoxetine (Wong et al., 1974) were the first of the Selective Serotonin 
Reuptake Inhibitors (SSRIs), which were followed in due course by paroxetine, 
citalopram, escitalopram and sertraline, among others (zimelidine was subsequently 
withdrawn).   
 
There remains considerable debate about the extent to which noradrenaline reuptake 
block is an important property of the antidepressant class. Healy (2016) has noted 
that, some time before the production of zimelidine, it was known that the tricyclic 
antidepressants nortriptyline and desipramine were relatively selective for 
noradrenaline reuptake, and yet were effective antidepressants. Therefore the 
relationship between serotonin reuptake blockade and antidepressant efficacy is 
arguably not as straightforward as that, for example, between dopamine D2 receptor 
block and antipsychotic efficacy. It has also been noted that SSRIs are less effective 
for more severe or hospitalized depression(Healy, 2016) than medications which also 
target the noradrenergic system.  
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The monoamine hypothesis of depression has been repeatedly challenged in more 
recent times and is no longer considered an all-encompassing explanation of MDD 
pathophysiology. It has been noted that monoamine depletion in healthy subjects 
does not consistently produce depressive symptoms and that tryptophan depletion in 
MDD patients does not worsen depressive symptoms (Hillhouse and Porter, 2015).  
 
Following the development of the SSRIs, there was interest in developing 
antidepressants which also targeted the noradrenergic system, but which had a more 
favourable toxicity profile than TCAs or MAOIs. Shortly after the introduction of 
fluoxetine, the ‘atypical’ antidepressant bupropion was released. Bupropion is 
primarily a dopamine-noradrenaline reuptake inhibitor and has highest binding affinity 
for dopamine transports and minimal binding affinity for serotonin transporters. 
Nevertheless, it is an efficacious antidepressant (Feighner et al., 1986) although in 
the UK, unlike the USA, bupropion is not licensed for depression and only used as an 
“ off-label “ antidepressant.  
 
The next class of antidepressants to be released, in 1993, were the serotonin-
noradrenaline reuptake inhibitors (SNRIs), of which venlafaxine and duloxetine are 
the most prominent examples in UK clinical practice. Reboxetine was developed to 
more specifically target the noradrenergic reuptake system, with the idea that it could 
prove useful for more atypical forms of depression, but it has had a relatively 
chequered reception in clinical practice (Cipriani et al., 2018).  
 
Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), was 
released in 1996 and acts by antagonising adrenergic alpha-2 autoreceptors as well 
as by antagonising 5-HT2 and 5-HT3 receptors, thereby enhancing noradrenaline 
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and serotonin synaptic transmission (Anttila and Leinonen, 2001). Mirtazapine has 
become a clinically popular alternative antidepressant in outpatient practice from the 
SSRI/SNRI/TCA antidepressants. Other examples of atypical antidepressants 
include low dose oral antipsychotics (especially flupentixol), the serotonin precursor 
tryptamine, the 5-HT2A receptor and alpha-1-adrenoceptor antagonist trazodone, 
and the melatonin receptor agonist agomelatine.  
 
In 2013, vortioxetine, a serotonin receptor agonist, antagonist and reuptake-inhibitor 
(with dopamine and noradrenaline reuptake inhibiting properties), was released, but 
was not in common clinical practice during the period analysed in this thesis. Other 
experimental or novel treatments that were not in common clinical use during the 
period studied include glutamatergic agents, NMDA receptor antagonists (e.g. 
ketamine) and glycine-like modulators. 
 
The British National Formulary (BNF) (Joint Formulary Committee, 2012) classifies 
antidepressants in Chapter 4, Section 3, and provides the following classes : TCA, 
SSRI, MAOI and “other” antidepressants. The BNF is the standard formulary used in 
UK clinical practice, and is also in clinical use worldwide, and is the standard therefore 
adopted in this thesis. However, other standards exist, including the Anatomical 
Therapeutic Chemical Classification System (ATC) of the World Health Organisation 
(2012), which defines antidepressants under ATC code N06 (psychoanaleptics):  
Section A (antidepressants), incorporates non-selective monoamine reuptake 
inhibitors, SSRIs, non-selective MAOIs, monoamine oxidase-A inhibitors and ‘other’ 
antidepressants.  Another recently adopted convention within the European Union is 
Neuroscience-based Nomenclature (Worley, 2017) which names medication via their 
mechanism of action (thus citalopram is a ‘serotonin reuptake inhibitor’). This reflects 
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an understanding that the names of many psychiatric medication classes are historic 
and not necessarily specific (i.e. ‘antidepressants’ are also commonly used for 
anxiety, and also are not thought to work by chemically counteracting or opposing 
depression but through a more complex mechanism).  Nevertheless, throughout this 
thesis, the BNF approach has been adopted, in accordance with common UK clinical 
practice and its use in routinely-collected administrative health data within the UK.  In 
some cases, however, the SNRIs have been distinguished from the rest of BNF 
Section 4.3.4 “other antidepressant drugs”, as will be specified where applicable.  
 
It is also important to recognise that antidepressant medications are not the only 
medications which treat depression. The BNF additionally lists a class of medications 
which have been variously described as “mood stabilizers”, including lithium 
carbonate, lithium citrate, a number of anticonvulsants (including sodium valproate, 
carbamazepine and lamotrigine), a number of antipsychotics (including olanzapine, 
quetiapine and aripiprazole) and medications under development as antidepressants 
such as ketamine (used off-label). It is also the case that anxiolytic, sedative and 
antihistamine medications can be beneficial in depression. The description of a 
particular medication as “antidepressant” is therefore to a degree arbitrary rather than 
definitive, as reflected by expert consensus in the BNF. In this study when discussing 
“antidepressants” I have defined this as those agents within BNF Chapter 4 Section 
3, which are understood to be licensed for and employed for the treatment of major 
depressive disorder, in both primary and secondary care. Where possible and 
practical I have provided additional information on the medications that can be 
described as “mood stabilizers” (although as discussed in Chapter 4 there is 
considerable confusion about this concept) and also other anxiolytic agents. 
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It is equally important to appreciate that BNF Chapter 4 Section 3 antidepressants 
have wider indications that simply the treatment of depression, and in fact the number 
of indications is growing, with considerable pharmaco-epidemiological significance, 
as discussed in Chapter 5. Clomipramine, the TCA with the most serotonergic action, 
has been found to be a useful anxiolytic with specific indications for phobic and 
obsessional states (Healy, 2016). The SSRI class has widespread use in the 
treatment of anxiety states ranging from generalized anxiety disorder (GAD), 
obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) to 
panic disorder and social phobia (Joint Formulary Committee, 2012). Additionally, 
antidepressant drugs often have clinical uses outside of psychiatry. Amitriptyline, a 
tricyclic antidepressant, is now more commonly prescribed for non-psychiatric 
purposes such as chronic pain, fibromyalgia, insomnia and headache than it is for 
depression or anxiety, as discussed in Chapter 5. SSRIs are commonly prescribed to 
treat sexual disorders, bed-wetting and premenstrual dysphoria. Duloxetine, a SNRI, 
is commonly prescribed to treat urinary incontinence in women. As discussed in 
Chapters 4 and 5, the widespread use of antidepressants for a growing number of 
indications places particular challenges on research into antidepressant pharmaco-
epidemiology and exposure.  
 
1.9 Self-Harm, Suicidality and Attempted Suicide  
 
Self-harm (SH) is defined as self-injury or self-poisoning, irrespective of the apparent 
purpose of the act (National Collaborating Centre for Mental Health, 2004). Self-harm 
is distinguished from purely accidental injury (at least theoretically). Terms like 
‘deliberate self-harm’ (DSH) are no longer preferred in research due to their 
potentially judgemental overtones (Chapter 6) and the difficulty of distinguishing 
causality for self-injury in research and clinical practice. The aetiology, epidemiology, 
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comorbidities and nosological issues of self-harm are discussed in detail in  Chapter 
6. Distinction can be made theoretically between nonsuicidal self-injury (NSSI), 
suicide attempts (SA), suicidal ideation and completed suicide, although in many 
cases such distinctions are more difficult to make in practice.  
 
While self-harm as a behaviour can occur in the absence of depressive illness, 
individuals with major depressive disorder are 20-times more likely to die by suicide 
in comparison to the general population (Chesney et al., 2014) and individuals with 
depression have a risk ratio of 14.1 (95% Confidence Interval 14.0-14.3) for self-harm 
in a record-linkage study of patients presenting to hospital as admissions or day cases 
(Singhal et al., 2014). It is further estimated that 50% of worldwide suicides annually 
are attributable to major depressive disorder (Otte et al., 2016). 
 
Information on self-harm in research studies is typically collected retrospectively 
through self-report (Marrs, 2016). However, given its emotive content  the self-report 
of self-harm is particularly likely to be affected by reporting issues including denial, 
self-stigma, problems with recall, misinterpretation of study questions and response 
bias (Velting et al., 1998). Research of self-harm in adolescents has demonstrated 
that individuals are two to three times less likely to disclose suicide attempts if their 
anonymity is not guaranteed (Safer, 1997). There is also evidence that those 
individuals who self-harm are more likely to be non-responders or lost to follow up in 
research studies (Wolke et al., 2009; Kidger et al., 2012).  
 
In this context, record linkage to administrative data has significant potential to 
ameliorate under-reporting of self-harm in research studies (or at least that self-harm 
which can be detected in administrative data, such as self-harm associated with 
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hospital or general practice attendance). For example, a data linkage study 
comparing self-harm questionnaire responders and non-responders in the ALSPAC 
adolescent cohort found that self-harm leading to hospital admission was greater in 
non-responders (2.0%) than responders (1.2%) (Marrs, 2016). Thus research studies 
that combine self-report with other sources of data, including linkage to administrative 
health data, are arguably more likely to produce accurate phenotyping of cases, 
particularly for hospital-associated self-harm which, while less common (the majority 






1.10 Concluding Remarks  
 
This chapter has provided background to the epidemiology, aetiology and conceptual 
development of the major outcomes of interest in this thesis (antidepressant usage 
and self-harm) and the major associated covariates (major depressive disorder and 
neuroticism). Emphasised throughout is that while major depression is clearly linked 
with antidepressant usage and also with self-harm, the overlap is certainly not 
complete. Similarly, while depression (especially neurotic depression) and 
neuroticism share a common history in the development of psychopathological ideas, 
they are similarly distinct entities – the former a mental illness and the latter a 
dimension of personality.  
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This chapter has also shown that contemporary research into major depression, 
antidepressant usage and self-harm has benefited in recent years from the availability 
of linked data studies. In Chapter 2, I shall discuss the conceptual and methodological 






Chapter 2 : Record-Linkage as Applied to Mental Health 
Research 
 
2.1 Data Linkage, ‘Big Data’ and Psychiatric Research  
 
Note : Some of the material presented here is based on material also published in 
Hafferty et al. “Invited Commentary on Stewart and Davis “’Big Data’ in mental health 
research- current status and emerging possibilities” Soc Psychiatry Psychiatr 
Epidemiolol (2017) 52:127-129;   and Russ TC, Woelbert E, Davis KAS, Hafferty JD 
et al. “How data science can advance mental health research”, Nature Human 
Behaviour, (2019) Vol 3, 24-32.  
* * * 
In recent years there has been a revolution in the way data is processed, utilised and 
analysed for a variety of enterprises, with psychiatric research being no exception. 
An entirely new research discipline, data science, has been at the forefront of this 
change. ‘Data science’ was reportedly coined as recently as  2008 (Davenport and 
Patil, 2012) and has been defined as “a set of fundamental principles that support 
and guide the principle extraction of information and knowledge from data” (Provost 
and Fawcett, 2013).  
 
These principles encompass computer-driven processes, algorithms and methods 
(such as data linkage, data mining and machine-learning) as applied to quantities of 
high-dimensional (i.e. multi-layered) structured (i.e. highly formatted and organised) 
and unstructured data. Critics have sometimes disparagingly referred to data science 
as a synonym for a (perhaps less robust and principled form of) statistics, or within 
the medical sciences as an ‘old-wine-in-new-bottles’ rebadging of computational 
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epidemiology. More positively, data science can be seen as a ‘fourth paradigm’ of 
science (alongside theoretical, empirical and computational science) which lies at the 
interface between mathematical/statistical methods, cutting-edge computational 
applications and skills, and evidence-based domain knowledge (see Figure 2.1) 
(Russ et al., 2019).  
 
 
Figure 2.1 – The Meaning of Data Science  
 
Image source : http://www.datascienceassn.org/content/data-science-venn-diagram-shelly-palmer-2015  [Accessed 07-06-19] 
 
Data science can be conceptualised as a means of “generating new knowledge from 
real-world data” (Russ et al., 2019). Within medicine, this has already had significant 
impact. Firstly, with the establishment of new research enterprises dedicated to the 
exploitation of data for medical purposes, such as Health Data Research UK 
(https://www.hdruk.ac.uk) and the Farr Institute of Health Informatics Research 
(https://farrinstitute.org). Secondly, with advancements related to the use of this data 
for medical science, such as data-driven approaches to the study of aetiology and 
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pathogenesis of cancer (Hamada et al., 2017), data mining for heart disease 
prediction (Singh et al., 2018) and the development of anonymised electronic mental 
health record databases for mental health research (McIntosh et al., 2016b; Stewart 
and Davis, 2016). 
 
Closely allied with the development of data science is the accumulation of ‘big data’. 
‘Big data’ has been defined as data sets which are so large in size, so fast to change 
and so complex in structure that traditional data processing techniques are 
overwhelmed (Hafferty et al., 2017). ‘Big data’ has become possible due to 
technological advances in data processing and storage, computer networking, mobile 
technology, the internet-of-things and platforms for data manipulation.  
 
The challenges of working with such data are typically described through the 
taxonomy of ‘Vs’ – especially volume, velocity and variety of data – as originally 
described by Laney (2011). In this context, volume reflects the size of the datasets in 
terms of the number of cases and also the quantity of data attached per record (which 
can be massive if imaging and genetic data is included). Velocity reflects the speed 
at which the data is changed and updated, which can even be in near real-time in 
datasets which use medical health records and/or data provided by sensors. Variety 
reflects the sources of data and the data organisation principles within them, which 
can be very different in the case of, for example, datasets combining administrative 
health data whose predominant function is for financial/billing purposes, free-text 
medical notes used by clinicians, standardised psychological research instruments 
and tests, output from sensors, and repositories of biological data.   ‘Veracity’ and 
‘variability’ are often added to reflect the range and potential unreliability of 
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information arising from some sources, especially when datasets are combined 
(Stewart and Davis, 2016). 
 
The opportunities for using data science and ‘Big Data’ in mental health research 
have been reviewed by McIntosh (2016b) and Stewart and Davis (2016). One of the 
most tractable approaches within the UK is to apply these techniques to massive 
population cohorts which are deeply phenotyped with clinical, psychological and 
sociodemographic data in addition to genetic, imaging and other biological data 
(examples include two of the cohorts that will be further discussed in this study, UK 
Biobank and Generation Scotland, other examples include the Avon Longitudinal 
Study of Parents and Children and, outside the UK, the US Million Veteran 
Programme and the BioBank Japan Project).  
 
An exciting development which will be further explored within this study is the ability 
to use record-linkage (discussed below) to combine these cohorts with routinely 
collected healthcare and other administrative data. This can be done within 
population-based cohorts as described, and also to more domain-specific cohorts 
focused on mental health (examples include the collaboration of the Welsh National 
Centre for Mental Health (NCMH) cohort of approximately 6000 individuals with the 
Secure Anonymised Information Linkage (SAIL) databank of healthcare, child health, 
education, deprivation and demographic data). Additionally, cohorts can be created 
de novo using electronic health records, data structuring techniques and 
deidentification pipelines, as has been done with the Clinical Practice Research 
Datalink (CPRD) of GP practices and more recently with the Clinical Record 
Interactive Search (CRIS) database of mental health records developed at South 
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London and Maudsley NHS Foundation Trust in 2007 and since extended further in 
London as well as Oxford and Cambridge. These are summarised in Table 2.1  
 
Table 2.1 United Kingdom ‘Big Data’ Resources for Psychiatric Research, 
adapted from Stewart and Davis (2016) 
Name  Mental  
Health  
Specific? 
Description  Size 
Clinical Practice Research Datalink 
(CPRD) 
No National sample based on a sample of 
primary care providers  
 
Clinical Record Interactive Search (CRIS) Yes Local secondary care psychiatry 




Generation Scotland  No Regional family- and population-based 
research cohort with record-linkage to 
administrative data 
21,000+ 
GriST Yes Primary and secondary care psychiatry 
records, multiple locations 
 
Public Health England Mental Health 
Dementia and Neurology Intelligence 
Network 
Yes Regional study from mixed 
administrative sources  
 
Qresearch GP database  No Database of national sample of primary 
care providers (600 practices) 
Approx. 
12m  
The Health Improvement Network 
(THIN) 
No Database of national sample of primary 
care providers  
Approx. 
10m 
UK Biobank No National sample of volunteers with 
record-linkage to administrative data  
500,000+ 
Secure Anonymised Information 
Linkage (SAIL) 




PsyCymru Yes E-cohort of psychosis cases linked to 
SAIL 
12,000 
Source : Adapted from Stewart and Davis “’Big data’ in mental health research : current status and emerging possibilities”   Soc 






Record-linkage, also known as data matching, is a discipline with a long history which 
predated the computer age and is described by Christen (2012). The appeal of linking 
patient medical records with other types of information is well understood within 
epidemiology. Within psychiatric research, routine clinical data has been employed in 
some of the earliest studies of asylum records through to the growth of ‘case register’ 
series in the middle part of the twentieth century (Stewart and Davis, 2016).  However, 
early studies were often linked between records ‘by hand’ and were cumbersome and 
time consuming as well as prone to matching and other errors. With the development 
of Electronic Health Records (EHRs) larger volumes and varieties of information are 
now accumulated than would have been conceivable in traditional epidemiological 
research, posing both a tremendous transformative research opportunity and a 
considerable technical challenge to investigators.  
 
The term record linkage was coined by Dunn in 1946 (Dunn, 1946) as a proposal for 
a ‘Book of Life’ for every individual, which would start with birth records, link to 
educational, health, marriage and social security records and end with death records, 
and would provide a solid foundation to plan services, research public health and 
improve national statistics. At an early stage, Dunn recognised the potential 
challenges of variability within the data, including errors and difficulties providing 
reliable linkage for records of individuals with common names. The idea of using 
computers to automate and standardise the data matching process was proposed by 
Newcombe et al. (1959) who also utilised a distinction between (a)deterministic 
record linkage which is a wholly automatic process where a fixed criterion (such as a 
combination of name, birth date, gender and postcode; or a unique identifier number) 
is used to link individuals, and (b)probabilistic record linkage where statistical 
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techniques are used to apply probabilistic weights within an algorithm, to determine 
the likelihood that records relate to the same individual.  
 
For example, the relative likelihood that a pair of records belong to the same individual 
can be made using the calculation of probability weights (Fellegi and Sunter, 1969) 
based on the founding principle of frequency ratios (Fleming et al., 2012; Newcombe 
et al., 1959). In comparing two records, an algorithm can be used to compute a 
weighted score proportional to the probability that the records belong to the same 
person. The ‘m probability’ measures the reliability, quality, accuracy and stability of 
a variable and the probability that a given identifier will agree for a pair of records that 
truly belong to the same individual. The ‘u probability’ is the probability that a given 
variable will randomly match across two records(Fleming et al., 2012; Mason and Tu, 
2008). Varying levels of positive and negative weight are produced based on the 
levels of agreement or disagreement between an identifier and two records being 
compared. Once a weight is calculated for each variable in the linkage process, the 
sum of all weights for all variables utilised is made to provide an overall weight for the 
record pairing, which is then used to determine if the threshold for a link has been 
met. 
 
Deterministic record linkage is fast but depends on the ability to define linkage criteria 
of sufficient granularity to be truly discriminatory, which may be difficult across wide 
ranges of datasets. Probabilistic record linkage allows multiple data sets, where there 
may not be a unique identifier, to be integrated. However, it is a statistically complex 
method which requires significant clerical review to minimise error rates.  
 
 60 
More recently, another important research area within record linkage has been that 
of data cleaning, especially the eradication of duplicate records and the processing 
of variables into an appropriate form for statistical analysis. Another important 
principle, especially for sensitive health data, is that of privacy-preserving record 
linkage, whereby the need for exchange of private and confidential data between 
organisations involved in data matching is minimised.  
 
The accurate and deterministic linkage of data is significantly aided in those countries 
which have utilised an unique identification number for its health and other records. 
The Nordic European countries are relatively well-known for this, allowing large 
population-based register record-linkage studies in Sweden, Denmark and Finland 
(Hargreaves et al., 2015). As will be discussed below, Scottish studies have also been 
able to apply these techniques through the existence since the 1970s of an unique 
Community Health Index (CHI) number for every individual registered to a GP 
practice in Scotland. This is a 10-character code consisting of the patient’s date of 
birth (in six-digit format), two assigned digits, a digit which is odd for males and even 
for females, and an arithmetical check digit. 
 
An advantage of record-linkage of administrative data to large population-based 
cohorts is that such studies potentially offer much larger patient numbers, wider 
parameters of study, and longer timescales of follow-up, than are typical of 
randomised control trials (RCTs) or standard cross-sectional or cohort studies 
(Hafferty et al., 2017). A further advantage of record-linked administrative health data 
is that it necessarily arises out of naturalistic clinical settings, in terms of both clinical 
practice and patient health and comorbidity, thereby obviating one of the criticisms of 
the RCT, the ‘gold standard’ of medical research, which can be prone to unrealistically 
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overly-strict exclusion criteria. Routine clinical data sets can, therefore, be 
complementary to RCT data, while also making research findings more relevant to 
everyday clinical practice. In addition, the quantity of clinical ‘big data’ potentially 
allows analysis of rarer clinical conditions, or subject areas that would be unlikely to 
meet ethical approval for more conventional studies (for example, medication usage 
in pregnancy). ‘Big data’ record-linked studies thereby potentially provide the scale 
and breadth of patient numbers required for stratified, predictive and personalised 
medicine research.  
 
Such methods do, however, have important drawbacks. As discussed, an important 
consideration in the use of ‘Big Data’ is veracity of data. It is important to remember 
when employing record-linkage to administrative data that this data has not usually 
been collected with consideration for its use in research. It may indeed have factors 
in the recording of information which introduce biases or errors for research studies. 
For example, when using data employing diagnostic codes (such as the International 
Statistical Classification of Diseases 10th Revision,  ICD-10, (World Health 
Organisation, 2017)) the coding is likely to have been inputted by an administrator 
rather than a clinician, and the necessity to input codes in a highly structured format 
often means that underlying clinical uncertainties are not accurately reflected in the 
coding (and there is often no supplementary clinical information to draw on in later 
research). This can be a particular challenge in psychiatry, as a number of important 
diagnoses are relatively under-recognised in clinical records, including dementia, 
major depression and anxiety, although their recognition and reporting is improving 




2.3 Privacy and Research Governance in Record-Linkage Studies 
 
Additional important considerations in record-linkage studies are public trust, ethics, 
privacy and clinical data governance. This area is arguably under-researched. 
Privacy, informed consent, data stewardship, and the long-term ownership of data by 
academic and commercial entities are becoming ever more pertinent issues as the 
pace of data accumulation increases. Data collected from individuals with psychiatric 
illnesses may come with additional privacy concerns as attitudes research suggests 
that mental health data are among the most personal and sensitive (Taylor and 
Taylor, 2014).  
 
It is important, however, that legitimate concerns about privacy do not inadvertently 
create an excessively restrictive regulatory environment. There is a critical role for 
policymakers in striking the right balance between privacy and realising the research 
potential of big data, as was recently illustrated in the debate regarding what become 
the EU General Data Protection Regulation (GDPR) in the research community 
(Mittelstadt and Floridi, 2016). The MRC Farr Institute, the European Data in Health 
Research Alliance, and Patients4Data group have all promoted the importance of 
data sharing for research and health-care improvement while acknowledging the 
potential risks of inaccurately recorded information and data breaches (McIntosh et 
al., 2016b).   
 
Within this context, it is encouraging that the majority of mental health service users 
agree to the use of their health records for research, especially when they are 
provided with appropriate communication and opportunity for informed consent about 
use and potential benefits (McIntosh et al., 2016b). The UK Biobank model of consent 
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is a good example of public willingness to consent to multiple uses of their data for 
research purposes (Russ et al., 2019).  
 
However, this has to be weighed against the relatively low response rate for 
population-based cohort studies, even very large ones. For example, in UK Biobank 
approximately 9.2m individuals were invited but only 5.45% (approximately 500,000) 
were recruited(Fry et al., 2017). Also, there was evidence of a “healthy volunteer” 
selection bias (participants were less likely to be obese, to smoke, drink alcohol and 
had lower all-case morbidity and mortality than found in the general population). This 
has led to calls for caution in terms of the generalizability and external validity of 
findings that might not apply to the target population(Keyes and Westreich, 2019).  
 
2.4 Health Data-Linkage Studies in Scotland  
 
Scotland is one region of the UK where research governance procedures for linked 
data have been particularly well established (Figure 2.2). There are several reasons 
why this is the case. Firstly, through the existence of the ten-digit Community Health 
Index (CHI) number, which covers between 96.5-99.9% of the Scottish population of 
5 million, and which allows for pseudonymised data linkage between a variety of 
health records from birth to death as discussed (Figure 2.3) (Pavis and Morris, 2015). 
Secondly, Scotland possesses and has developed over considerable time a robust 
research governance framework, underpinned by the Scotland Data Protection Act 
1998 and overseen in the health research sphere by the Privacy Advisory Committee 
(PAC), which also mandates significant public input for review of grant applications.  
Thirdly, Scotland possesses a network of safe and transparent repositories of clinical 
data involving the Scottish branch of the Farr Institute of Health Informatics Research 
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(involving a consortium of six Scottish universities and the NHS),  and National 
Service Scotland (NSS) Information Services Division (ISD) and its associated 
National Safe Haven (https://www.isdscotland.org/Products-and-services/Edris/Use-
of-the-National-Safe-Haven/). Finally, further support to researchers is provided by 
an eData Research and Innovation Service (eDRIS) to help researchers navigate the 
system and understand which data is available and the access procedures involved 
(Pavis and Morris, 2015). 
 
Figure 2.2 The ‘Scottish Model’ of Data Linkage using the Principle of 
Separation of Functions, from Pavis and Morris (2015) 
 
Source: Pavis S and Morris AD, “Unleashing the power of administrative health data: the Scottish model”   
Public Health Research & Practice. September 2015. Vol 25(4):e2541541 
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Figure 2.3 Scottish national-level data resources which employ the CHI number, 
from Pavis and Morris (2015)  
 
Source: Pavis S and Morris AD, “Unleashing the power of administrative health data : the Scottish model”  Public Health Research 
& Practice. September 2015. Vol 25(4):e2541541 
 
2.5 Record-Linkage to Administrative Data and Psychiatric Research 
 
The research literature of computer-based record-linkage studies in psychiatry dates 
back to the 1970s (Baldwin, 1971). An early application of the technique was the 
linking of death registers to psychiatric medical records to investigate suicide in 
psychiatric patients (Barner-Rasmussen et al., 1986; Black et al., 1985). Making use 
of the availability of deterministic linkage via Swedish  personal identification 
numbers, linkage between inpatient registers with diagnostic information and cause-
of-death registries enabled one of the first large scale (N=8895) analyses of predictors 
for completed suicide (Allgulander and Fisher, 1990), although the authors 
commented that the lack of detailed psychological and sociodemographic 
phenotyping constrained the specificity and utility of the predictors found. Such 
studies were extended to investigate other causes of potentially avoidable mortality 
in the psychiatric population by linking community health records to local mortality 
databases (Amaddeo et al., 2007).  
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A pioneering record-linkage study comparing self-reported use of mental health 
services with administrative healthcare records as ‘gold standard’ was performed in 
36,892 individuals in Ontario, Canada. It found that there were significant 
discrepancies in those (mostly depressed) individuals self-reporting mental health 
service use and the usage ascertained from their records (Rhodes and Fung, 2004). 
This was an early attempt to utilise record-linkage as a means of validating self-
reported research variables (see Chapter 4).  
 
Using the Oxford Record Linkage study, which collated brief abstracts of medical and 
psychiatric hospital contacts and mortality in the former Oxford NHS Region 1963-
1999, Goldacre et al. conducted an innovative study exploring the potential link 
between major depression (and anxiety) and development of cancer (Goldacre et al., 
2007). The study demonstrated a potential link between depression and brain and 
lung cancers (smoking was not controlled for and the authors pointed out this was 
likely to be significant), but the risk ratios for other cancers was not significant (0.98, 
95% Confidence Interval 0.92-1.04). A large Canadian record-linkage study 
(N=247,344) linking primary care and mental health records with oncology and death 
registries found evidence of increased cancer mortality in the mentally ill although this 
was not evidently due to increased incidence (Kisely et al., 2008). 
 
The potential for utilising record-linkage to ICD coding in physician billing and hospital 
discharge abstracts for the purposes of ascertaining psychiatric disease prevalence 
was employed in a Canadian study which was able to thereby estimate the 
prevalence of mood and/or anxiety disorders in four Canadian provinces as between 
8-10%. The authors commented that administrative data provided an economical and 
useful tool for disease surveillance, but that the lack of specificity in disease coding 
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and data capture limited the granularity of the estimates (Kisely et al., 2009). By 
linking patient registers to national prescribing databases, researchers were able to 
make similar prevalence estimates for use of psychiatric medication. A Norwegian 
study employing this technique found a significant increase in antidepressant use 
among the adolescent population 2004-2013 (Hartz et al., 2016). 
 
In 1996, Womersley published an opinion piece arguing for greater use of the 
Community Health Index (CHI) number for record-linkage studies based in Scotland 
(Womersley, 1996).  An early initiative was the foundation of the Medicines Monitoring 
Unit (MEMO) in Tayside, a university-based organization that used record-linkage to 
construct an observational pharmaco-epidemiological and pharmaco-vigilance 
database of 400,000 people (Evans et al., 2001). Using this population, MacDonald 
and colleagues conducted an early study of antidepressant usage and the duration 
of antidepressant episodes which indicated that – at this time – many doses and 
treatment durations for TCAs and SSRIs were probably sub-therapeutic (MacDonald 
et al., 1996). Chapter 5 provides a significant update to this early research making 
use of CHI-based record-linkage to Scottish prescribing data, in a population-based 
cohort including the Tayside population.  
 
2.6 Concluding Remarks  
 
In this chapter I have charted the evolution of record-linkage from a relatively labour 
intensive and small-scale practice undertaken at the local hospital level to the 
massively scaled, computer-based and nationally applicable technology which exists 
today. Future developments of this technology include more sophisticated data 
mining, machine learning and Bayesian modelling approaches as will be discussed 
in Chapter 7.  
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The success of record-linkage research depends upon the fidelity of the data linkage 
and also on the quality and depth of the datasets being thereby connected. In the 
next chapter I will overview the population-based cohorts and nationally based 










Chapter 3: Profiles of Cohorts and Datasets  
 
3.1 Introductory Remarks  
 
In this chapter I will review the two main cohorts that will be utilised in this study, 
which are Generation Scotland (and including the follow-on STRADL re-contact 
study) and UK Biobank. I will also survey the main administrative health datasets that 
will be employed for record-linkage purposes, the Scottish Morbidity Records and 
Prescribing Information System. Some of this information will be repeated, as 
appropriate, in the Methods sections of the research chapters which follow, although 
this chapter is dedicated to a move general overview of the datasets which will be 
used herein.    
 
3.2 Generation Scotland : Scottish Family Health Study (GS:SFHS) 
 
Generation Scotland:Scottish Family Health Study (GS:SFHS) is a population- and 
family-based epidemiology study (N=21,474), with socio-demographic, clinical and 
genetic phenotyping. A full cohort profile is provided in Smith et al. “Cohort Profile: 
Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its 
participants and their potential for genetic research on health and illness” International 
Journal of Epidemiology 2013: 42:689-700 (Smith et al., 2006; Smith et al., 2013a). 
 
A list of General Practices willing to participate in GS:SFHS was generated with 
General Practice involvement being assisted by the Scottish Practices and 
Professionals Involved in Research (SPPIRe) network(Smith et al., 2006). An 
 70 
independent party, based in the NHS, generated a list of eligible people registered 
with each collaborating general practice, by utilising the Community Health Index 
(CHI) number (randomisation technique not stated). The names of all potential 
participants were then screened by their GP, and individuals who it would be 
inappropriate to approach (e.g. terminal illness, unable to consent to research) were 
excluded(Smith et al., 2006). Letters of invitation to eligible participants were then 
generated on practice-headed notepaper and signed by one of the GP principals. 
These letters were then dispatched by an independent party and up to two reminders 
were permitted. The invitation was for agreement to discuss the study with family 
members with a view to potential involvement. If the contacted person returned the 
consent slip, their name and contact details would be provided to the research team.  
 
In the UK, 96% of the population is registered with a GP and thus this recruitment 
method was favoured for recruiting a population-based sample. Invitations to 
participate were blinded to health status.   
 
Potential participants were invited to the study and also to identify at least one first-
degree relative (aged 18+) who would also participate. Nominated first-degree 
relatives could be from any location. The first recruitment phase (2006-10) involved 
potential participants aged 33-65 years and at least one nominated first-degree 
relative (aged 18+) from GP practices in Glasgow and Tayside areas of Scotland. In 
the second phase (2010-2011) the study was extended to include Aryshire, Arran and 
North-eastern Scotland, and the age of potential participants was broadened to 18-
65 years (invited relatives remaining aged 18+).  
 
 71 
In total, 126,000 potential participants were invited and 12.3% volunteered and met 
study criteria. Not all participants were recruited, for logistical reasons or due to failure 
to recruit additional family members, leaving a total recruitment of 6665 (5.3% overall 
response rate). An additional 1288 individuals volunteered directly (age >18 years 
and at least one additional relative who agreed to participate). A further 16,007 family 
members associated with these invited participants and volunteers were also 
recruited, giving a total of 23,960.  
 
A total of 21,474 individuals attended Generation Scotland research clinics in 
Glasgow, Dundee, Perth, Aberdeen or Kilmarnock. Prior to their appointment they 
completed a pre-clinic questionnaire. At the clinic appointment, a variety of measures 
were taken by trained clinic staff. This included screening for emotional and 
psychiatric problems using the structured clinical interview for DSM-IV disorders 
(SCID)  (99.6% of cohort completed) (First et al., 2002). In the case of positive 
screening, the mood sections of the SCID were then completed (18.8% completed).   
 
Psychological traits of neuroticism and extraversion were self-reported using the 
Eysenck Personality Questionnaire Short-Form Revised (99.4% completed) 
(Eysenck et al., 1985), consisting of twenty four questions with total scores on each 
subscale ranging from 0-12.  Four groups of cognitive tests measuring intelligence 
were also administered during the clinic assessment. Processing speed was 
measured by the Wechsler Digit Symbol Substitution Task (98.8% completed) 
(Wechsler, 1958). Verbal declarative memory was measured using one paragraph 
from the Wechsler Logical Memory Test I & II (98.7% completed) (Wechsler, 1945).  
Vocabulary was measured using the Mill-Hill Vocabulary Scale (98.2% completed) 
(Raven, 1958), using combined junior and senior synonyms. Executive function was 
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measured using a Verbal Fluency Test employing phonemic lists of C, F and L 
(Wechsler, 1958) (99.3% completed).  
 
Psychological distress was self-reported using the General Health Questionnaire 
(GHQ-28), involving the scoring of 28 questions concerning recent psychological 
symptoms from 0 (“not at all”) to 3 (“much more than usual”) with total scores ranging 
from 0 to 84 (Goldberg and Hillier, 1979), higher scores indicating greater 
psychological distress. Socioeconomic deprivation was measured using the Scottish 
Index of Multiple Deprivation (Payne and Abel, 2012) which is an official tool utilised 
by the Scottish government which scores deprivation by combining different 
indicators (e.g. income levels, crime levels) into a single index. The SIMD (in this 
thesis the 2012 version of SIMD is used) divides Scotland into 6505 small geo-zones 
(called datazones) with roughly equal populations, based on participant postcode. 
Each datazone is assigned a relative ranking from 1 (most deprived) to 6505 (least 
deprived). The Scottish population is 5.45m (2019) and thus a typical datazone would 
contain 838 people. Rural datazones would be significantly larger geographically than 
urban ones.  
 
Written informed consent was also obtained for 98% of GS:SFHS for data linkage to 
routinely collected health records and only those individuals who provided consent 




In 2015, a project entitled ‘STRADL: Stratifying Resilience and Depression 
Longitudinally’ was launched to re-contact participants from GS:SFHS. The purpose 
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of the study was to obtain additional information (by questionnaire) from GS:SFHS 
participants regarding their mental health (especially presence of Major Depressive 
Disorder), and additional psychological measures relevant to psychological resilience 
(the ability to maintain psychopathological health despite exposure to known risk 
factors) (Luthar et al., 2006). A full cohort profile is provided in Navrady et al. “Cohort 
Profile : Stratifying Resilience and Depression Longitudinally (STRADL): A 
questionnaire follow-up of the Generation Scotland: Scottish Family Health Study 
(GS:SFHS)” International Journal of Epidemiology (2017) (Navrady et al., 2018).  
 
Individuals were eligible to be re-contacted for the STRADL study if they (i) had 
originally taken part in GS:SFHS  (ii) had a Community Health Index (CHI) number, 
thereby enabling record linkage to administrative health data (iii)were alive and living 
in Scotland  (iv) had given informed consent for re-contact. On this basis, 
21,525(89%) of GS:SFHS participants were eligible for recontact and all were sent a 
questionnaire booklet by an independent party. In total 785 completed an online 
questionnaire and 8833 returned a paper copy (total STRADL respondents 9,618, 
45%) (Navrady et al., 2018).  
 
STRADL respondents also consented to the use of their data for ‘future medical 
research into health, illness and medical treatment’ on the basis that this data would 
remain anonymous and be added to that already securely held as part of the 
GS:SFHS study. All components of STRADL received formal, national ethical 
approval from NHS Tayside Committee on Research Ethics (Reference 14/SS/0039).  
 
The STRADL cohort was predominantly female (62%, compared to 59% for 
GS:SFHS and 52% for Scottish population) with a mean age of 50.48 (SD=13.41) 
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(Navrady et al., 2018) (mean age Scottish population 38). Compared to the Scottish 
population, the STRADL cohort was generally healthier and wealthier and better 
educated. The prevalence of having a degree qualification was 37% (Scottish 
population 33%) and having no qualifications was 5% (Scottish population 33%). The 
average SIMD was 4123 compared to a Scottish population average of 3252. 18% 
were retired compared to a Scottish population average of 15.1%, and 71% were in 
employment compared to a Scottish population average of 62.8%(Smith BH, 2012). 
Nevertheless, the cohort contained significant representation from all the Scottish 
Index of Multiple Deprivation (SIMD) strata.  
 
STRADL participants completed the Composite International Diagnostic Interview -
Short Form (CIDI-SF) (Kessler, 1998). The CIDI-SF is a self-report questionnaire (by 
contrast with the SCID used in GS:SFHS, which is scored by a researcher). The CIDI-
SF is based on DSM-IV (American Psychiatric Association, 2003) criteria for Major 
Depressive Disorder as part of a larger Composite International Diagnostic Interview 
developed by the World Health Organization (Robins et al., 1988). CIDI-SF employs 
two symptomatic screening questions related to low mood or anhedonia, with a 
minimum of four other symptoms requiring endorsement to meet criteria for caseness. 
In the entire STRADL cohort, 16% of respondents met the CIDI-SF criteria for lifetime 
history of MDD (N=1,506) and a further 16% of these individuals reported being 
currently depressed (Navrady et al., 2018). 
 
With regard to psychological measurements, the General Health Questionnaire-28 
(Goldberg and Hillier, 1979), also used in GS:SFHS, was repeated in STRADL. 
Responses were scored using the Likert method (0-3), with higher scores 
representing greater levels of psychological distress. Psychological resilience was 
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scored using the Brief Resilience Scale (Smith et al., 2008). Coping styles employed 
in response to stress (defined and discussed further in Chapter 6) were self-reported 
using the Coping Inventory for Stressful Situations (CISS) (Endler, 1990) which 
categorised coping styles along three distinct scales : task-oriented, emotion-
orientated and avoidance-oriented coping (see Chapter 6 for further details). Self-
report was also obtained of experience of twelve common and threatening life events 
that may have occurred in the previous six months and the contextual response to 
these (List of Threatening Experiences, LTE, (Brugha et al., 1985). 
 
3.4 UK Biobank 
 
UK Biobank (UKB) is a population-based cohort (N=502,682) recruited across the UK 
in 2006-10. UKB consists of adults aged between 40 and 69. UK Biobank was 
recruited by the investigators sending 9,238,453 postal invitations to individuals 
registered with the National Health Service and living within approximately 25 miles 
of one of 22 assessment centres located in England, Wales and Scotland(Fry et al., 
2017). 
 
The average age in UK Biobank was 56.52 years (UK mean age 40.2 in 2019). The 
proportion of females was 54.4% (UK proportion of females 51.2%). The proportion 
unemployed was 6.9% (UK proportion unemployed 2020 4.8%). The proportion with 
college education or above was 47.1% (UK 2018 proportion 49%). The proportion 
with no qualifications was 14.5% (UK 2015 figure 8.4%).  The average Townsend 
Deprivation Index (see below) was -1.29 (UK mean score 0)(Hewitt et al., 2016; 
Zhang et al., 2021). Note that these comparisons are influenced by the age restriction 
in UK Biobank to 40-69. 
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Like GS:SFHS, UKB contains biological, physical, socio-demographic, psychological, 
cognitive and mental health data, much of which was collected by a touch-screen 
questionnaire (Smith et al., 2013b). 
 
In UK Biobank, lifetime history of depression was ascertained using self-reported 
lifetime history of depressive symptoms and contact with mental health services (for 
an overview of the methodology see Smith et al. (2013b).  
 
Neuroticism was assessed using the same Eysenck Personality Questionnaire Short 
Form-Revised (EPQ-SF) (Eysenck, 1985) as also used in GS:SFHS, assessed using 
12 questions administered via touch-screen questionnaire.  
 
Cognitive ability was also measured using a touch-screen questionnaire. This 
consisted of measurements of bespoke indicators of reaction time (mean response 
over 12 trials), verbal-numerical reasoning (number of correct answers within 2 
minutes) and visual memory (number of errors when matching card pairs) (Smith et 
al., 2013b). 
 
Measurement of socio-economic deprivation was also made in UK Biobank, using the 
Townsend Deprivation Index (Townsend, 1987). This consists of a single index of a 
variety of factors (including household overcrowding, unemployment, and non-home 





3.5 Scottish National Prescribing Information System  
 
The Scottish National Prescribing Information System (PIS) is an NHS data system 
which is managed by NHS National Services Scotland (NHS NSS). It is described 
comprehensively in Alvarez-Madrazo et al. “Data Resource Profile : The Scottish 
National Prescribing Information System (PIS)” International Journal of Epidemiology 
(Alvarez-Madrazo et al., 2016).  
 
PIS provides for NHS prescriptions prescribed, dispensed and reimbursed within the 
community (i.e. does not include hospital-dispensed prescriptions). These 
prescriptions are written by a wide variety of practitioners, including General 
Practitioners (GPs), dentists, nurse prescribers, pharmacists, hospital doctors and 
non-medical prescribers.  
 
PIS covers the entire geography of Scotland with its population of 5.3 million people.  
Summary information on reimbursed medicines has been available via PIS since 
1993 but from April 2009 individual-level prescribing and dispensing data is available. 
Data linkage to PIS is made possible through the Community Health Index (CHI) 
number. New prescribing data is uploaded to PIS on a monthly cycle and usually 
made available approximately two months after the prescription was dispensed to the 
patient.  As of 2014, PIS contained records of 507 million individual items prescribed 
and 344 million items dispensed since 2009 (Alvarez-Madrazo et al., 2016).  
 
The availability of fine-grained patient-level data within PIS is described by the CHI 
capture rate, and has attained almost 100% coverage for prescribed and dispensed 
items within PIS, excluding only those who have an invalid CHI number (Alvarez-
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Madrazo et al., 2016). Prescriptions are free in Scotland, and records show that in 
the calendar year 2014 in excess of 70% of men and 85% of women had at least one 
prescription reimbursed.  
 
PIS records a variety of data about each prescription. This includes patient-level data, 
such as the CHI number, age, gender and SIMD socio-economic ranking. Prescriber 
data includes the profession and location where the prescription was written, and 
some demographic data of the associated GP practice if applicable. Dispenser data 
includes the type and geographical location of dispensing practice. Drug/medication 
data includes the approved name of the medication (normally listed using the 
International Non-proprietary Names (INN) standard), product name, formulation and 
strength of medication. Quantity of medication is expressed as the number of tablets 
(for example) supplied and the corresponding World Health Organisation Defined 
Daily Doses (WHO, 2011), a standard for making comparisons of typical daily doses 
within medication types. Each medication is also identifiable and searchable via its 
British National Formulary (Joint Formulary Committee, 2012) structured code.  
 
It is important to state that the indication for medication usage is not recorded in PIS, 
although some basic assumptions can be made using the BNF structured code 
(which differs, for example, when a medication such as duloxetine is used as an 
antidepressant versus being used for urinary incontinence).  
 
In accordance with research information governance procedures, PIS data is 
provided to researchers via the electronic Data Research and Innovation Services 
(eDRIS) using pseudo-anonymised extracts (i.e. CHI numbers replaced by unique 
study numbers and other personal identifiers removed). The specific PIS variables 
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included with the extract are tailored to the individual research project and must be 
specifically justified within the study grant and application to the Privacy Advisory 
Committee (PAC), which oversees the process. The PIS extracts undergo significant 
data cleaning processes, including more than 10 stages of quality checking (Alvarez-
Madrazo et al., 2016) before they are released to researchers for further data 
checking and cleaning. 
 
Over-the-counter (OTC) medication sales are not recorded in PIS, unless the 
medication is supplied in community pharmacies under specific schemes such as the 
Minor Ailments Service (MAS). The vast majority of OTC medications utilised by 
patients are therefore not included in PIS.  
 
3.6 Scottish Morbidity Records 
 
Healthcare data for Scottish NHS patients is collected by Information Services 
Division (ISD) Scotland as a series of Scottish Morbidity Records (SMR) which 
provide a continuum of data from birth to death. In this respect Scotland has some of 
the best health service data in the world, combining high levels of data integrity and 
consistency, nationwide coverage, and ability to securely record-link for research 
purposes (Information Services Division, 2019). Patient-identifiable records of 
hospital discharges, cancer registrations and deaths have been held in central 
systems in Scotland since 1968 and have been further computerised since the 1980s 
(Fleming et al., 2012).  
 
At present there are two main permanently linked data sets held by ISD Scotland: 
(1)the Scottish Morbidity Database, containing records related to non-obstetric 
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hospital contacts plus cancer and death registrations since 1980/81;  and (2)the 
Maternity and Neonatal Linked Database, containing mother and baby records since 
1975.  Records for individual patients are completed and submitted by hospitals and 
NHS boards to ISD Scotland who record-link and securely maintain them. Record-
linkage is performed on the basis of deterministic CHI-linkage and probability 
matching techniques based on surname, full forename and first initial, sex, date of 
birth and postcode (Fleming et al., 2012). Utilising the two techniques prevents errors 
that might arise from using CHI-linkage alone, where problems can be caused by CHI 
mis-coding, or an individual having multiple CHI numbers in error. The methodology 
employed to probabilistically record-link SMR records includes ‘blocking’ whereby 
only those record pairs which share a minimum amount of initial similarity are 
subjected to the matching process (Kendrick, 1997).  
 
SMR01 is an episode-based record of all inpatient and day cases discharged from 
non-psychiatric, non-obstetric hospital wards in Scotland (i.e. acute hospital 
admissions). These records have been available in computerised form since 1968 
but the current SMR01 records are from 1981 to the present. A new record is formed 
each time a patient is discharged from hospital, transferred to a new hospital or a 
different hospital department, or changes consultant responsible for care. Over 1.5 
million records are created annually (Scottish Public Health Observatory, 2019). 
SMR01 is used to plan the financial management of hospitals, but curated releases 
of this data are also available to researchers using CHI-based data linkage. SMR01 
contains information of a clinical and non-clinical nature for each record, including 
duration of admission, admitting department, diagnostic information utilising ICD-10 
coding (World Health Organisation, 2017) (and in older records ICD-9) and details of 
any operations or procedures. The completion of SMR01 records is often delegated 
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to clerical staff who are not routinely supervised by clinicians. As a result, regular 
quality assessments are undertaken by Information Services Division (ISD) Scotland 
to maintain quality assurance of the records.  
 
SMR00 is an episode-based based record of all outpatients receiving care when an 
outpatient clinic is attended (whether in hospital clinic, nurse run clinic or outpatient 
session at the patient’s home). SMR00 contains details of the patient’s identifier (CHI 
based), date of attendance, specialty code of hospital specialty (which includes 
medicine, surgery and psychiatry specialities) and related ICD-10 diagnostic codes.  
 
SMR04 is an episode-based counterpart to SMR01, but detailing inpatients and day 
cases discharged from psychiatric hospitals in Scotland (1981-present). A new record 
is created for any new admission, transfer to another hospital or transfer to new 
consultant. Diagnoses are based on ICD-10 coding and include a list of admission 
diagnoses and discharge diagnoses.  
 
Maternity records are detailed in SMR02 (Scottish Maternity Record) which collects 
data on inpatient and day case discharges within obstetrics and covers 98% of all 
births and pregnancies in Scotland (Scottish Public Health Observatory, 2019) from 
1975 to the present. Birth records detailing all a baby’s neonatal care are included in 
the Scottish Birth Record (SBR) and in its forerunner, SMR11, which operated from 
1975 to 2002.  
 
SMR06 is the Scottish Cancer Registry which contains information about Scottish 
residents diagnosed with tumours (malignant and some benign) from 1980 to the 
present. The registry began in 1956 and since 1997 has been fully electronic, 
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recording details of tumour stage, grade and treatment information as well as 
sociodemographic data.  
 
The Scottish Drug Misuse Database (SDMD, SMR25) is an SMR-related dataset 
which is also curated by ISD Scotland, which provides systematic recording of clients 
seen at services from drug misuse. The database includes diagnostic information 
(ICD-10) for each record, as well as details of related prescriptions, contact with 
services, illicit drug profile, injecting/sharing details and sociodemographic 
information.  
 
Since 1st January 2000, deaths in Scotland have been coded in accordance with ICD-
10 and have been stored in a database of deaths that is available with SMR records.  
 
Access to the data within the Scottish Morbidity Records requires compliance with 
the information and data governance infrastructures of the Scottish NHS, to maintain 
public confidence in secondary use of data. The SMR data is quality assured and 
held in the Information Services Division (ISD) on behalf of NHS Scotland. The ISD 
is a branch of a special Health Board in NHS Scotland, named National Services 
Scotland(NSS). It is in turn regulated by the UK Statistics Authority. Release of data 
must be compliant with legislation including the Data Protections Act(1998), Human 
Rights Act(1998), Freedom of Information Scotland Act (2002) and the General Data 
Protection Regulation (2018)(Murray, 2019).  
 
The Privacy Advisory Committee (PAC) is an advisory committee to the NSS Board 
and Registrar General of Scotland, which is responsible for confidentiality, data 
protection and information governance of SMR. Applications to access the SMR data 
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must go through the PAC. It is an important principal of PAC applications that the 
data requested is justified and is no more than is required to complete the research.  
Once PAC approval has been gained, the ISD will begin to compile and release the 
data. Any further data releases, or requests for additional data, require further 
permissions from the PAC. This can cause some practical difficulties and delays for 
research studies that are looking to take a longitudinal approach, and certainly 
prevents ‘near real time’ data upload as has been developed with CRIS. The ISD also 
requires a period of some months to compile and quality check the SMR data. Annual 
releases of data in a rolling manner became possible in 2019, but any further changes 
require additional PAC approval.  
 
3.7 Concluding Remarks  
 
This chapter has summarised the population-based cohorts and datasets of 
administrative health data that will be utilised in the research chapters to follow. It is 
clear that the Scottish provenance of GS:SFHS and the existence of the Scottish CHI 
number as a basis for linkage provided an unique opportunity for psychiatric linked 
data research, as the forthcoming research chapters will hopefully show. As record-
linkage technology and governance processes develop over time, the potential to 
utilise these methods on other large cohorts and datasets such as UK Biobank, CPRD 






In the following three research chapters, I return to the objectives stated in Chapter 
1, which are to address the following questions :  
1. Are users of psychiatric medications less likely to accurately self-report their 
usage in research studies compared to users of other medications?  
2. Has exposure to antidepressant medications significantly increased in recent 
years and, if so, is this due to a change in how antidepressants are used ?  
3. Is the psychological trait of neuroticism an independent risk factor for the 
MDD-associated outcomes of antidepressant use and self-harm ?  
 
I will begin by addressing the first of these objectives in the next chapter.    
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Chapter 4 : Validating Pharmacoepidemiological Research 
Data using Record-Linkage 
 
4.1 Introductory Remarks  
 
In Chapter 2, we saw that a major potential application of record-linkage to 
administrative health data in psychiatric research is validation. Cohort studies depend 
on complete and accurate ascertainment of potential risk factors and outcomes of 
interest in order to reach meaningful conclusions. For many research variables there 
can be considered a “gold standard” approach which ensures maximum fidelity for 
the research data (such as detailed patient interview by a trained professional or 
exhaustive survey of medical notes) but such methods are often so resource intensive 
to be rendered impractical, particularly for very large studies and/or over large periods 
of time. Resultantly, more practical approaches to phenotyping, such as self-report 
(discussed in Chapters 1 and 2) are often utilised. However, self-report is subject to 
a range of potential biases and researchers need a means to be confident about its 
veracity. 
 
In this chapter I will demonstrate the utility of routinely collected national prescribing 
data for the validation of self-reported medication usage in the cohort GS:SFHS. 
Participants were asked to self-report their regular usage of a number of common 
medication types, including two psychiatric classes (antidepressants and mood 
stabilizers) which are commonly used in major depression and other affective 
disorders. Concerns have been raised about the quality of self-report of medications 
in general (potentially due to factors such as participant recall errors) and psychiatric 
medications in particular (potentially due to factors such as respondent bias and self-
stigma) (Van den Brandt et al., 1991; Cotterchio et al., 1999; Knudsen, 2002). The 
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ability to link the participants of GS:SFHS to national prescribing data via the 
Prescribing Information System (PIS) provided a significant opportunity to validate 
the medication self-report, using prescribing data as the ‘gold standard’. 
 
The following chapter has been published in the Journal of Clinical Epidemiology 
(Hafferty et al., 2018). As the first author of the publication I jointly conceived the 
study, performed the analysis, wrote the manuscript and prepared all the tables and 
figures. To acknowledge the contribution of the co-authors (see also Publications 
section of this thesis for breakdown of author contributions) the term “we” rather than 
“I” is used throughout this chapter.  
 
 
4.2  Paper:  Self-Reported Medication Use Validated Through Record 







Researchers need to be confident about the reliability of epidemiological studies that 
quantify medication use through self-report. Some evidence suggests that psychiatric 
medications are systemically under-reported. Modern record linkage enables 
validation of self-report with national prescribing data as gold standard. Here, we 





4.3.2 Study Design and Setting 
 
Participants in the Generation Scotland population-based cohort (N=10,244) 
recruited 2009-11 self-reported regular usage of several commonly prescribed 
medication classes. This was matched against Scottish NHS prescriptions data using 
three- and six-month fixed time windows. Potential predictors of discordant self-
report, including general intelligence and psychological distress, were studied via 




Antidepressants self-report showed very good agreement (k=0.85, (95% Confidence 
Interval (CI) 0.84-0.87)), comparable to antihypertensives (k=0.90, (0.89-0.91)). Self-
report of mood stabilizers showed moderate-poor agreement (k=0.42 CI 0.33-0.50). 
Relevant past medical history was the strongest predictor of self-report sensitivity, 




In this large population-based study, we found self-report validity varied among 
medication classes, with no simple relationship between psychiatric medication and 
under-reporting. History of indicated illness predicted more accurate self-report, for 
both psychiatric and non-psychiatric medications. Although other patient-level factors 
influenced self-report for some medications, none predicted greater accuracy across 
all medications studied. 
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4.3.5 What is New In This Study  
 
• Self-reported medication use shows high validity in the general population 
although there is variation between medication classes. 
• A simple relationship between psychiatric medications and under-reporting 
was not found. Mood stabilizers show moderate-poor agreement, due to 
both under-report and false positives, whereas antidepressant reporting is 
comparable to other long-term non-psychiatric medications.  
• Medical history of an indicated health condition is the strongest predictor of 
accurate report. General intelligence was not associated with the accuracy 
of reporting. 
• Medication-related factors such as range of indications, prescribing cycles, 
and phrasing of self-report question may also influence accuracy of self-
report.  
• When matching self-report to prescribing data, longer fixed time windows 
produce higher levels of agreement and positive predictive values, at the 
expense of some loss of sensitivity.  
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4.4 Introduction  
 
Cohort studies, and other epidemiological studies using self-reported data, depend 
on the accuracy of the self-report to make accurate and reliable conclusions. This 
includes pharmaco-epidemiological and large-scale biobanking studies which are 
based on self-reported medication use. Self-reported medication use can be 
determined by questionnaire (Lokkegaard et al., 2004; Rauma et al., 2013); by 
telephone or internet survey (West et al., 1995); or by face-to-face interview (Nielsen 
et al., 2008; Goodman et al., 1990; Sjahid et al., 1998; Norell et al., 1998). However, 
self-report is subject to recall errors and biases (Klungel et al., 2000; Cotterchio et al., 
1999) and patients may be less willing to disclose details of certain medications than 
others.  
 
The accuracy of self-report can be verified by comparison to a trusted measure or 
“gold standard”. For medication utilization, the choice of gold standard depends to an 
extent on the purpose of the study (i.e. estimating patient adherence, or monitoring 
prescribing behaviour of clinicians), and there is therefore no universally applicable 
and accepted gold standard (Kwon A, 2003) (Klungel et al., 1999). One option is for 
a third party to perform a home inventory (Lau et al., 1997) or record individual 
medications produced by the patient (Caskie et al., 2006), but these assessments are 
difficult to perform on a large scale. An alternative is to compare self-report data to 
prescriptions, healthcare insurance claims, or general practice medical records 
(Goodman et al., 1990; Monster et al., 2002; Nielsen et al., 2008; Klungel et al., 1999).  
Prescribing databases have been shown to be highly accurate in recording 
medication utilization (Tamblyn et al., 1995), at least for those medications that 
require prescriptions.  
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Among published studies comparing medication self-report to prescribing data, the 
majority have been relatively small in size (Nielsen et al., 2008; Caskie et al., 2006; 
Haukka et al., 2007; Lau et al., 1997; Saunders et al., 1998; Jain et al., 1999; Klungel 
et al., 1999; Kwon A, 2003; Norell et al., 1998; Sjahid et al., 1998). Many studies are 
restricted to certain medications or medication types, such as antihypertensives 
(Klungel et al., 1999); cardiovascular drugs (Sjahid et al., 1998);  antidepressants 
(Saunders et al., 1998), or hormone replacement therapy (Lokkegaard et al., 2004); 
or to special populations, such as the elderly (Lau et al., 1997; Sjahid et al., 1998; 
Tamblyn et al., 1995); postmenopausal women (Goodman et al., 1990; Rauma et al., 
2013); or psychiatric illnesses (Haukka et al., 2007). Few studies utilize large 
population-based samples (Monster et al., 2002; Nielsen et al., 2008; Caskie et al., 
2006; Haapea et al., 2010) or multiple disparate medication types (Caskie et al., 2006; 
Haapea et al., 2010; Noize et al., 2009; Richardson et al., 2013). Such comparisons 
are important, however, for they enable study of systematic over- and under-reporting 
of medication utilization between drug classes. 
 
Self-report can be compromised by a number of factors, including not understanding 
the question, poor recall, and intended non-disclosure (Nielsen et al., 2008). There is 
no consensus on patient-level factors predisposing to discordance between 
medication self-report and gold standard measures, but previous reports have 
implicated advancing age (Cotterchio et al., 1999; Haapea et al., 2010), being 
unmarried (Haapea et al., 2010; Richardson et al., 2013),  number of medications 
regularly dispensed (Van den Brandt et al., 1991; Jain et al., 1999), suffering poor 
health (Haapea et al., 2010), and lower educational attainment (Richardson et al., 
2013). Within medication classes, there is some evidence that psychiatric 
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medications are less likely to be accurately self-reported (Haapea et al., 2010; Van 
den Brandt et al., 1991). Potential explanations for this include confusion regarding 
medication indication but also non-disclosure due to social desirability bias 
(Cotterchio et al., 1999) or self-stigmatization (Knudsen, 2002; Nielsen et al., 2008; 
Rauma et al., 2013; Kwon A, 2003).  Factors that have not to date been found to 
influence reporting include gender (Richardson et al., 2013; Haapea et al., 2010) and 
cognitive health (Richardson et al., 2013). 
 
Prescribing data can be sourced from local health providers or insurers (Kwon A, 
2003), pharmacy records (Caskie et al., 2006; Monster et al., 2002; Saunders et al., 
1998; Klungel et al., 1999; Sjahid et al., 1998; Richardson et al., 2013), social 
insurance databases (Haukka et al., 2007; Haapea et al., 2010) or national health 
service databases (Nielsen et al., 2008; Rauma et al., 2013; Lokkegaard et al., 2004). 
The recording of the dispensing and collection of medication, as well as its 
prescribing, is important for studies that seek to measure patient utilization (although 
even collection of a medication is not a hard indicator of usage). The country of origin 
of the study, and respective prescription legislation, dispensing and reimbursement 
practices, are also relevant to interpreting self-report against prescribing data (for 
example, over-the-counter medications may not appear in this data), and to making 
comparisons between national studies.  
 
In this study, we sought to ascertain agreement between medication self-report, 
derived from a large UK cohort study, compared to record-linked national prescribing 
data as gold standard, across a range of commonly used psychiatric and non-
psychiatric medications. We hypothesised that agreement would be lower for 
psychiatric medication types, due to systemic under-reporting. To our knowledge this 
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is one of the largest population-based studies of medication self-report also 
incorporating a covariate analysis method across a range of medications.  
 
4.5 Method 
4.5.1 Study Population 
Our study utilized the Generation Scotland: Scottish Family Health Study (GS:SFHS) 
family- and population-based cohort of Scottish adult volunteers (n=21,474), recruited 
February 2006-March 2011, which has been described elsewhere(Smith et al., 2006; 
Smith et al., 2013a). The cohort has a higher proportion of females (59%) and older 
median age (47 males: 48 females) than the Scottish population at the 2001 census 
(37 and 39 respectively) (Smith BH, 2012; Smith et al., 2013a).  Written informed 
consent was obtained for 98% of GS:SFHS for data linkage to routinely collected 
healthcare records.  
4.5.2 Medication Self Report Data 
 
All participants in GS:SFHS were asked to complete a pre-clinic questionnaire prior 
to their enrolment in the study. The first phase of the study used a text-based 
questionnaire which is not part of this analysis. Those individuals recruited between 
June 2009 – March 2011 (n=10,980, 59.5% female) completed a coded questionnaire 
where the Medications section was a “Yes” versus “No” checkbox, with the 
accompanying question “Are you regularly taking any of the following medications?”. 
The available options were: (1) “Cholesterol lowering medication (e.g. Simvastatin)” 
(2) “Blood pressure lowering medication” (3) “Insulin” (4) “Hormone replacement 
therapy” (5) “Oral contraceptive pill or mini pill” (6) “Aspirin”  (7)“Antidepressants” 
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(8)“Mood stabilizers”. The completed questionnaires were then machine read and 
electronically recorded using anonymised patient linkers.  
 
4.5.3 Additional Covariate Data 
 
Additional sociodemographic information collected in the questionnaire included 
gender, age, educational attainment, smoking status and relationship status. 
Compared to the rest of GS:SFHS, our sample was moderately older and contained 
more individuals with no school qualifications and also more degree level educated 
individuals (Table 4.1, Figure 4.1). Lifetime history of affective disorder (major 
depression and bipolar disorder) was obtained using the Structured Clinical Interview 
for DSM-IV Disorders (SCID) (Smith et al., 2013a). Self-reported history of 
hypertension, heart disease and diabetes was recorded.  
 
In addition, during the GS interview a variety of cognitive tests were performed (Smith 
et al., 2006). including (1) Digit Symbol Coding substitution task from the Wechsler 
Adult Intelligence Scale III (Wechsler D, 1998b),a screening instrument for 
neuropsychological dysfunction and processing speed with impairment of 
contributing ability yielding a low score (max score 133, typical range 24-116)(Habota 
et al., 2019);   (2) Logical memory from the Wechsler Memory Scale III (Wechsler D, 
1998a) which measures immediate and delayed recall of one paragraph (max score 
for combined test 50, typical range 9-48); (3) Mill-Hill Vocabulary Test (maximum 
score 44, typical range 16-44) which is used as a measure of acquired verbal 
intelligence; (4) Controlled Oral Word Association task(Verbal Fluency Test) which 
measures executive function through word generation using letters C, F and L each 
for one minute (no maximum score, typical range 12-88) (Lezak MD, 1995).  
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From these tests, we derived a measure of general intelligence (g) as the first un-
rotated principle component, explaining 44% of the variance in scores (Navrady LB, 
2017; Marioni et al., 2014). The loadings for processing speed, vocabulary, verbal 
declarative memory and executive function on the first principal component were 
0.44, 0.53, 0.49 and 0.54 respectively. The range of g in the cohort was -4.48 to 8.92, 
mean 0.0, standard deviation 1.28.  Psychological distress was measured using the 
General Health Questionnaire-28 (Likert scoring, maximum score 84) (Goldberg and 
Hillier, 1979). 
 
4.5.4 Prescribing Data and Linkage 
 
All Scottish citizens registered with a General Practitioner (more than 96% of the 
population) are assigned a unique identifier (Community Health Index (CHI) number). 
This was employed to record link GS:SFHS questionnaire data to the national 
Prescribing Information System (PIS) administered by NHS Services Scotland 
Information Services Division (Alvarez-Madrazo et al., 2016). PIS is a database of all 
Scottish NHS prescriptions for payments for medications prescribed by GPs; nurses; 
dentists; pharmacists; and hospitals where the medication was dispensed in the 
community. There is no prescription charge in Scotland.  Hospital dispensed 
prescriptions and over-the-counter medications are not included. Patient level data 
has been available in PIS since April 2009 (Information Services Division, 2014). We 
obtained PIS prescribing data for April 2009-March 2011. We used the dates of 






Figure 4.1.  Flowchart of derivation of study population, and subset used in logistic 
regression analysis, from the Generation Scotland cohort.  
 
Abbreviations :  GS = Generation Scotland; PIS = Prescribing Information System; CHI = Community Health Index
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Table 4.1.  Socio-demographic, clinical and cognitive characteristics of study populations compared to whole Generation Scotland cohort.  
      
 GS:SFHS   
(N=21474) 
 
 Individuals in the current 
study 
(N=10244) 
 Subset of individuals in current study used in complete case 
multivariate logistic regression analysis (N=9043) 
 
Female 12674 (59.02%)  6065 (59.21%)  5329 (58.9%) 
Age 18-39 6769 (31.52%)  3072(29.99%) †  2797(30.93%) ‡ 
Age 40-64 12346 (57.49%)  6015 (58.72%) †  5304(58.65%) 
Age 65-99 2359 (10.99%)  1157(11.29%)  942(10.42%) 
Affective Disorder (SCID) 2848 (13.26%)  1329 (12.97%)  1159 (12.82%) 
Diabetes (Self-Report) 659 (3.07%)  323 (3.15%)  277 (3.06%) 
Hypertension(Self-
Report) 
2836 (13.21%)  1297 (12.66%) †  1125 (12.44%) 
Cardiac Disease(Self-
Report) 
777 (3.62%)  345 (3.37%) †  284 (3.14%) ‡ 
No School Certificate 2452 (11.42%)  1432 (13.98%) †  1296 (14.33%) ‡ 
Postgraduate Education 6323 (29.44%)  3273 (31.95%) †  3164 (34.99%) ‡ 
Smoker 3662 (17.05%)  1733 (16.92%)  1484 (16.41%) ‡ 
Relationship Status – 
Single 
6720 (31.29%)  3236 (31.59%)  2866 (31.69%) ‡ 
      
GHQ Likert Score 16 (8.87)  15.73 (8.74) †  15.66 (8.69) ‡ 
Wechsler Logical 
Memory Test I &II 
30.7 (8.48)  30.95(8.15)  31.17 (8.05) ‡ 
Mill-Hill Vocabulary Test 30.06 (4.76)  30.09 (4.66)  30.23 (4.62) ‡ 
Wechsler Digit Symbol 
Substitution Task 
72.23 (17.22)  71.71 (17.15) †  72.52 (16.88) ‡ 
Verbal Fluency Test 39.71 (11.72)  39.89 (11.70) †  40.22 (11.65) ‡ 
 
Abbreviations: GS:SFHS, Generation Scotland : Scottish Family Health Study. GHQ, General Health Questionnaire.  
All values are totals with percentages, unless shown in italics where they are means with standard deviations in parentheses. 
† = Significant differences (alpha=0.05) between Generation Scotland and Study Population as determined by Chi square / t tests.  
‡ = Significant differences (alpha=0.05) between Study Population and subset used in multivariate logistic regression analysis as determined by Chi square / t tests. 
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4.5.5 Matching Prescribing to Self-Report 
 
For each individual and medication type, concordance with GS:SFHS self-report was 
checked against PIS prescribing record dispensing dates within a “fixed time window” 
(Nielsen et al., 2008; Rauma et al., 2013; Monster et al., 2002; Haukka et al., 2007) 
including the month of questionnaire completion, and two months preceding (total 
three months), and also five months preceding (total six months). The majority of 
prescriptions, including in Scotland, are dispensed in quantities of 90 days duration 
or less (Reid I, 2012; Caskie et al., 2006). A previous Dutch study (Lau et al., 1997) 
also found that fixed time windows shorter than 90 days are less sensitive, although 
the generalizability of this finding is uncertain. Accordingly, we employed two fixed 
time windows, three- and six-months duration, in order to assess their relative 
benefits in terms of agreement, sensitivity and positive predictive value.  
 
To ensure all individuals had at least six months of potentially available prescribing 
records, we restricted analysis to GS:SFHS participants who had completed their 
medication questionnaire in September 2009 or later. This equated to 10,244 
participants (6065 females and 4179 males) enrolled September 2009-March 2011 
(Table 4.1, Figure 4.1). Of these, 96.5% had medication records available (the 
remainder were presumably not using prescribed medication) which compared to 
95.6% for the whole GS cohort.  
 
The PIS data allows medications to be identified by approved drug name and/or 
associated British National Formulary (Joint Formulary Committee, 2012) paragraph 
code. Medication indication is not recorded. Our matching criterion for each 
medication type is detailed in Table 4.2.  
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Table 4.2: Matching and exclusion criteria used for prescribing database searches. 
Self-Reported Medication Matching criteria used in PIS Exclusion criteria  
Cholesterol lowering medication 
(e.g. simvastatin) 
BNF Paragraph code “212000”.  
Antihypertensives BNF Paragraph codes “205051” 
(ACE inhibitors); “205052” 
(Angiotensin II antagonists); 
“204000” (beta blockers); “206020” 
(calcium channel blockers); 
“202010” (thiazides and 
aldosterone antagonists); “202020” 
(loop diuretics); “202030” 
(potassium sparing diuretics); 
“205040” (alpha adrenoceptor 
blocking drugs); “202040” 
(combined K sparing diuretics); 
“205010” (vasodilator 
antihypertensive drugs); “205020” 
(centrally acting hypertensives); 
“205053” (renin inhibitors) 




hydrochloride with bumetanide”, 
“co-amilofruse”, “triamterene with 
furosemide”, “sildenafil”, “clonidine 
hydrochloride”    [These 
medications are not specifically 
indicated for hypertension] 
Insulin BNF Paragraph codes “601011” 
and “601012” 
 
Hormone replacement therapy  BNF Paragraph codes “604011”  
Oral contraceptive pill or mini pill  BNF Paragraph codes containing 
“^7030*” 
BNF Paragraph codes “703050” 
(emergency contraceptives); 
“703040” (spermicidals); “703030” 
(contraceptive devices) 
Aspirin Prescribable Item Approved Name 
containing “aspirin” 
Formulations containing aspirin as 
additional ingredient  
Antidepressants BNF Paragraph codes containing 




serotonin reuptake inhibitors) and 
“403040”(other antidepressant 
drugs). 
Records containing: “amitriptyline” 
[An antidepressant which is no 
longer commonly prescribed for 
depression in the UK and which is 
often used short-term for other 
indications]  
Mood stabilizers  Prescribable Item Approved Name 










4.5.6 Missing Data 
 
The self-report questionnaire employed a ‘Yes’/’No’ checkbox, but some individuals 
ticked neither box (or data was otherwise missing, Table 4.3). In our main analysis 
we treated each medication separately, excluding the missing self-report values for 
each case. However, to mitigate the potential of hereby introducing biases, or not 
accounting for individuals who intended to deny medication use by leaving the section 
blank, we conducted two additional analyses – one with all individuals with any 
missing data excluded (n=7836), and the other with missing data coded as denial of 
medication use (Table 4.5).  
 
 
4.5.7 Statistical Analysis 
 
All analyses were carried out using R version 3.2.3 (R Core Team, 2015). Level of 
agreement between self-report and prescribing data was ascertained using Cohen’s 
kappa (k) method of rating inter-observer variation (Cohen, 1960).  Kappa scores of 
<0.40 were considered fair to poor; 0.41-0.60 moderate; 0.61-0.8 substantial; and 
>0.81 good or better (Viera and Garrett, 2005; Landis JR, 1977). We also calculated 
sensitivity, specificity and positive predictive values (PPV). Ninety five percent 
confidence intervals (CI) were included.  
 
We performed multivariable logistic regression analysis on predictors of false 
negative self-report compared to true positive (sensitivity). Due to some covariate 
missing data, the sample size of this analysis was reduced to 9043 for complete case 
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analysis (Table 4.1, Figure 4.1). Odds ratios with 95% CI were calculated. Multiple 
testing was adjusted for using the False Discovery Rate method with significance 
level (alpha) 0.05. As Generation Scotland is a partly family-based cohort, we 
adjusted for any correlation due to family relatedness using the Generalized 




Of the 10,244 individuals in the study, 6164 (60.17%) ticked ‘No’ to every medication 
question (Figure 4.1). In addition, 485 (4.74%) left blank or had missing data for every 
question. The proportion of completed responses differed between medications and 
was greatest for antihypertensives (86.44%) and lowest for mood stabilizers (77.87%, 
χ2 =256.07, p<2.2x10-16) (Table 4.3). The most commonly prescribed medication (six-
month window) was antihypertensives, prevalence 19.05%, whereas antidepressants 
prevalence was 12.22% and mood stabilizers 1.32%. The prevalence of lifetime 
history of affective disorder in our sample was 12.66% (n=1297) for major depressive 
disorder and 0.31% for bipolar disorder (n=32).  The self-reported prevalence of 
hypertension was 12.66% (n=1297), heart disease 3.37% (n=345) and diabetes 
3.15% (n=323) (Table 4.1)
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Table 4.3. Medication self-report and prescribing data prevalences, agreements, sensitivities, specificities and positive predictive values, measured on 
two fixed time windows – 3 months and 6 months duration respectively – in the current study (n=10,244, including 6065 females) 
     
3 MONTH FIXED TIME WINDOW 
 

















to PIS (%)* 
 
Agreement 


























Antidepressant**  8333 
(81.35) 

















Mood stabilizer *** 7977 
(77.87) 

































































































































HRT (female only) *4794 
(79.04) 




















































Abbreviations :  PIS, Prescribing Information System.    HRT, Hormone Replacement Therapy 
* Six month time window employed  
** Note that a broader definition of antidepressant than that shown in table, which included amitriptyline, returned an agreement of k=0.83(0.81-0.85) at six month time window with sensitivity of 0.75(0.73-0.78) 
*** Note that a narrower definition of mood stabilizer than that shown in table, which comprised only lithium, sodium valproate, lamotrigine and carbamazepine, returned an agreement of k=0.29(0.20-0.38) at 




Figure 4.2.  Agreement and Validity of Medication Self-Report Compared With 
Prescribing Data As Gold Standard Using Three And Six Month Fixed Time Windows, 
With 95% Confidence Intervals  
 







4.6.1 Agreement and Validity 
 
Agreement (Table 4.3, Figure 4.2) between medication self-report and prescribing 
data was generally very good across medication classes. Greatest agreement was 
found for cholesterol lowering medication (k=0.95, CI 0.94-0.96) (6-month fixed time 
window unless otherwise stated). Agreement for antidepressants (k=0.85, CI 0.84-
0.87) was lower than antihypertensives (k=0.90, CI 0.89-0.91) but still within the 
highest kappa banding of >0.81. By contrast, agreement for mood stabilizers was 
moderate-poor (k=0.42, CI 0.33-0.50). Comparing the six-month fixed time window 
to three-month, k scores were higher, although only to a degree beyond 95% 
confidence intervals in the case of HRT and oral contraceptives.  
 
Self-report sensitivity (Table 4.3, Figure 4.2) was slightly reduced in the six-month 
time window versus three-month, but was still greater than 0.80 for all medications 
except mood stabilizers. Antidepressant sensitivity (0.85, CI 0.82-0.87) was 
comparable to antihypertensives (0.86, CI 0.85-0.88). Sensitivity for mood stabilizers 
was comparatively poor (0.40, CI 0.31-0.50) indicating a high rate of false negatives.  
 
The positive predictive value (Table 4.3, Figure 4.2) for antidepressant use (0.89, CI 
0.87-0.91) was substantial, albeit less than antihypertensives and cholesterol 
lowering drugs, and contrasted with modest PPV for mood stabilizers (0.45 CI 0.35-
0.56). The six-month fixed time window significantly improved PPV for most 
medication groups, with greatest effect for HRT and oral contraceptives (which 




4.6.2 Predictors of Failure To Self-Report Medication Usage 
 
Multivariable logistic regression (Table 4.4) found no covariates universally 
associated, across all medications, with failure to self-report medication usage, as 
determined by the prescribing data gold standard. General intelligence (g) was not 
associated with increased false negatives for any medication. Psychological distress 
(GHQ) reduced odds of false negatives for antidepressants (OR 0.98, CI 0.96-1.00, 
pFDR 0.081) and mood stabilizers (OR 0.96 CI 0.91-1.01, pFDR 0.197), but this 
relationship was not significant for multiple testing.  
 
There was reduced discordant self-reporting for several medications if the patient had 
a history of an illness for which that medication was indicated, such as affective 
disorder and mood stabilisers (OR 0.09, CI 0.02-0.35 pFDR 0.005), and hypertension 
and antihypertensives (OR 0.04, CI 0.02-0.06 pFDR>0.001). Similar associations were 
found for affective disorder and antidepressants, and cardiac disease and aspirin, 
with p values of <0.1 after correcting for multiple testing.  
 
Age and gender showed no consistent association, although older age was 
associated with lower false negatives for antihypertensives, antidepressants and 
possibly aspirin (pFDR 0.074), and female gender was associated with increased false 







Table 4.4.  Odds Ratios (with 95% Confidence Intervals) For Factors Associated With Failure 














































































































































































































       
 
Significant associations are shown in bold (alpha=0.05 and adjusted for multiple testing by False Discovery Rate 
method) and near-significant associations (alpha <0.10) are shown in italics.  
The following factors were used as controls and do not appear in the table : male sex; age 18-39; secondary 
school education only; no affective disorder found on SCID; no history of self- reported high blood pressure/heart 
disease/diabetes; smoking status –never smoked; relationship status –single. 
Insulin and hormone replacement therapy (HRT) are not shown in the table as no significant associations with 












4.6.3 Influence of Missing Data 
 
Recoding missing data as negative self-report (Table 4.5) resulted in somewhat lower 
levels of agreement and lower sensitivities for all medications. However, agreement 
remained good for antidepressants (k=0.81 CI 0.79-0.83) and poor for mood 
stabilisers (0.34 CI 0.26-0.41). There was a demonstrable reduction in sensitivity for 
antidepressants (0.78 CI 0.75-0.80) but this reduction was not confined to psychiatric 

















Table 4.5.   
Comparison of Agreement (Cohen’s kappa), Sensitivity and Positive Predictive Value with prescribing data for 
study population with:  
(A) missing self-report medication data recoded as medication denied  
(B) all records with any missing self-report medication data excluded  
 A. All missing data recoded as medication 
denied, Six-month fixed time window 
(N=10,244) 
B. Complete cases analysis with all missing data of 
medication responses excluded, Six-month fixed 
time window 












      



































































































4.7 Discussion  
 
In this population-based cohort, we found substantial to very good agreement 
between medication self-report and electronic prescribing records, for most 
medications studied. We hypothesised that psychiatric medications would show less 
agreement and systematic under-reporting. Agreement for mood stabilizers was 
indeed considerably worse, although we found evidence of both under- and over-
reporting (false positives). However, for antidepressants the agreement, sensitivity 
and PPV were broadly comparable to other medications studied. We did not identify 
any generalizable single predictors of failure to self-report prescribed medications, for 
psychiatric medications or for medications generally. However, past medical history 
of an indicated health condition showed the strongest effect in promoting self-report 
accuracy across classes, and this was also true for psychiatric medications.  
 
In general, the six-month fixed time window outperformed the three-month for 
agreement and PPV, at the expense of modest loss of sensitivity. This was most 
evident for HRT and oral contraceptives in women, which could imply these 
medications are dispensed in longer time cycles, and require longer fixed time 
windows, relative to other medications.  
 
4.7.1 Predictors of Discordant Self-Report 
 
We found that a medical history of an indicated health condition for a given 
medication, such as affective disorder for mood stabilizers, or hypertension for 
antihypertensives, reduced the odds of false negatives. If systematic under-reporting 
of psychiatric medications due to self-stigma was taking place, we might have 
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expected to find the reverse. Relationship status and educational status did not 
predict discordance, except in the case of mood stabilizers where lack of school 
qualifications was associated with false negative reporting. This could indicate 
reduced understanding of the definition of “mood stabilizer” among the less educated. 
It might also represent association between lesser educational achievement and use 
of medications (such as antipsychotics) included in our definition of mood stabilizers.  
 
We found that general intelligence (g) did not influence concordance of medication 
self-report with prescribing data, which to our knowledge has not been previously 
reported. We also believe we are the first to investigate psychological distress and 
medication self-report. Interestingly, while psychological distress might be posited as 
a potential factor in under-reporting psychiatric medications (e.g. through self-stigma), 
we found some evidence of a relationship between the increased GHQ score and 
greater sensitivity of self-reporting of antidepressants (p<0.1). Gender was not 
generally associated with accuracy, except in the case of antihypertensives, where 
increased odds of false negatives (OR 1.75 CI 1.16-2.62) were found, perhaps 
indicating greater usage of these medication types for non-antihypertensive purposes 
among females. 
 
4.7.2 Questionnaire Phrasing  
 
One possible explanation for the poor agreement, sensitivity and PPV for mood 
stabilizers is confusion among questionnaire respondents about the meaning of 
“mood stabilizer”. There is no consensus definition of mood stabilizer among 
clinicians (Bauer and Mitchner, 2004) and laypersons may therefore be unsure as to 
its meaning. Klungel et al. (2000) have previously reported that sensitivity of 
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medication self-report is influenced by the specificity of question phrasing. In our 
matching to prescribing data we employed a broad definition of mood stabilizers, but 
when a narrower definition (excluding antipsychotics) was employed the agreement 
was even worse (k=0.29, CI 0.20-0.38).  
 
4.7.3 Comparison with Other Studies 
 
Table 4.6 describes the agreement of this present study, using the 6-month fixed time 
window, with other large published studies. We report a higher level of agreement 
(k=0.86) for antidepressants than Nielsen (k=0.66) (Nielsen et al., 2008), Rauma 
(k=0.65) (Rauma et al., 2013) and Noize (k=0.81) (Noize et al., 2009). When making 
comparisons with studies performed in other healthcare systems, it is important to 
recognise the variations between countries in prescribing legislation and access to 
medication. Scotland has a national health system, with no prescription charges, and 
prescribing data is collated nationally, which might explain a higher concordance with 












Table 4.6.  Comparison of Study Results With Other Published Studies Of Similar 
Methodology (Fixed Time Window). 
Study and method  Medication Kappa 
(95% CI) 
Sensitivity Specificity PPV 














Nielsen et al (2008) (n=16,688) 
Interview based Danish nationally 
representative survey compared 
with national prescription records. 
Age 16+. 90-day time window (and 





   
Caskie et al (2006) (n=1430) 
Longitudinal USA population 
based study ages 23-97 years. 
Comparison of medication “brown 
bag” interview with pharmacy 
prescription records (4 fixed month 
time window).  
Antidepressants   0.86   
Rauma et al (2013) (n=11031) 
Postal questionnaire of 
postmenopausal Finnish women 
(age 58-67, mean age 62.3) 
compared to national prescription 
register, 4 month fixed time 
window  (also 12 month fixed time 
window – not shown) 
Antidepressants  0.65 0.55 0.99  
Haapea et al (2010) (n=7625) Postal 
questionnaire of Finnish birth 
cohort (all born 1966, data 
collected 1997) compared with 
register of social insurance 
institution, 6-month fixed time 
window 




   
Richardson et al (2013) (n=2621) 
Irish Longitudinal Study on ageing. 
50 years’ age and older community 
dwelling population compared with 
pharmacy dispensing records, 6-
month fixed time window  
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Noize et al (2009) (n=4112) French 
older adult (65 years+) cohort 
study comparing questionnaire to 
national health insurance system, 
60-day fixed time window (also 30 
day – not shown) 










Haukka et al (2007) (n=905) Finnish 
population based genetic study of 
schizophrenia of which 422 had 
schizophrenia or bipolar disorder. 
Age range 30-65. Participants were 
interviewed about their medication 
and compared to social insurance 
prescription database. 180-day 
fixed time window. 
Antidepressants  0.77    
Study and method  Medication Kappa 
(95% CI) 
Sensitivity Specificity PPV 

























   




   
Rauma et al (2013) Other psychoactive 
medication 
0.30 0.29 0.97  
Haapea et al (2010) Antipsychotics  0.77 
(0.69-
0.85) 
   














   
      
 
 
Study and method  Medication Kappa 
(95% CI) 
Sensitivity Specificity PPV 
Current Study 6 Month Fixed Time 
Window 














Monster et al (2002) Oral contraceptives 0.65 0.80  0.64 
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Study and method  Medication Kappa 
(95% CI) 
Sensitivity Specificity PPV 

















Monster et al (2002) (n=8592) 
Questionnaire from Netherlands 
population based study (ages 
28-75 years, mean 49.5) 
compared with pharmacy data 1 
year fixed time window 
Lipid lowering drugs 0.81 0.85  0.79 





   











      




















   




 0.89 – 0.95   
Monster et al (2002) Antihypertensives 0.69 0.89  0.62 
Haapea et al (2010) Beta blocking agents  0.55 (0.46-
0.64) 
   
Richardson et al (2013) Beta blocking agents, 
Calcium channel 
blockers, Diuretics  
0.77 (0.73-
0.81) –  
0.80 (0.76-
0.84) 
   









Sjahid et al (1998) (n=1682) 
Dutch cohort study of older 
adults (age 55+), patient 
interview compared with 
pharmacy records, 6 month fixed 
time window  
Beta blocking agents, 
Calcium channel 
blockers, Diuretics 
0.90-0.97    
Rauma et al (2013) (n=11031) 
Postal questionnaire of 
postmenopausal Finnish women 
(age 58-67, mean age 62.3) 
compared to national 
prescription register, 4 month 
fixed time window  (also 12 
month fixed time window – not 
shown) 
Diuretics  0.82 0.83 0.98  
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Study and method  Medication Kappa 
(95% CI) 
Sensitivity Specificity PPV 















Nielsen et al (2008)   Antithrombotic agents 0.75 (0.70-
0.80)  
 
   
Caskie et al (2006) Salicylates  0.40   
Richardson et al (2013) Antithrombotic agents 0.72 (0.68-
0.76) 
 
   
      




















   
Caskie et al (2006) Diabetic agents  0.97   
Haapea et al (2010) Antidiabetics 0.92 (0.87-
0.97) 
   





   












      























   
Caskie et al (2006) Oestrogens   0.82   
Monster et al (2002) Hormone 
replacement therapy 
0.49 0.60  0.46 
Lokkegard et al (2004) 
Questionnaire to Danish nurses 
(n=2666) compared to 
administrative national health 
service prescribing databases 
(time window up to 9 years, non-
fixed) 
Hormone 










Kwon (2003) compared survey antidepressant self-report in a longitudinal depression 
study (n=164) with pharmacy claims data and a three-month fixed window and found 
substantial levels of agreement (k=0.69). Interestingly, where there were 
discrepancies in prescription record antidepressant use, they found on notes review 
that most cases could be explained by antidepressants being used for other 
indications, or due to recent discontinuation. In our study, we attempted to minimise 
the rate of antidepressant false positives due to other indications by excluding 
amitriptyline from our searches (amitriptyline is widely prescribed but now rarely for 
depression in the UK).  
 
With regard to mood stabilizers, a recent study comparing self-reported medication 
use in a genetic study of schizophrenia (n=905) (Haukka et al., 2007) found 
substantial levels of agreement (k=0.74) between self-report of mood stabilizers and 
an administrative prescription database. This is a much higher level of agreement 
than found in our study, although we note that Haukka’s was not a community-based 
sample and had a much higher prevalence of mood stabilizer use. A comparison of a 
postal medication survey (n=11,031) with national prescription records reported by 
Rauma et al. (2013) found substantial levels of agreement for antidepressant 
reporting (k=0.65) but poor agreement (k=0.30) for other psychoactive medications, 







4.7.4 Study Strengths and Weaknesses  
 
Our study used a large (n=10,244) population-based cohort linked to high fidelity 
Scottish PIS records (capture rate in excess of 95%) (Information Services Division, 
2014). PIS collates data for the whole of Scotland and is therefore a comprehensive 
and ‘closed’ pharmacy recording system which also allows measurement of refills at 
several points in time. Such closed pharmacy systems enable measurement of the 
rate of refilling prescriptions which in turn gives an accurate measure of overall patient 
adherence, because the risk of patients obtaining refills elsewhere is greatly 
reduced(Osterberg and Blaschke, 2005). Self-report of medication use was via a 
short, simply worded questionnaire which obviated interviewer bias and did not 
require long-term recall of medication use. Response rate was high. We employed a 
variety of methods to compare the two data sources over two fixed time windows and 
performed covariate analysis of predictors of discordant self-report.  
 
However, our method of verifying medication utilization took no account of dose and 
concordance with medication was assumed. Patients may be prescribed a drug but 
not fill their prescription (primary noncompliance). Although our use of date of 
dispensing rather than prescribing date would have obviated this to an extent, it would 
still be unknown if the dispensed drug was collected. A further issue is that the date 
of prescribing or dispensing may not be known, as only the “paid date” of financial 
settlement is always recorded in PIS. When the prescribed or dispensed date is 
missing it is frequently “back-filled” from the paid date. This therefore introduced some 
uncertainty in our determination of the dispensing date and potentially introducing 
false negatives and (particularly) false positives due to medication being apparently 
‘dispensed’ weeks after it was in fact. However, the use of three- and six-month time 
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windows reduced the likelihood of false negatives and false positives compared to 
shorter fixed time windows.  
 
In addition, patients may not take the drug, or not take as intended (secondary 
noncompliance), and concordance can be as low as 50% for antidepressants and 
antihypertensives (Haynes et al., 2008; Nielsen et al., 2008).  In addition, the 
questionnaire referred to “regularly” taken medication whereas our method recorded 
any prescription within the fixed time window as positive use. The absence of data in 
PIS on medication indication increased the risk of over-inclusion and false positives, 
particularly for medications with broader indications, although we attempted to 
decrease this using our exclusion criteria (Table 4.2). Fixed time windows also 
potentially record false positives for medications discontinued during the window, but 
prior to self-report, although this is more common with medications taken acutely, 
such as antibiotics (Lau et al., 1997).  
 
We must therefore concede that prescription data is by its nature an imperfect gold 
standard, although its use enables very large sample sizes which improve overall 
accuracy. The use of prescribing data as a gold standard involves some strong 
assumptions, including that the patient could not have obtained the medication 
without it being recorded in the prescribing data. The extent to which this is true 
depends on a variety of variables, including the medication type, prescribing 
legislation of the country of study, and the movement of individual patients between 
healthcare providers. Indeed, some studies are performed on the basis of self-report 
as gold standard to analyse the validity of clinical or prescribing records (Rikala et al., 
2010).   However, the advantage of prescribing data as a gold standard is that it is an 
objective measure, with definitions of medication usage that can be readily replicated 
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across studies and countries (whereas self-report questionnaires can vary 
considerably in definition and interpretation), which can be utilised at large scale 
across multiple medication types, and that is not subject to potential recall and 
desirability biases of self-report studies (Lam and Fresco, 2015).  
 
Data linkage is also a fast-moving field, and though the PIS data from 2011 we used 
in this study had high fidelity and a capture in excess of 95%, future studies using 
larger datasets and more complex linkage may enable even more accurate estimates 
of validity. For example, as data linkage improves, cross referencing to other sources 
of clinical data such as GP and hospital records should assist identifying true cases 
and also reduce the incidence of false positives for those who have discontinued 
medication through the time windows analysed.  
 
As discussed, the use of the term “mood stabilizer” may have caused confusion. Many 
individuals did not tick either checkbox, and moreover response rate differed between 
medication types, from 86.44% for antihypertensives to 77.87% for mood stabilizers. 
This may have reflected variations in understanding of, or willingness to answer, the 
question, and could have biased our results or inflated the kappa scores. However, 
we demonstrated that recoding this missing data as denial of use still produced 
substantial levels of agreement (Table 4.5). The Cohen’s kappa method itself may 
inflate values depending on the proportion of subjects in each category (Thompson 
and Walter, 1988), hence we have also tabulated the raw proportions (Table 4.7). 
GS:SFHS is a partly family-based cohort and this could potentially have introduced 
some correlation bias into our analysis, although we accounted for this in our 










Table 4.7:  Self-Reported Medication Utilization Compared To Prescribing (PIS) Records (Six Month Fixed Time Window) 
 







NEGATIVES   











































ANTIDEPRESSANTS 7404 88.85 129 1.55 87 1.04 713 8.56 8333 1911 78 4.08% 




7519 85.55 42 0.48 56 0.64 1172 13.33 8789 1455 40 2.75% 
ANTIHYPERTENSIVES 7134 80.56 229 2.59 34 0.38 1458 16.47 8855 1389 159 11.44% 
ASPIRIN 7626 90.30 35 0.41 175 2.07 609 7.21 8445 1799 29 1.61% 
INSULIN 7927 98.89 0 0.00 11 0.14 78 0.97 8016 2228 4 0.18% 
HRT  4488 93.62 20 0.42 86 1.79 200 4.17 4794 1271 14 1.105 
OCP 4029 83.09 111 2.29 200 4.12 509 10.50 4848 1216 24 1.97% 
 








Our study provides convincing evidence that medication self-report is accurate 
compared to prescribing data, particularly for medication classes that are more 
precisely definable. We have shown that self-report of antidepressant use meets the 
highest threshold for Cohen’s kappa agreement and can be considered valid for 
research and clinical purposes. Our analysis of potential patient-level predictors of 
reporting discordance, such as gender, age, education and general intelligence, did 
not identify generalizable factors across all medication classes, although there was 
some evidence that medical history of an indicated condition improves sensitivity of 
self-report. As discussed above, medication-level factors such as range of possible 
indications, and length of dispensing cycles, may also be important when validating 
self-report across a fixed time window with prescribing data as gold standard.  
 
Our study also demonstrates the utility of record linkage of longitudinal population-
based cohorts to nationally administered prescribing datasets, as a useful adjunct to 
epidemiological and large biobanking studies. Utilising administrative health data for 
verification and quality control of self-report has applications beyond epidemiological 
studies and can be potentially exploited in clinical applications, such as data-linked 
clinical support tools acting as adjuncts to clinical interview, and in formulating 







4.8 Concluding Remarks  
 
In this chapter I have demonstrated the application of record-linkage to administrative 
health data in the validation of self-reported cohort phenotyping, in this case for 
medication usage. The first objective of this thesis, as described in Chapter 1, was to 
answer the question “are users of psychiatric medications less likely to accurately 
self-report their usage in research studies compared to users of other medications?”.  
Interestingly, the validation exercise did not provide evidence for our hypothesis that 
psychiatric medication was systematically under-reported. However, it did 
demonstrate clearly (in the case of mood stabilizers especially) the potential risks of 
relying on self-report alone. 
 
I have also shown that there are potential risks inherent with over-reliance on either 
self-report or indeed record-linked administrative data. As stated in the chapter, the 
selection of record-linked prescribing data as ‘gold standard’, while clearly justifiable, 
was to an extent arbitrary because neither self-report nor prescribing data is an 
unimpeachable ‘gold standard’ for ascertaining medication use. While record-linked 
data can clearly be used for validation, this chapter has also hopefully shown the 
potential for linked data to be used improve signal and power for discoveries and the 
reduction of false associations. In other words, by combining self-report and linked 
data in defining cases and controls, future highly scaled research studies can 
significantly increase the veracity of their research data and its conclusions. In the 
following chapter, I shall show this technique can be applied to the problem of 
measuring antidepressant pharmaco-epidemiology, where through combining self-
report and linked data, new research-grade measures of antidepressant usage can 
be produced.   
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Chapter 5 : Transforming Cross-Sectional Data on 
Antidepressant Use into a Longitudinal Study using Linked 
Data  
 
5.1 Introductory Remarks  
 
As discussed in Chapter 1, antidepressant medication is a mainstay of treatment for 
major depressive disorder, although it is more appropriately used for certain types of 
major depression and also is extensively used for a variety of other indications.  
 
Recent reports that antidepressant prescriptions in the UK are now at the highest 
levels on record have caused considerable academic and media interest. There has 
been extensive debate about whether antidepressant medication levels are 
appropriate to clinical need or represent a significant overtreatment and 
medicalisation of aspects of the human condition which do not require 
pharmacological management (Information Services Division, 2014; Reid I, 2013; 
Spence D, 2013). Clearly, there is a need for a robust reassessment of antidepressant 
pharmaco-epidemiology in the general population.  
 
In the following chapter record-linkage to national prescribing data is used to 
transform GS:SFHS into a longitudinal cohort for the study of antidepressant 
incidence, prevalence, adherence and patient-level factors indicating usage. This is 
used to demonstrate the potential of record-linked data generally in undertaking this 
type of longitudinal study, while answering  two important public health questions 
relevant to mood disorder research :  (a) has exposure to antidepressant medications 
significantly increased in recent years and, if so, is this due to a change in how 
antidepressants are used?,  and (b) is the psychological trait of neuroticism an 
independent risk factor for the MDD-associated outcome of antidepressant use? 
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The following chapter has been published in the Journal of Psychopharmacology 
(Hafferty et al., 2019b). As the first author of the publication I jointly conceived the 
study, performed the analysis, wrote the manuscript and prepared all the tables and 
figures. To acknowledge the contribution of the co-authors (see also Publications 
section of this thesis for breakdown of author contributions) the term “we” rather than 
“I” is used throughout this chapter.  
 
5.2 Paper : Pharmaco-epidemiology of Antidepressant Exposure in a 
UK Cohort Record-Linkage Study  
 
5.3 Abstract  
 
5.3.1  Objective   
 
Antidepressants are the most commonly prescribed psychiatric medication, but 
concern has been raised about significant increases in their usage in high income 
countries. We aimed to quantify antidepressant prevalence, incidence, adherence 
and predictors of use in the adult population.  
 
5.3.2 Method  
 
The study record-linked administrative prescribing and morbidity data to the 
Generation Scotland cohort (N=11052), between 2009-16. Prevalence and incidence 
of any antidepressant use was determined. Antidepressant adherence was measured 
using Proportion of Days Covered (PDC) and Medication Possession Ratio (MPR) 
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metrics. Time-to-event analysis for incident antidepressant use within 5 years of 




Almost one third (28.0%, 95%CI 26.9-29.1) of the adults in our sample were 
prescribed at least one antidepressant in the five-year period 2012-16. There was a 
36.2% increase in annual prevalence between 2010 and 2016. Incidence was 2.4 
(2.1-2.7)% per year. The majority of antidepressant episodes (57.6%) were greater 
than 9 months duration and adherence was generally high (69.0% with Proportion of 
Days Covered >80%). Predictors of new antidepressant use included history of 
affective disorder, being female, physical comorbidities, higher neuroticism scores, 




Antidepressant prevalence is greater than previously reported but incidence remains 
relatively stable. We found the majority of antidepressant episodes to be of relatively 
long duration with good estimated adherence. Our study supports the hypothesis that 
increased long-term use among existing (and returning) users, along with wider 
ranges of indications for antidepressants, has significantly increased the prevalence 
of these medications.   
  
 126 
5.4  Introduction 
 
Antidepressants are the most commonly prescribed psychiatric medication and one 
of the most commonly prescribed medicines (Raymond et al., 2007; Olfson and 
Marcus, 2009). In the last 30 years, there has been a significant increase in 
antidepressant usage in high income countries (Ilyas and Moncrieff, 2012; Kendrick 
et al., 2015; Moore et al., 2009; Meijer et al., 2004; Huijbregts et al., 2017; Lockhart 
and Guthrie, 2011; Munoz-Arroyo et al., 2006; Petty et al., 2006; Raymond et al., 
2007; Exeter et al., 2009; Mojtabai and Olfson, 2014; Olfson and Marcus, 2009; 
Gonzalez-Lopez et al., 2015; Mars et al., 2017). Antidepressant consumption has 
reportedly increased 400% in the USA between 1998-2008 (Pratt et al., 2011), while 
antidepressant prescriptions in the UK increased twofold between 1995-2011 
(Spence et al., 2014). Comparison of electronic prescribing records in five European 
countries suggests that antidepressant prescribing is comparatively high in the UK for 
adults aged 20-60, especially among females (Abbing-Karahagopian Huerta et al., 
2014). In the USA, annual antidepressant prevalence for 2011 was estimated at 
14.4% (Zhong et al., 2014) compared to an annual prevalence of depression in 2015 
of 6.7% (National Institute of Mental Health, 2017b) and 2.7% for generalized anxiety 
disorder (National Institute of Mental Health, 2017a).   
 
The extent to which this rising tide of antidepressant prescribing is appropriate to 
clinical need is an area of ongoing controversy (Cruickshank et al., 2008; Lockhart 
and Guthrie, 2011; Reid I, 2013; Spence D, 2013). Antidepressant use has risen to a 
significantly greater degree than any rise in the prevalence of depression (Munoz-
Arroyo et al., 2006) or of anxiety disorders (Bandelow and Michaelis, 2015). There is 
some evidence that illnesses treated by these medications, such as depression and 
anxiety, are now better recognised and treated at the primary care level (Kessler et 
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al., 2005) and that GPs and patients are more willing to utilise antidepressant 
treatment for a wider range of indications (Trifiro et al., 2007; Kessler et al., 2005; 
Mojtabai and Olfson, 2014). It has also been argued that a greater antidepressant 
prescription rate does not correspond to an upsurge in incident cases, but rather 
represents a significant lengthening in the treatment period for existing users (Moore 
et al., 2009; Raymond et al., 2007; Mojtabai and Olfson, 2014; Mars et al., 2017; Reid 
I, 2013). Advisory bodies such as NICE and the WHO now recommend a minimum 
of six to nine months antidepressant treatment for moderate major depressive 
disorder (MDD) and two years or more treatment for chronic or relapsing illness (Petty 
et al., 2006; Reid I, 2013; Mars et al., 2017). This can serve to increase prescribing 
prevalence rates without necessarily increasing incidence.  
 
Nevertheless, concerns have been raised about a medicalisation of ordinary distress 
with antidepressants (Hollinghurst et al., 2005), and there are ongoing debates about 
the efficacy of antidepressants in mild-moderate depressive illness (Olfson and 
Marcus, 2009; Kirsch et al., 2008; Cipriani et al., 2018). There has been increased 
attention to potential adverse effects of antidepressants (Bet et al., 2013), including 
discontinuation syndromes (Petty et al., 2006; Bosman et al., 2016), adverse physical 
outcomes in older adults (Coupland et al., 2011), risk of epilepsy (Hill et al., 2015), 
increased risk of suicidal thoughts in teens and young adults (Zhong et al., 2014) and 
increased rates of attempted suicide in the first 28 days after starting and stopping 
antidepressant treatment (Coupland et al., 2015). There are concerns that 
antidepressants are insufficiently reviewed by clinicians, leading to unnecessarily 
long treatment durations (Bosman et al., 2016; Johnson et al., 2012).   
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Estimating the true prevalence and incidence of antidepressant usage is difficult and 
there have been few large population-based studies of antidepressant pharmaco-
epidemiology. Many research studies of antidepressant use have relatively short 
follow-up periods (Huijbregts et al., 2017). A number of studies have used survey 
data (Lewer et al., 2015; Mojtabai and Olfson, 2014; Olfson and Marcus, 2009), 
although such data is potentially susceptible to recall biases. Other studies have 
concentrated on use of antidepressants in depressive illness (Kendrick et al., 2015; 
Moore et al., 2009), which can underestimate the true population prevalence due to 
the wide range of indications for antidepressants. Record-linking existing population-
based cohorts to routinely collected administrative health data presents an 
opportunity to improve pharmaco-epidemiological estimates of antidepressant use.  
 
Understanding patterns of antidepressant use is important in ensuring appropriate 
allocation of healthcare resources for patients and in maintaining effective monitoring 
systems for prescribing and adverse effects. In this study we have used a subset 
(N=11,052) of Generation Scotland, a large population- and family-based cohort of 
Scottish adults, with record-linkage to national prescribing data for the period 2009-
2016. We aimed to provide a contemporaneous and population-scale quantification 
of patterns of antidepressant use, in terms of prevalence, incidence, duration of 




5.5  Method  
 
 
5.5.1 Study Sample 
 
We used the Generation Scotland: Scottish Family Health Study (GS:SFHS) 
population- and family-based cohort (N=21,474) of adult volunteers across Scotland, 
recruited February 2006-March 2011, which has been described elsewhere (Smith et 
al., 2006; Smith et al., 2013a) (for overview, see Chapter 3).  
 
Recruitment to GS:SFHS began in 2006, but prescribing data was available only from 
2009 onwards. We therefore restricted our analysis to those individuals in GS:SFHS 
recruited from September 2009 to March 2011 (N=11052, 6518 females and 4534 
males, see Figure 5.1 and Table 5.1). This ensured that all individuals had at least 
six months of prescribing data prior to their enrolment in GS:SFHS, with which to 
ascertain their pre-enrolment medication usage, and at least five years’ worth of 
prescribing data following their enrolment. Of these, 96.5% had medication records 
available in the prescribing data (the remainder were presumably not using 
prescribed medication), which compared with 95.6% for the whole GS:SFHS cohort.  
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Table 5.1 :  Demographics of Individuals Used In Current Study Compared to Entire Generation Scotland Cohort And To The 
Scottish Adult Population  
 
 Individuals in the 
current study  N(%) 
GS:SFHS 
N(%) 
Significance (p) of 
difference in proportion 
between study sample 
and GS:SFHS 








Female 6518  (59.0%) 12246 (59.0%) p=0.98 2.24M (52.1%) 
Age 18-24 (Age in 2012) 801 (7.3%) 1194  (5.8%) p=1.6x10-07h = 0.06 501152  (11.7%) 
Age 25-34 1460  (13.2%) 2810 (13.5%) p=0.42 691908 (16.1%) 
Age 35-44 1837  (16.6%) 3416  (16.5%) p=0.70 688418  (16%) 
Age 45-54 2246  (20.3%) 4422  (21.3%) p=0.04    h=0.02 800265  (18.6%) 
Age 55-64 3022  (27.3%) 5447  (26.2%) p=0.03   h=0.03 663701  (15.5%) 
Age 65-74 1295  (11.7%) 2649  (12.8%) p=0.007  h=0.03 522236  (12.2%) 
Age 75+ 
Affective Disorder History 
391  (3.5%) 821  (4.0%) p=0.06 424626  (9.9%) 
No MDD on screening 9624  (87.1%) 17998  (86.7%) p=0.34  
SCID Single episode MDD 729  (6.6%) 1360  (6.6%) p=0.88  
SCID Recurrent MDD 660  (6.0%) 1327  (6.4%) p=0.14  












































SIMD 1 – Most Deprived 1325(  12.6%)* 2597  (13.3%)* p=0.11    
SIMD 2nd quintile 1576  (15.0%)* 2761  (14.1%)* p=0.04  h=0.03  
SIMD 3rd quintile 1693  (16.1%)* 3137  (16.0%)* p=0.84  
SIMD 4th quintile  2604  (24.8%)* 5009  (25.6%)* p=0.12  

































Table 5.1 cont. 
 
 Individuals in the 
current study  N(%) 
GS:SFHS 
N(%) 
Significance (p) of 
difference in proportion 
between study sample 
and GS:SFHS 




EPQ Neuroticism  
Mill-Hill Vocabulary Test 
Wechsler Digit Symbol 
Substitution Task  
Verbal Fluency Test  


























 Abbreviations: MDD = Major Depressive Disorder. SCID = Structured Clinical Interview for DSM-
IV Disorders.          SIMD = Scottish Index of Multiple Deprivation. GHQ = General Health 
Questionnaire. EPQ = Eysenck Personality Questionnaire.  
* Variable contained missing data which was imputed (see below) 
† Total GS:SFHS cohort 21474 but number who had consented to data linkage and where data 











Like GS:SFHS as a whole, the study sample had a higher proportion of females (59%) 
and was of older age (mean 49 males SD 15.3, 49 females SD 15.2) compared to the 
Scottish general population (mean 37 males, 39 females, 2001 census) (Smith et al., 
2013a). The study sample was typically healthier and more affluent that the general 
Scottish population, nevertheless 32.9% of individuals lived in areas with socio-
economic deprivation worse than the average (median), as measured by the Scottish 
Index of Multiple Deprivation (Smith et al., 2013a). 99% of the study sample was of 
white ethnicity (Scottish population 98%). 
 
 
5.5.2 Phenotyping in Generation Scotland 
 
Sociodemographic information recorded in GS:SFHS included sex, age, smoking 
status and relationship status, collected by pre-clinic questionnaire at recruitment 
(see Table 5.1). Lifetime history of affective disorder (major depressive disorder 
(MDD) and bipolar disorder) was obtained using the Structured Clinical Interview for 
DSM-IV disorders (SCID) (Smith et al., 2013a). This was operationalised in the pre-
clinic questionnaire using two screening questions, with those who answered 
affirmatively going on be interviewed with the mood sections of the SCID. The 
screening questions were: “Have you ever seen anyone for emotional or psychiatric 
problems?” and “Was there ever a time when you, or someone else, thought you 
should see someone because of the way you were feeling or acting?”.  
 
Cognitive tests included the digit symbol substitution test from the Wechsler Adult 
Intelligence Scale III (Wechsler D, 1998b), logical memory from the Wechsler Memory 
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Scale III (Wechsler D, 1998a), and verbal fluency (Lezak, 1995). From these tests, 
we derived a measure of cognitive ability (g) as the first unrotated principal 
component, explaining 44% of the variance in scores (Marioni et al., 2014). Loadings 
for processing speed, vocabulary, verbal declarative memory and executive function 
were -0.41, -0.55, -0.47 and -0.56. The range of g was -6.5 to 4.5, with a mean of 0.0 
and one standard deviation equating to 1.3.  
 
Psychological distress was measured using the General Health Questionnaire (GHQ-
28, Likert scoring) (Goldberg and Hillier, 1979). An overall score of 24 or greater has 
been used to identify cases of potential psychiatric disorder (Swallow, 2003). 
Neuroticism was measured using the Eysenck Personality Questionnaire Short Form 
Revised (EPQ-SF) (Eysenck and Eysenck, 1964). The EPQ-SF is a self-report 
questionnaire consisting of twelve Yes/No questions which are used to assess 
neuroticism (on a scale 0-12, with higher scores representing greater neuroticism). 
The EPQ-SF has been validated with other quantitative measures of neuroticism 
(Gow et al., 2005) with high reliability (Eysenck et al., 1985). The extraversion scale 
from the EPQ-SF was not used in this study as it was not found to be significant on 
model fitting. Schizotypal traits were elicited using the Schizotypy Personality 
Questionnaire (SPQ) (Raine, 1991). Socioeconomic deprivation was determined 
using the Scottish Index of Multiple Deprivation 2009 (SIMD) (Scottish Government, 
2009). 
 
5.5.3 Prescribing Data and Linkage 
 
All Scottish citizens registered with a General Practitioner are assigned a unique 
identifier, the Community Health Index (CHI). This was used to deterministically 
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record-link GS:SFHS participants to the national Prescribing Information System 
(PIS) administered by NHS Services Scotland Information Services Division(ISD) 
(Alvarez-Madrazo et al., 2016). PIS is a database of all Scottish NHS medications 
prescribed by GPs, nurses, dentists, pharmacists, and hospitals, where the 
medication was dispensed in the community. There is no prescription charge in 
Scotland since 2011. Hospital-dispensed prescriptions and over-the-counter 
medications are not included. We obtained PIS prescribing data for April 2009 (the 
earliest date available) to December 2016.  
 
We additionally linked to the Scottish Morbidity Records (SMR00, SMR01 and 
SMR04) to obtain information about appointments with outpatient or inpatient 
secondary mental health services during the period of study. The SMR records 
Scotland-wide outpatient, day-case and inpatient hospital (including psychiatric 
hospital) attendances per annum since 1981. We also linked to ISD data on mortality 
to determine which participants of GS:SFHS had died during the period of follow up 





5.5.4 Identification of Psychiatric Medication Usage 
 
The PIS data allows medication to be identified by approved drug name and/or 
associated British National Formulary (BNF) (Joint Formulary Committee, 2012) 
paragraph code. Medication indication is not recorded in PIS. PIS records medication 
name, type and dose. Dosage instructions are not available in standardised, coded, 
machine-readable form in PIS raw data. However, the Information Services 
Division(ISD) have developed a Natural Language Processing (NLP) algorithm to 
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extract dosage instructions from unstructured free text which are part of the PIS 
records. The algorithm has been verified as accurate although there are issues 
discerning ‘as required’ from ‘as directed’ in the metadata(Nangle et al., 2017). The 
number of defined daily doses (DDDs) for each medication are also computed in PIS. 
DDDs are a measure for standardising drug doses (WHO, 2011). For a small part of 
the dataset (4.9%) the dosage instructions were missing, and these were imputed (as 
described below).  
 
We defined antidepressants (drugs for depression) as any drug included in BNF 
Chapter 4.3, entitled “Antidepressant Drugs”.  Selective Serotonin Reuptake 
Inhibitors (SSRIs) were identified via BNF Section 4.3.3, Tricyclic Antidepressants 
(TCAs) via Section 4.3.1 and Selective Serotonin and Noradrenaline Reuptake 
Inhibitors (SNRIs) were identified from Section 4.3.4 (venlafaxine and duloxetine). We 
defined ‘other antidepressants’ as including Monoamine Oxidase Inhibitors (MAOIs), 
identified via Section 4.3.2, and the remaining drugs within Section 4.3.4. To comply 
with Neuroscience-based Nomenclature (Worley, 2017), a glossary of the 
mechanisms of action of each of the medications included in our study is provided in 
Table 5.2 below.  
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Table 5.2: Medications that previously antidepressant naïve (n=1250) 
antidepressant users in GS:SFHS were first commenced on during the entire 
period studied 2009-2016 







Amitriptyline Reuptake inhibitor 
(SERT and NET), 
receptor antagonist (5-
HT2) 
TCA 37 3.0 
Citalopram Reuptake inhibitor 
(SERT) 
 
SSRI 499 39.9 
Duloxetine  Reuptake inhibitor 
(SERT and NET) 
 
SNRI 31 2.5 
Fluoxetine  Reuptake inhibitor 
(SERT) 
SSRI 270 21.6 
Mirtazapine Receptor antagonist (NE 
alpha-2, 5-HT2, 5-HT3) 
Other  87 7.0 
Nortriptyline Reuptake inhibitor (NET) TCA 49 3.9 
Paroxetine Reuptake inhibitor 
(SERT) 
SSRI 5 0.4 
Sertraline Reuptake inhibitor 
(SERT) 
SSRI 177 14.2 
Tranylcypromine Enzyme inhibitor (MAO-
A and -B), releaser (DA, 
NE) 
MAOI 0 0 
Venlafaxine Reuptake inhibitor 
(SERT and NET) 
 
SNRI 19 1.5 
Lofepramine Reuptake inhibitor (NET 
and SERT) 
 








Other  22 1.8 














(SERT and NET) 
 
TCA 11 0.9 
Doxepin Reuptake inhibitor (NET 
and SERT), receptor 
antagonist (5-HT2) 
 
TCA 4 0.3 
Escitalopram  Reuptake inhibitor 
(SERT) 
 
SSRI 12 1.0 
Flupentixol Receptor antagonist 
(D2, 5-HT2) 
 










(SERT and NET) 
 







TCA 0 0 
Moclobemide Reversible enzyme 
inhibitor (MAO-A) 
 
MAOI 0 0 
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Table 5.2 cont.  







Phenelzine Enzyme inhibitor (MAO-
A and -B) 
 
MAOI 0 0 
Reboxetine Reuptake inhibitor (NET) 
 
Other 0 0 
Trimipramine Receptor antagonist (5-
HT2 and D2) 
 
TCA 0 0 
Tryptophan Essential amino acid, 
precursor to 5-HT and Me 
Other 0 0 
* = source: Neuroscience-Based nomenclature http://www.nbn2.org/ [Accessed 26-10-18] 
Abbreviations:   SERT = serotonin transporter. 5-HT = 5-hydroxytryptamine/serotonin. NE=noradrenaline. NET = noradrenaline 
transporter. DA/D=dopamine. Me=Melatonin. MAO=monoamine oxidase.   SSRI=selective serotonin reuptake inhibitor.                       
TCA=tricyclic antidepressant. MAOI=monoamine reuptake inhibitor. SNRI=selective serotonin and noradrenaline reuptake 
inhibitor. 
 
We recorded antidepressant medication use as any dispensed prescription during 
the period analysed (which was the defined 5 year period 2012-2016 in some 
analyses and 1-5 years following individual GS:SFHS recruitment in others, as 
specified).  We also applied additional thresholds : in the majority of our analyses, 
and unless otherwise stated, we repeated our analyses excluding low dose (<75mg) 
amitriptyline prescriptions, as this medication and dosage is most commonly 
prescribed for non-psychiatric purposes (such as neuropathic pain, migraine and 
tension headache) and frequently for very short periods (Mars et al., 2017). With 
regard to antidepressant dosage, we produced estimates for antidepressants of all 
dosages, and separate estimates for antidepressants prescriptions which met at least 









5.5.5 Prevalence and Incidence 
 
For each one-year period, we calculated the number of patients receiving any 
antidepressant prescription. Annual prevalence was calculated as the number of 
living cohort members using at least one antidepressant prescription that year, as a 
proportion of the reference sample. We also calculated the period prevalence for 
2012-16 and the period prevalence for antidepressant use in the five years following 
each individual’s enrolment in GS:SFHS.   
 
To calculate incidence, we defined antidepressant naïve individuals as those who 
(a)were not on any antidepressant at the time of enrolment to GS:SFHS, or the 6 
months preceding, and  (b) did not report antidepressant use on the medication self-
report questionnaire included in GS:SFHS, and (c) did not have a history of MDD or 
bipolar disorder on the SCID (which would indicate likely, although not definite, 
previous antidepressant use) (d) did not have a previous diagnosis of affective or 
anxiety disorders in the Scottish Morbidity Record (SMR) prior to GS:SFHS 
recruitment. We calculated incidence on the basis of the number of new users from 
the antidepressant naïve group, divided by the number of cohort members without 
antidepressant use in the preceding year.  
 
The antidepressant naïve group were used solely in the calculation of incidence. In 
the Cox analysis of time to antidepressant use (see below), those currently on 
antidepressants were excluded, but the subset included those who had likely 
previously been on antidepressants. This is because a history of Major Depressive 
Disorder is known to be an important risk factor in antidepressant use and excluding 
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those with a history of MDD from the analysis would significantly bias the results 
regarding predictors of use.   
 
5.5.6 Identification of Antidepressant Episodes and Adherence 
 
We defined a drug treatment “episode” as consecutively dispensed prescriptions with 
a maximum interval between prescribing events of 90 days after the expected end 
date of the previous prescription, based on the dosage instructions (Gardarsdottir et 
al., 2010). We used 90 days as the cut-off point as it is unusual in the UK to be given 
more than three months medication per prescribing event (for sensitivity analyses 
with alternative cut-off points see Table 5.3). The end of a prescribing episode is 
therefore the duration from the final prescription to the time when the prescription 
ends based on dosage instructions, up to a maximum of 90 days.  
 
We did not include new episodes which began in the second half of 2016, as it was 
not possible to estimate their duration. We defined “long-term” antidepressant use as 
a consecutive antidepressant episode of at least 15 months (based on three months 
for acute treatment, nine months for continuation-phase treatment, and three months 
















Part A : Sensitivity Analysis of Medication Possession Ratio (MPR) per Antidepressant Episodes During 5 Year Period 2012-































60 2385 4370 526 231 10.9 90.3 100 99.3 103.4 411.8 
90 2385 3595 679 307 10.6 86.5 99.1 96.3 100.5 411.8 
120 2385 3280 777 372 11.7 84.9 98.1 95 101.1 411.8 
150 2385 3117 839 411 11.7 83.5 97.4 94 100.7 411.8 
180 2385 3008 891 452 11.7 82.2 96.6 93.2 100.7 411.8 
270 2385 2813 997 557 11.7 79.9 95.7 91.4 100.4 283.7 










Part B : Sensitivity Analysis of Proportion of Days Covered (PDC) per Antidepressant Episode During 5 Year Period 2012-2016 




































60 2385 4370 526 231 10.7 80.3 88.9 87.4 100 100 76 
90 2385 3595 679 307 10.6 77 86.3 84.9 99.3 100 69 
120 2385 3280 777 372 5.8 74.4 85.1 82.7 96.9 100 64.6 
150 2385 3117 839 411 3.1 72.3 84.5 81.4 96.3 100 61.7 
180 2385 3008 891 452 3.1 70.4 83.6 80.1 95.5 100 59.3 
270 2385 2813 997 557 3.1 65.9 82.2 77.6 94.5 100 55.5 









Part C : Comparison of Proportion of Days Covered for Antidepressant Episodes involving Different Medication Classes (SSRI, 






























PDC  (>= 80% 
PDC) 
SSRI 90 1924 672 326 1 76.7 85.8 84.5 96.8 100 68.1 
TCA* 90 422 937 488 1 76.8 85.5 84.3 100 100 67.8 
SNRI 90 310 1120 931 25.7 76.3 84.2 83.2 90.8 100 67.3 
MAOI 90 14 1251 1110 52.4 71 77.1 77.3 82.7 100 31.3 
Other 90 414 908 522 28.5 76.8 85 83.9 94.1 100 65.9             
MDD 
history:  
           
Bipolar 
disorder 
90 29 813 568 62.9 72.9 81.8 83.5 94.2 100 56.3 
Recurrent 
MDD 
90 421 968 576 23.2 76.1 84.7 83.3 92.3 100 66.1 
No MDD 
history 
90 1611 578.9 265.5 10.6 77.7 87.4 85.5 100 100 70.3 
* = TCA  - excluding low dose amitriptyline  







We calculated medication adherence (Figure 5.2) using the Medication Possession 
Ratio (MPR) and Proportion of Days Covered (PDC) metrics (Keyloun et al., 2017). 
MPR is defined as the sum of the day’s supply for all dispensed medication in the 
episode divided by the number of days in the period, expressed as a percentage. 
PDC is defined as the number of days in a prescribing episode that are adequately 
“covered” by the preceding prescribing event, divided by the number of days in the 
episode, expressed as a percentage.  
 
Compared to MPR, PDC is generally regarded as a more conservative and preferred 
measure and is the primary method utilised in the study. Satisfactory adherence was 
defined as MPR or PDC >80% for the antidepressant episode (Keyloun et al., 2017). 
Sensitivity analyses (Table 5.3 Part A and Part B) indicated that PDC was the more 
discriminatory measure compared to MPR, although both measures are reported (see 
Results section).     
 
 









the-difference-between-these-adherence-measures [Pharmacy Times, July 05, 2015, Accessed 9th July 2019] 
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5.5.7  Statistical Analysis 
 
All analyses were carried out using R version 3.2.3 (R Core Team, 2015). Prevalence 
and incidence rates were expressed as percentages, together with 95% confidence 
intervals. These estimates were reweighted by age and sex to reflect the Scottish 
population, using the 2011 Scottish census (Scottish Government, 2011). Age-sex 
reweighting was performed using the direct standardisation method using the R 
package “epitools”.  
 
As GS:SFHS is a family based cohort, which could lead to biases due to the 
hierarchical structure of the data, we used a mixed model implementation of Cox 
regression (with inter-relatedness controlled using pedigree as a random effect), 
using the R package “coxme”. We controlled for potential confounding related to the 
recruitment area from which each participant was enrolled using a categorical 
variable in the model.  
 
There was some (range 0.8-5.1%) missing data for some of the variables collected in 
Generation Scotland (see below and Table 5.4) and this missing data was imputed 
using the Multiple Imputation by Chained Equations method implemented in the R 
package “mice” (van Buuren, 2012). The final estimates were the result of pooling 
n=100 imputed datasets, using Rubin’s rules (van Buuren, 2012). P values were 






5.5.8 Imputation method for missing drug dosage data 
 
There were 8048 records in the antidepressant data with missing prescription 
instructions (out of 134290 records in total, or 6.0% missing data).  A five-step 
imputation strategy was employed for these missing records.  
(1) If a missing data prescribing record could be matched to one with the same 
user (unique ID), the same antidepressant medication, at the same dose, and 
the same dispensed quantity, then these prescribing instructions were used 
to impute for that individual. This reduced the missing data from 8048 records 
to 814 records.  
(2) If a prescribing record has the same user (unique ID), the same 
antidepressant, and the same strength as another prescription for the same 
users, then these prescribing instructions were used. This step did not reduce 
the count (did not improve upon the step above).  
(3) If a missing data prescribing record could be matched to one with the same 
user (unique ID) and the same antidepressant, then these prescribing 
instructions were used to impute. This reduced missing data from 814 to 553 
records.  
(4) For the remaining 553 records (0.4% of the total dataset) the median dosage 
instructions for that specific antidepressant in the cohort were used.  
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5.5.9 Missing Data and Imputation of Generation Scotland phenotypic 
variables  
 
As shown in Table 5.4, there was some missing data in the phenotypic variables used 
in the analyses of this study. The amount of missing data was <5% for every variable 
apart from SIMD quintile (5.1%) with the proportion of individuals with missing data in 
at least one field being 12.6%.  
 
Imputation of these variables was performed using Multiple Imputation by Chained 
Equations in the R package “mice”. An assumption of multiple imputation is that the 
missing data is not Not Missing At Random (NMAR) and can credibly be defined as 




As shown in Table 5.4, when stratified against the affective disorder status of 
GS:SFHS participants, there are no significant differences in the total missingness 
between those with a history of affective disorder and those without. We imputed the 
missing data on the basis of the hypothesis that the missingness was MAR type.  
 
 
Table 5.4 : Missing Data in GS:SFHS Variables 
Variable name Missing records  
(N=11052) 
% missing data 
(which was 
imputed) 
% missingness in 
individuals with 
no history of 
affective disorder 
% missingness in 
individuals with history 
of affective disorder 
(p= p value of two 
sample test for equality 
of proportions) 
Sex 0 -   
Age 0 -   
SCID affective 
disorder status 
0 -   
SIMD Quintile 561 5.1% 5.0% 5.7%(p=0.3) 
BMI 91 0.8% 0.8% 0.8% (p=0.9) 
SPQ 261 2.4% 2.3% 2.7%(p=0.05) 
Neuroticism 254 2.3% 2.4% 1.9%(=0.3) 
Smoking  384 3.5% 3.5% 3.4%(p=0.9) 
Alcohol 535 4.8% 4.7% 5.5% (p=0.2) 
Physical Health 254 2.3% 2.3% 2.6%(p=0.05) 
Appointment 
location 
0 -   
Cognitive 
function (g) 
203 1.8% 1.9% 0.9%(p=0.007) 
Individuals with 
missing data in at 
least one field 







5.6  Results  
 
5.6.1  Sample 
The basic demographics of the sample compared to the Scottish population are 
presented in Table 5.1. An antidepressant was prescribed at least once to 3742 
individuals (33.9(95%CI 33.0-34.8)%) of the 11,052 in our study between April 2009 
and December 2016. There was a 36.2% increase in the annual prevalence of 
antidepressant prescribing between 2010 (age-sex reweighted prevalence 
12.7(95%CI 12.0-13.5)%) and 2016 (17.3(16.5-18.3)%). During the seven year period 
2010-16, 79,857 antidepressant prescriptions were dispensed (22 for every 
antidepressant user in GS:SFHS).  
 
Low dose amitriptyline prescriptions (<75mg) accounted for 18.3% of prescriptions 
and 943 individuals (25%) were only prescribed low dose amitriptyline. Discounting 
low dose amitriptyline, there were 2624 antidepressant users with a mean of 1.8 
antidepressant episodes (range 1-9, S.D. 1.1) during the period 2010-16. Although 
we had no data on specific indication, 84.2% of these episodes reached a dosage 
equivalent to at least the required BNF minimum for the treatment of Major 
Depressive Disorder.  
 
The most commonly prescribed class of antidepressants was Selective Serotonin 
Reuptake Inhibitors (SSRIs), accounting for 54% of prescriptions in 2010 and 52.7% 
in 2016 (65.6% and 64% respectively if low dose amitriptyline excluded). The 
proportion of Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) prescribed 
increased from 9.1% in 2010 to 10.9% in 2016, and the proportion of other 
antidepressants (such as mirtazapine) increased from 6.7% to 8.3% during the same 
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period. The proportion of Tricyclic Antidepressants (TCAs) was 27.8% in 2016, or 
12.3% if low dose amitriptyline excluded.  
 
5.6.2  Period Prevalence 2012-16 
 
The 5-year 2012-2016 age-sex reweighted period prevalence of antidepressant use 
was 28.0 (95%CI 26.9-29.1)% for the cohort. With low dose amitriptyline excluded, 
the prevalence was 20.8 (19.9-21.8)% (see Table 5.5). The five-year prevalence was 
considerably higher among females, 34.9 (33.3-36.6)%, than males, 20.4 (19.0-
22.0)%. There was a bimodal distribution of antidepressant use by age, with 2012-16 
period prevalence highest in the 45-54 age group for all antidepressants (33.3 (31.3-



































excluding low dose 
amitriptyline  
 2012-16 n 2012-16 n 2012-16 n 2012-16 n 2012-16 n 
Crude Rate  29.5(28.6-30.4) 3167 17.4(16.7-18.2) 1883 15.0(14.3-15.7) 1619 5.8(5.4-6.3) 630 21.9(21.1-22.7) 2366 
Reweighted Rate 28.0(26.9-29.1)  16.5(15.7-17.4)  14.1(13.4-15.0)  5.6(5.1-6.2)  20.8(19.9-21.8)  
Sex -Male (crude) 20.4(19.2-21.7) 900 11.1(10.2-12.1) 489 10.0(9.1-11.0) 440 4.4(3.8-5.1) 195 14.7(13.7-15.8) 647 
                    (RW) 20.4(19.0-22.0)  11.1(10.1-12.3)  9.9(8.7-11.1)  4.4(3.8-5.2)  14.7(13.5-16.1)  
Sex – Female        
                    (crude) 35.4(34.3-36.6) 2267 21.8(20.8-22.8) 1394 18.4(17.4-19.4) 1179 6.8(6.2-7.5) 435 26.9(25.8-28.0) 1719 
                     (RW) 34.9 (33.3-36.6)  21.4(20.2-22.7)  18.1(16.9-19.3)  6.7(6.0-7.5)  26.4(25.0-27.9)  
Age – 18-24 22.6(19.8-25.7) 181 18.4(15.8-21.3) 147 6.6(5.0-8.6) 53 4.0(2.8-5.7) 32 19.5(16.8-22.4) 156 
25-34 23.0(20.9-25.3) 335 17.5(15.6-19.5) 255 8.5(7.1-10.0) 123 4.7(3.7-6.0) 71 19.5(17.5-21.7) 284 
35-44 32.9(30.7-35.1) 601 22.5(20.6-24.5) 411 14.1(12.5-15.8) 257 7.3(6.2-8.7) 134 26.6(24.6-28.7) 487 
45-54 33.3(31.3-35.3) 739 20.6(19.0-22.4) 458 16.8(15.3-18.4) 373 6.1(5.1-7.2) 136 25.2(23.4-27.1) 560 
55-64 29.1(27.4-30.7) 858 14.9(13.6-16.3) 440 17.0(15.7-18.4) 503 6.0(5.2-6.9) 177 20.6(19.1-22.1) 607 
65-74 28.3(25.8-30.9) 346 10.6(9.0-12.5) 130 19.5(17.4-21.9) 239 4.6(3.5-5.9) 57 16.4(14.4-18.7) 201 
75+ 33.3(28.3-38.8) 107 13.1(9.7-17.4) 42 22.1(17.8-27.1) 71 7.2(4.7-10.7) 23 22.1(17.8-27.1) 71 
Abbreviations : RW=age-sex reweighted.  SSRI=Selective Serotonin Reuptake Inhibitors. TCA=Tricyclic Antidepressants. n = total number within grouping with 











5.6.3  Prevalence of Antidepressant Prescribing in One to Five Years Follow-
Up 
 
In the first year following each individual’s GS:SFHS enrolment, 11.2 (95%CI 10.6-
11.8)% of the cohort had at least one antidepressant prescription (excluding low dose 
amitriptyline, as does all analysis in this section), which increased to 20.8 (20.0-
21.6)% after five years. 
 
Among those with a history of recurrent MDD on recruitment, 52.4 (48.5-56.2)% were 
prescribed at least one antidepressant within one year following GS recruitment and 
for bipolar disorder the proportion was 46.2 (30.4-62.6)%. For those with no history 
of MDD on recruitment, 6.9 (6.5-7.5)% were prescribed at least one antidepressant 
within one year – or 2.5 (2.2-2.9)% if those already on antidepressants at recruitment 
were excluded.  
 
Among those with a GHQ-28 Likert score of 24 or above at the time of GS:SFHS 
recruitment, 31.7 (95% CI 29.4-34.1)% had at least one antidepressant prescription 
within 1 year.  
 
Among the antidepressant naïve subgroup at the time of GS:SFHS recruitment, 6.6 
(5.1-8.6)% of those with a GHQ-28 Likert score of >=24 were prescribed 
antidepressants within one year and 9.2 (4.1-18.6)% of those scoring over three 
standard deviations above the mean on the GHQ depression subscale (subscale D) 
were prescribed an antidepressant within 1 year.  
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5.6.4  Incidence of Antidepressant Prescribing 2012-16 
 
The age-sex reweighted incidence of antidepressant prescribing was 2.4 (2.1-2.7)% 
per year for all antidepressants and 1.6 (1.4-1.9)% if low dose amitriptyline was 
excluded. Incidence was greater in females 2.7 (2.4-3.2)% than males 2.0 (1.6-2.5)%.  
 
77.1% of incident antidepressant users were commenced on an SSRI, with 11.9% on 
a TCA (low dose amitriptyline excluded), 4.0% on a serotonin and noradrenaline 
reuptake inhibitor (SNRI) and 7.0% on other antidepressants (especially mirtazapine). 
The most common individual medication for new users was citalopram (39.9%), 
followed by fluoxetine (21.6%) and sertraline (14.2%). Less than 1% were 
commenced on paroxetine and none on reboxetine or MAOIs. The most common 
tricyclic antidepressant for new users was nortriptyline (3.9%) followed by higher dose 
amitriptyline (3.0%).  
 
5.6.5  Antidepressant Episodes 
 
In the five years period 2012-16, 2385 individuals used antidepressants and we 
determined 3595 antidepressant episodes (low dose amitriptyline excluded). Some 
86.6% (n=3112) of episodes reached at least minimum dose required for treatment 
of MDD (although actual indication was not available). We allowed antidepressant 
switching or combination during episodes, with the majority of episodes (79.3%) 
having just one antidepressant, 13.6% having two and 7.1% having three or more 
(range 3-6).  
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Over half (57.6%) of antidepressant episodes were of 9 months or greater and 44.8% 
met our 15-month criteria for long term use, with the majority of antidepressant users 
(57.7%) having a least one episode of long-term duration. Nevertheless, 
approximately one tenth (10.6%) of episodes were of less than 30 days duration and 
a further 12.6% were of 31-90 days, meaning that approximately one quarter of 
episodes were less than three months duration.  
 
5.6.6  Adherence 
 
For the 3595 antidepressant episodes between 2012-16 (n=2385 individuals), the 
mean Medication Possession Ratio (MPR) per antidepressant episode was 96.0% 
(range 11-412) and the mean Proportion of Days Covered (PDC) was 84.9% (range 
11-100). Using PDC >= 80% as defining adherence, 69.0% of antidepressant 
episodes were adherent, when using 90 days as the cut-off point between 
antidepressant episodes (for sensitivity analysis see Table 5.3). Mean PDC was 
similar across medication classes (SSRI 84.5%, TCA 84.3%, SNRI 83.2%, MAOI 
77.3%, other 83.9%, see Table 5.3).  
 
5.6.7 Polypharmacy  
 
Other medications that were also prescribed with antidepressants during an 
antidepressant episode were determined, with simultaneous use on at least three 
occasions being classed as “regular” use.   
 
Anxiolytics (medicines for anxiety) were also prescribed to 34.1% of antidepressant 
users (16.4% regularly), including benzodiazepines 23.6% (10.7% regularly) and “Z-
 157 
drugs” (the benzodiazepine-receptor agonists zopiclone, zolpidem and zaleplon) 
18.9% (7.6% regularly).  
 
Pregabalin or gabapentin (alpha-2 delta calcium channel blockers often used to treat 
anxiety and neuropathic pain as well as epilepsy) were also prescribed to 12.8% of 
users (8.9% regularly). Antipsychotics (medicines to treat psychosis) were also 
prescribed to 6.8% antidepressant users (5.1% regularly). Lithium compounds or 
sodium valproate, which are also used to treat mood disorders, were also prescribed 
to 1.6% (1.4% regularly).  
 
Opiate-based analgesic (pain relieving) medications were also prescribed to 22% of 
antidepressant users (13.3% regularly), compared to a general five-year prevalence 
of 15.6% (Figure 5.4).  Opioid use was also higher in those with a history of bipolar 
disorder (33.3%,regular 18.5%) and recurrent MDD (27.8%, regular 17.3%) on 
GS:SFHS recruitment, compared to those with no affective disorder history (20.5%, 



















Figure 5.4: Age-Sex Reweighted Prevalence of Antidepressants And Other Medications In GS:SFHS 
 
  




5.6.8 Use of Psychiatric Services 
 
Using record linkage to hospital data, 10.0 (8.9-11.2)% of antidepressant users in the 
five years following GS:SFHS enrolment, who were prescribed at least the minimum 
BNF recommended dosage for MDD,  had a psychiatric outpatient appointment 
during at least one of their antidepressant treatment episodes. Some 1.8(1.4-2.5)% 
of antidepressant users were admitted to psychiatric hospital during at least one 
episode of antidepressant treatment.  
 
5.6.9 Predictors of Antidepressant Use :  Time to Event Analysis  
 
We performed time-to-antidepressant-use Cox regression analysis for the five years 
following individual GS:SFHS enrolment, excluding those individuals already on 
antidepressants (Figure 5.5 and Table 5.6).  
 
Female gender was predictive of commencing antidepressants in the multivariable 
model (Hazard Ratio (HR)=1.74, 95% CI 1.53-1.98, pFDR<0.0001). Greater levels of 
deprivation (lower SIMD score) were associated with increased likelihood of 
antidepressant prescriptions in univariate analysis (and in complete case analysis, 
see Table 5.7) although this was not significant in the multivariable model.  
 
Neuroticism (HR 1.12,1.09-1.14 per unit, pFDR<0.0001), previous history of 
unemployment (HR=1.24, 1.06-1.45, pFDR=0.02)  and smoking status (current 
smokers HR 1.57 (1.34-1.84, pFDR <0.0001) were also positively associated with 
antidepressant use, whereas cognitive function (g) scores were negatively associated 
(HR 0.89, 0.85-0.93, pFDR 0.001). Multiple physical comorbidities (3+) were positively 
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associated with antidepressant use (HR 1.85,1.33-2.57, pFDR 0.002). The most 
predictive factor for antidepressant use was previous history of affective disorder on 
GS:SFHS recruitment, with history of a single episode of MDD having a hazard ratio 
of 2.22 (1.85-2.67, pFDR<0.0001).  
 
Table 5.6 : Cox Regression of Time-To-Antidepressant-Use in GS:SFHS 
(Excluding those Already Using Antidepressants At Time Of Recruitment),  




Hazard Ratio p 
Multivariable 
Hazard Ratio p(FDR) Sig 
Intercept      
Sex – male Ref Ref Ref Ref  
       – female 1.94(1.72-2.19) <0.0001 1.74(1.53-1.98) <0.0001 *** 
Age :18-24 Ref Ref Ref Ref Ref 
        :25-34 0.81(0.64-1.03) 0.16 0.79(0.62-1.01) 0.119   
        : 35-44 1.03(0.83-1.28) 0.92 0.95(0.75-1.21) 0.787   
        : 45-54 0.99(0.80-1.22) 0.92 1.00(0.79-1.26) 0.993   
        : 55-64 0.72(0.58-0.89) 0.007 0.72(0.57-0.92) 0.021 *  
        :65-74 0.49(0.37-0.64) <0.0001 0.48(0.35-0.64) <0.0001 *** 
        :75+ 0.93(0.67-1.29) 0.92 0.74(0.52-1.07) 0.193   
No MDD on Screening Ref Ref Ref Ref Ref 
MDD – Single Episode 3.17(2.69-3.76) <0.0001 2.22(1.85-2.67) <0.0001 *** 
MDD – Recurrent  4.33(3.54-5.30) <0.0001 2.10(1.68-2.62) <0.0001 *** 
MDD – Bipolar 4.84(2.38-9.85) <0.0001 2.11(0.99-4.47) 0.109   
Never Smoked Ref Ref Ref Ref Ref 
Currently Smoke 2.05(1.78-2.37) <0.0001 1.57(1.34-1.84) <0.0001 *** 
Ex-Smoker 1.30(1.14-1.48) <0.0001 1.33(1.15-1.53) 0.001 * 
Neuroticism 1.20(1.18-1.22) <0.0001 1.12(1.09-1.14) <0.0001 *** 
SPQ  1.11(1.09-1.12) <0.0001 1.03(1.01-1.05) 0.003 * 
Cognitive function (g)  0.85(0.81-0.89) <0.0001 0.89(0.85-0.93) <0.0001 *** 
No physical health complaints Ref Ref Ref Ref Ref 
1-2 physical health complaints 1.22(1.08-1.38) <0.0001 1.27(1.11-1.44) 0.003 * 
3+ physical health complaints  1.79(1.34-2.41) <0.0001 1.85(1.33-2.57) 0.002 * 
Unemployment history    1.24(1.06-1.45) 0.021 * 
SIMD – Most Deprived quintile  2.03(1.70-2.42) <0.0001 1.23(1.01-1.49) 0.086 . 
SIMD – 2nd quintile 1.47(1.23-1.76) <0.001 1.07(0.88-1.29) 0.64  
SIMD – 3rd quintile 1.27(1.06-1.52) 0.013 1.06(0.88-1.28) 0.64  
SIMD – 4th quintile  1.02(0.87-1.21) 0.79 0.93(0.78-1.10) 0.54  
SIMD – Least Deprived quintile Ref Ref Ref Ref Ref 
N.B. The following covariates were in the model but not shown as not significant in multivariable analysis: Location of GS:SFHS 
enrolment(not significant in univariate or multivariable analyses), self-reported alcohol use, body mass index (bmi).  
Abbreviations:  Sig=significance level *p<0.05, **p=<0.001, ***p<0.0001  Ref=reference level g = cognitive function score. 
GHQ = General Health Questionnaire. MDD = Major Depressive Disorder. SIMD = Scottish Index of Multiple Deprivation.   SPQ 









History of affective disorder is defined as previous history of single or recurrent episode MDD or bipolar disorder on the SCID interview. ‘High’ neuroticism is defined as a neuroticism score occurring in 
the upper tertile of Eysenck Personality Questionnaire-Short Form neuroticism scores, and ‘low’ is defined as occurring in the lower tertile. Abbreviations :   “F” = Female. “M”=Male.  
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For comparison with Table 5.6, a complete case analysis (N=6855) for the time-to-




Table 5.7 : Complete Case Analysis Cox Regression of Time to 
Antidepressant Use in Generation Scotland Cohort  





Hazard Ratio p(FDR) Sig 
Intercept    
Sex: Male Ref Ref  
Sex:  Female 1.83(1.59-2.10) <0.001 *** 
Age 18-24 Ref Ref Ref 
Age 25-34 0.77(0.59-1.01) 0.126   
Age 35-44 1.00(0.78-1.28) 1.00   
Age 45-54 1.02(0.80-1.31) 0.919   
Age 55-64 0.77(0.60-0.99) 0.093 .  
Age 65-74 0.48(0.35-0.66) <0.0001 *** 
Age 75+ 0.77(0.51-1.15) 0.30   
No MDD on Screening Ref Ref Ref 
MDD – Single Episode 2.13(1.76-2.58) <0.001 *** 
MDD – Recurrent  1.99(1.57-2.51) <0.001 *** 
MDD – Bipolar 1.49(0.62-3.60) 0.491   
Never Smoked Ref Ref Ref 
Currently Smoke 1.54(1.31-1.82) <0.0001 *** 
Ex-Smoker 1.38(1.19-1.59) <0.0001 *** 
SIMD – Most deprived quintile 1.30(1.06-1.60) 0.026 * 
SIMD – 2nd quintile 1.15(0.95-1.40) 0.245  
SIMD – 3rd quintile 1.10(0.90-1.34) 0.458  
SIMD – 4th quintile 0.99(0.83-1.19) 0.951   
SIMD – Least deprived quintile Ref Ref Ref  
Neuroticism 1.12(1.10-1.15) <0.0001 *** 
SPQ  1.03(1.01-1.05) 0.002 * 
g  0.90(0.85-0.94) <0.0001 *** 
No physical health complaints Ref Ref Ref 
1-2 physical health complaints 1.25(1.09-1.44) 0.004 * 







Table 5.8: Crude and Age-Sex Reweighted Prevalence of Antidepressants in 
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5.7  Discussion  
 
5.7.1  Summary of Main Results 
 
In this study, we demonstrate an increase in antidepressant usage in this UK cohort, 
with an estimated 17.3% of the adult population using antidepressants in 2016, an 
increase of nearly one third (36.2%) on 2010 (see Table 5.8 above). We have found 
that, even if low dose amitriptyline use is discounted, one fifth of our sample (20.8%) 
has been prescribed an antidepressant at least once between 2012-16. The 
prescribing of antidepressants continues to be dominated by the SSRI class, but we 
observed a rise in the proportion of SNRIs, and other antidepressants such as 
mirtazapine, prescribed. This is an interesting trend and may be further stimulated by 
future revisions of clinical guidance, which may recategorize mirtazapine as a first-
line treatment in psychiatric disorders such as major depression, leading to further 
increases in prevalence of use and interest in the efficacy and safety profile of 
mirtazapine and other non-SSRI antidepressants (Coupland et al., 2015; Cipriani et 
al., 2018).  
 
Our findings accord with recent UK data which has found that antidepressant 
prescribing is the highest ever at 64.7m prescriptions for England in 2016 (NHS 
Digital, 2017). However, in this study we also found a reweighted incidence for new 
antidepressant users of just 2.4%, and a duration for antidepressant episodes of in 
excess of 15 months in nearly half of episodes identified. This supports the hypothesis 
of increased longer-term use by regular antidepressant users driving much of the 
increased prevalence of antidepressants we report.  Our study also found that 
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adherence to antidepressants was relatively high, meeting the more conservative 
PDC threshold adherence of 80% in 69.0% of cases.  
 
We found that history of affective disorder, multiple physical comorbidities, and being 
female, were the most predictive of antidepressant use. We also report an interesting 
association between neuroticism and antidepressant use, with considerably greater 
incident antidepressant use in the upper tertile of EPQ-SF neuroticism scores (Figure 
4.4). Neuroticism is a personality trait with significant clinical overlap with psychiatric 
disorder (Smith et al., 2016), which is relatively straightforward to measure 
prospectively, and our results suggest that it could be a useful predictor of future 
antidepressant usage. A recent study in older adults (Steffens et al., 2018)has found 
that neuroticism may be also associated with lower remission rates of antidepressant-
treated depression. As discussed in the methods, extraversion was not found to be 
significant on model fitting and was not included in this analysis. 
 
We also found that cognitive function had an inverse association with antidepressant 
use, in line with previous research indicating an association between cognitive 
impairment and MDD (Marazziti et al., 2010). Evidence is accumulating of the 
presence of cognitive impairment with depressive disorder(Sumiyoshi et al., 2019). It 
has also been shown that lower baseline cognitive performance (by the measure of 
lower IQ) carries increased risk of later depression(Zammit et al., 2004). It is therefore 
possible that greater antidepressant prescribing is associated with worsened 
cognitive function scores because lower cognitive function is associated with 
depression. In addition, depressive illness could be associated with cognitive 
impairment although evidence for this is mixed and studies in mild cognitive 
impairment (MCI) and dementia suggests that depression accompanies MCI but does 
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not preceed it(Richard et al., 2013). Antidepressant use is associated with 
improvement in some measures of cognitive function(Rosenblat et al., 2015).  
 
With this study methodology we cannot judge definitely whether the increasing 
antidepressant prevalence we found is appropriate to clinical indication. The 
prevalence of prescribing we report should be seen in the context of not only the 
prevalence of MDD, but the prevalence of anxiety disorders, eating disorders, sexual 
disorders, sleep disorders and other indications for antidepressant medication.  
 
Nevertheless, it has also been argued that current rates of antidepressant treatment 
may still not identify all those most likely to benefit (Kendrick et al., 2005). The 
National Health and Nutrition Examination Surveys 2005-08 (Pratt et al., 2011) found 
that only one third of those with severe depressive symptoms were on antidepressant 
therapy, and less than half of those taking multiple antidepressants had seen a mental 
health professional in the past year. In our study, we found that, among those 
antidepressant naïve individuals with the highest psychiatric ‘caseness’ according to 
GHQ scores in Generation Scotland, just 6.6% were prescribed an antidepressant 
within one year of follow-up, and less than 10% of those with the highest severe 
depression caseness (three standard deviations on the GHQ-28 D subscale) were 
prescribed an antidepressant within one year.  This might indicate potential unmet 
clinical need for antidepressants, although such a conclusion should be approached 
with caution as GHQ is a measure of psychiatric distress at one timepoint, and higher 
GHQ scores do not necessarily indicate requirement for antidepressants.  
 
It has also been previously argued that antidepressants are insufficiently reviewed by 
clinicians, leading to unnecessarily long treatment durations (Bosman et al., 2016; 
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Johnson et al., 2012). The European Study of the Epidemiology of Mental Disorders 
(ESEMed) demonstrated that 63.5% of those with mood disorders had not consulted 
health services in the previous 12 months (Alonso J, 2004), with similar findings in 
the US National Comorbidity Survey Replication (Wang et al., 2005).  We found that 
only a small minority of antidepressant users are being reviewed in outpatient 
psychiatry, suggesting that the majority of antidepressant monitoring takes place in 
primary care. The high prevalence of antidepressant use we report suggests that 
there may be scope for increasing the rate of medication reviews for long-term 
antidepressant users in primary (and secondary) care, with consideration of managed 
discontinuation of treatment. This can help manage the risks associated with 
prolonged antidepressant exposure when a sustained recovery from illness has been 
achieved.  
 
Indeed, in recent years there has been a drive by government in both the UK and 
Scotland to reduce the prevalence of antidepressants. The Chief Medical Officer of 
Scotland has convened a working group of experts (Short Life Working Group On 
Prescription Medicine Dependence And Withdrawal) to examine prescribing trends, 
including for antidepressants. This has made recommendations for further research 
to isolate withdrawal effects of antidepressants from the original disorder and its 
return; optimal recommended withdrawal regimes and prevention or treatment of 
dependence or withdrawal(Scottish Government, 2021). The Royal College of 
Psychiatrists has released a position statement on antidepressants and depression 
(Royal College of Psychiatrists, 2019). This document expresses concerns about 
long-term use of antidepressants (beyond 2 years) and withdrawal management. It 
recommends that all antidepressants are tapered prior to discontinuation to minimise 
withdrawal reactions and failed discontinuation. This study has identified that there is 
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increased antidepressant prevalence associated with long prescription cycles and 
that the vast majority is being managed, it would seem, in primary care. Regular 
reviews of the usefulness of continuing antidepressant medication in general practice 
would appear therefore to be the most tractable approach to meeting government 
objectives.  
 
Among medications frequently also prescribed with antidepressants, the most 
common psychiatric class was anxiolytics, especially benzodiazepines and “Z-drugs”. 
We found that prescribing of analgesic and opiate medication was appreciably higher 
in antidepressant users, especially those with a history of recurrent depression and 
bipolar disorder. An association between depression and pain has been previously 
described (McIntosh et al., 2016a) and could be related to altered pain sensitivity in 
depressed states and comorbidity of depression with painful conditions. 
 
 
5.7.2  Comparison with Previous Studies  
 
A previous prescribing database study of the Tayside population of Scotland 
(n=325,000) (Lockhart and Guthrie, 2011) found an increase in prevalence from 8.0% 
in 1995/96 to 13.4% in 2006/07. The standardised rate for 2006-07 antidepressants 
was 13.1% (SSRIs 7.9%, TCAs 5.2%, other antidepressants 1.9%) compared to the 
reweighted 2016 rates of 17.3% (10.5%, 5.8%, 3.2%) found in our study. Analysis of 
the UK Clinical Practice Research Datalink (CPRD, N=1,524,201) found that 23% of 
individuals were prescribed at least one antidepressant between 1995 and 2001 
(Mars et al., 2017).  
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Results from the US National Health and Nutrition Examination Survey (NHANES) 
found a 2009-10 annual prevalence of 10.4% (Mojtabai and Olfson, 2014), with 67.4% 
reporting use for 24 months or longer, and 17.1% for <6 months. Incidence was 
estimated at 2.55% (per 100 individuals per year) in comparison with our estimated 
incidence of 2.4%. In this US study, 32.5% of antidepressant users had visited a 
mental health professional in the previous year, compared with 10.0% in our UK-
based study.  
 
A prescription database study in British Columbia conducted in 2004 (Raymond et 
al., 2007) found a prevalence of 7.2% and found that lower socioeconomic groupings 
and lowest income groupings had higher prevalence of antidepressant use. In our 
time-to-event analysis we found the lowest SIMD quintiles were associated with 
antidepressant use in univariate analysis but not in the multivariable model.   
 
A recent study of routine general practice care data in a cohort based in Amsterdam 
(n=156,620) found 43.7% of antidepressant users were long-term users (Huijbregts 
et al., 2017), which is similar to our own finding of 44.8%.  
 
5.7.3 Strengths and Limitations 
 
This study benefitted from the relatively large population-based GS:SFHS cohort and 
the availability of structured clinical interview data alongside quantitative measures of 
non-specific psychiatric morbidity and numerous demographic, socio-economic and 
psychological variables. The national prescribing and morbidity data to which it was 
linked was of high fidelity (with a capture rate in excess of 95%) and, being nationally 
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based, reduced the chance of individuals being lost to follow up during the study 
period due to, for example, moving their GP practice.  
 
We were also able to record the date of dispensing as well as prescribing, and 
whether the medication was collected. By applying a longitudinal retrospective design 
rather than a cross-sectional approach, this study increased the potential for accurate 
measurement of the pharmaco-epidemiological variables.  
 
However, by using a cohort study as its basis, this analysis is also susceptible to 
selection and confounding biases. Another significant limitation is the lack of details 
of the indication of medication use in the PIS prescribing data (as with many other 
prescribing databases based on routinely collected administrative data). In GS:SFHS, 
previous history of affective disorder was collected via screening using the SCID, but 
we were not able to determine ongoing and subsequent psychiatric diagnoses in the 
period studied following GS:SFHS recruitment. It is likely that a proportion of those 
individuals with no previous history of affective disorder were subsequently diagnosed 
with such, or that other psychiatric disorders such as anxiety disorders were the 
indication for later antidepressant treatment. GS:SFHS did not provide data on 
baseline history of anxiety disorders to complement the SCID-derived history of 
affective disorders. We were also not able to determine the extent to which severity 
of psychiatric symptoms or level of functional impairment determines antidepressant 
usage.  
 
Prescribing data is also an imperfect proxy for medication use, given that the 
medication may not be taken (primary noncompliance) or may not be used as directed 
(secondary noncompliance). Noncompliance to antidepressant medication has been 
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previously estimated at 50% (Haynes et al., 2008).  The PIS prescribing data only 
covered prescriptions issued in the community, and therefore may underestimate true 
prevalence and treatment duration, although it would be expected that most 
antidepressant users commenced in hospital would continue medication in the 
community. A further limitation of our study being based on routinely collected 
administrative prescribing data is that it is also not possible to determine the extent 
to which the antidepressant prescribing we recorded was appropriate to clinical need 
or consistent with treatment guidelines. 
 
Although we attempted to apply stringent criteria for incident use of antidepressants 
– using prescription data, linked morbidity data, self-report and objectively measured 
history of affective disorder to screen antidepressant naïve cohort members – we may 
still have falsely identified some previous antidepressant users as incident cases, 
particularly as we did not have data preceding April 2009.  
 
Our Cox regression analysis of predictors of antidepressant use within 5 years was 
necessarily restricted by the variables available to us in GS:SFHS. We were able to 
derive effect sizes for numerous variables previously associated with antidepressant 
use, such as history of affective disorder, medical comorbidities and female gender. 
However, due to the limited diagnostic information available in GS:SFHS we were not 
able to quantify the association between non-affective psychiatric disorders such as 
anxiety disorders (which are likely to be significantly predictive) and antidepressant 
use. The conclusions of our time-to-event analysis need to be placed in the context 
of the variables available in our model.  
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The cohort was also for adults only, thereby not including antidepressant use among 
the under 18s, and the overall population prevalence and incidence would be 
expected to be lower than our figures since children are prescribed antidepressants 
less frequently.   
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5.7.4 Future Directions and Clinical Implications  
 
We found that antidepressant prevalence was higher than previously reported for the 
UK, but that incidence remains relatively stable. This suggests that increased 
antidepressant prevalence is driven by longer treatment durations and good levels of 
adherence, and previous users returning to medication for a wider range of 
indications, rather than an upsurge in incident cases.  
 
Our study also demonstrates the utility of record-linking administrative health data to 
population-based cohorts to provide enhanced pharmaco-epidemiological estimates 
of prevalence, incidence and adherence. We also found significant relationships 
between neuroticism and cognitive function for antidepressant use, even when 
affective disorder was controlled for. These tests are relatively easy to administer and 
could prove useful to clinicians in constructing predictive models of clinical risk.  
 
More research is required to investigate the clinical appropriateness of antidepressant 
prescribing. Our research suggests that the vast majority of antidepressant 
prescribing, and medication review, takes place in the primary care setting in the UK.  
Primary care will necessarily therefore remain the focal point for future efforts to 
improve antidepressant prescribing practices, monitoring of adherence and adverse 









5.8 Concluding Remarks  
 
In this chapter I have demonstrated using the example of antidepressant pharmaco-
epidemiology how linked data can be used to enhance a cross-sectional cohort study 
to address a longitudinal research question.  
 
The implications of this are potentially profound for existing population-based and 
selective cohorts, and also for biobanks. Increasingly, we can speculate that 
researchers will incorporate into the study design of cohorts the ability to link to 
administrative health data and also to regularly update this data. Further effort should 
be made by funding bodies, research ethics and governance administrations, and the 
research community to simplify the process of obtaining regular releases of new data 
to improve the quality of longitudinal analyses.  
 
However, it is important to remember that a data-linked cohort study is not the same 
as a true longitudinal study. When choosing appropriate statistical tools for analysis, 
researchers need to pay close attention to the time points at which predictor and 
outcome variables were measured. For example, in the cohort phenotypic data there 
is often only one time of measurement, at recruitment, whereas in linked data there 
are potentially far more available timepoints. The applicability of certain statistical 
techniques, such as structural equation modelling, depends on the temporal 
sequence of measurement of predictor and outcome variables.  
 
Nevertheless, the linkage of administrative data to existing cohort data breathes new 
life into these datasets and offers researchers a range of potential new avenues for 
research. As I shall explore in the next chapter, as well as allowing the adoption of a 
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more longitudinal approach to cohort data, record-linkage also enables the defining 
of entirely new cases and phenotypes within the research population, allowing study 
of phenotypes that are less predisposed to accurate self-report and which 








Chapter 6: The Identification and Study of a New Self-harm 
Phenotype within a Population-based Cohort through Record-
Linkage  
 
6.1 Introductory Remarks  
 
In Chapter 1, we saw that self-harm is a significantly prevalent behaviour which, given 
its emotive nature, is particularly likely to be affected by self-reporting and follow-up 
issues which constrain the ability of classical cohort studies to effectively study it.  
 
Record-linkage to administrative health data offers the potential to augment existing 
cohort data with information on self-harm (at least that which appears in healthcare 
records) which the individuals involved may not otherwise feel comfortable to 
disclose. Thus, in the following chapter I demonstrate how linked data has allowed 
the GS:SFHS cohort, which did not at the time of recruitment take much information 
regarding self-harm (outside of what was collected in tools like the SCID and GHQ), 
to be used for a highly scaled, replicated, study of self-harm and the stress-response 
associated psychological trait neuroticism. The ability to identify new phenotypes for 
study is one of the core features of record-linkage to administrative health data that I 
have argued for in this thesis.  
 
In the preceding chapter, I demonstrated that neuroticism is independently associated 
with antidepressant use, even when MDD status is included as a covariate. In this 
chapter I shall investigate whether neuroticism is also independently predictive of self-
harm, another major MDD-associated outcome.  
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The following chapter has been published in the journal Social Psychiatry and 
Psychiatric Epidemiology  (Hafferty et al., 2019a). As the first author of the publication 
I jointly conceived the study, performed the analysis, wrote the manuscript and 
prepared all the tables and figures. To acknowledge the contribution of the co-authors 
(see also Publications section of this thesis for breakdown of author contributions) the 
term “we” rather than “I” is used throughout this chapter.  
 
6.2 Paper: The Role of Neuroticism in Self-Harm and Suicidal Ideation 
– Results from Two UK Population-Based Cohorts  
 




Self-harm is common, debilitating and associated with completed suicide and 
increased all-cause mortality, but there is uncertainty about its causal risk factors, 
limiting risk assessment and effective management. Neuroticism is a stable 
personality trait associated with self-harm and suicidal ideation, and correlated with 
coping styles, but its value as an independent predictor of these outcomes is disputed.  
 
6.3.2 Methods  
 
Prior history of hospital-treated self-harm was obtained by record-linkage to 
administrative health data in Generation Scotland:Scottish Family Health Study 
(N=15,798; self-harm cases=339) and by a self-report variable in UK Biobank 
(N=35,227; self-harm cases=772). Neuroticism in both cohorts was measured using 
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the Eysenck Personality Questionnaire-Short Form (EPQ-SF). Associations of 
neuroticism with self-harm were tested using multivariable regression following 
adjustment for age, sex, cognitive ability, educational attainment, socioeconomic 
deprivation and relationship status. A subset of GS:SFHS was followed-up with 
suicidal ideation elicited by self-report (n=3342, suicidal ideation cases=158) and 
coping styles measured by the Coping Inventory for Stressful Situations. The 
relationship of neuroticism to suicidal ideation, and the role of coping style, was then 
investigated using multivariable logistic regression.  
 
6.3.3 Results  
 
Neuroticism was positively associated with hospital-associated self-harm in 
GS:SFHS (per EPQ-SF unit Odds Ratio 1.2 95% Credible Interval 1.1-1.2, pFDR 
0.0003) and UKB (per EPQ-SF unit Odds Ratio 1.1 95%Confidence Interval 1.1-1.2, 
pFDR 9.8 x10-17). Neuroticism, and the neuroticism-correlated coping style, emotion-
oriented coping (EoC), were also associated with suicidal ideation in multivariable 
models.  
 
6.3.4 Conclusions  
 
 
Neuroticism is an independent predictor of hospital-treated self-harm risk. 










Suicide is a major global health challenge and is the leading cause of death among 
young people aged 20-34 years in the UK (Office of National Statistics, 2017). A 
variety of sociodemographic, biological and psychological risk factors have been 
proposed for completed suicide (for review, see (Turecki and Brent, 2016)). Among 
the most predictive, and potentially amenable to clinical intervention, are (1) history 
of self-harm, which is associated with 37.2 times increased risk of completed suicide 
within the first year following an act of self-harm(Olfson et al., 2017), and (2) suicidal 
ideation, which in a recent meta-analysis is associated with increased risk ratios for 
competed suicide of 2.35-8.00 (Hubers et al., 2018).  
 
Self-harm is a common and debilitating behaviour characterised by self-injury or self-
poisoning, irrespective of the apparent purpose of the act (National Collaborating 
Centre for Mental Health, 2004). Estimated lifetime prevalence of self-harm is 1-6%, 
with the UK reportedly having the highest self-harm rate in Europe (Horrocks, 2002). 
Incidence is estimated at 400/100,000 population per year (University of York, 1998). 
However, many people who self-harm do not attend clinical services, and thus true 
prevalence may be considerably greater (Hawton et al., 2002).   
 
Self-harm is aetiologically associated with childhood maltreatment (Fergusson et al., 
2000; Statham et al., 1998) and physical illness (De Leo et al., 2001). In addition, a 
number of demographic factors are predictive of self-harm, including being female 
(Schmidtke et al., 1996); young adulthood (Schmidtke et al., 1996); being unmarried 
(Schmidtke et al., 1996); or separated/divorced (Petronis et al., 1990); being 
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socioeconomically disadvantaged (Taylor et al., 2004); unemployed (Platt S., 2000); 
or low educational attainment (Rappaport et al., 2017).  
 
Psychiatric illness also has well-known associations with self-harm (Skegg, 2005). 
One systematic review of non-fatal self-injury presenting to hospital reported a pooled 
prevalence for psychiatric disorder of 83.9%, with mood disorders the most common 
category (58.5%) (Hawton et al., 2013). The association between depressive disorder 
and self-harm has been found in numerous other studies (Colman et al., 2004; 
Beautrais, 2000).  
 
6.4.1 Types of Self-Harm 
 
Self-harm is performed with a variety of motivations, including attempted suicide, self-
mutilation, seeking psychological relief, and the communication of distress. Often, 
there is not a single readily definable motivation, but multiple factors occurring 
simultaneously (Kapur et al., 2013). In the majority of cases, the intention is not to die 
(Skegg, 2005).  
 
Given the difficulties encountered clinically in ascertaining intent and motivation, it 
has been argued that the terms ‘deliberate self-harm’, ‘self-harm’, ‘attempted suicide’ 
and ‘suicidality’ are imprecise for research purposes (Nock, 2010). Recently, the Fifth 
Edition of the Diagnostic and Statistical Manual for Mental Disorders (American 
Psychiatric Association, 2013) has proposed a distinction between ‘nonsuicidal self-
injury’ (NSSI) and ‘suicidal behaviour disorder’ as ‘Conditions For Further Study’. 
However, it remains controversial whether such discrete categorizations can be 
confidently made in clinical practice, or demonstrate differentiable suicidal outcomes, 
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given the biases inherent in self-report, and the close association of NSSI with suicidal 
behaviour (Kapur et al., 2013) (Cooper et al., 2005). Broadly defined ‘self-harm’ 
therefore remains an important clinical outcome in current suicidology literature 
(Kapur et al., 2013; Hawton et al., 2015). 
 
Another approach to subcategorising self-harm is on the basis of whether it has 
received hospital treatment. Hospital-treated self-harm is recognised as an important 
intervention point in suicide prevention (Carroll et al., 2014). Approximately one 
seventh to one fifth of those with hospital-treated self-harm will repeat their self-harm 
within one year (Olfson et al., 2015). Self-harm that requires medical attention 
significantly increases the future risk of suicide (Cooper et al., 2005), particularly if 
admission to hospital is required (Gibb et al., 2005). Within the UK, up to one fifth of 
those who die by suicide have attended hospital for self-harm in the preceding year 
(Gairin et al., 2003). 
 
6.4.2 Suicidal Ideation  
 
Suicidal ideation, additionally, is an important antecedent to progression to significant 
self-harm and suicide attempts (Kessler et al., 1999; Fergusson et al., 2000). 
Individuals who express suicidal ideation have significantly greater 12 month 
prevalence of self-harm and completed suicide, especially if there is associated 
planning (Turecki and Brent, 2016). Nevertheless, the relationship between self-harm 
and suicidal ideation is complex, with suicidal ideation having reportedly more than 




6.4.3 Self-Harm and Psychological Characteristics  
 
Both self-harm and suicidal ideation are associated with personality, including 
personality disorders (Haw et al., 2001) and normally-distributed personality traits. In 
particular, neuroticism is associated with suicidal ideation (Rappaport et al., 2017; 
Cox et al., 2004), suicide attempts (Pickles et al., 2010; Sharif et al., 2014),  and 
suicide (Draper et al., 2014; Tanji et al., 2015). A systematic review of personality 
traits and suicidality (Brezo et al., 2006) found that neuroticism (and hopelessness) 
were the most predictive traits in risk screening.   
 
Neuroticism is a partially-heritable personality trait which incorporates negative 
affectivity (McCrae and Costa, 1987; Eysenck, 1975) and increased sensitivity to 
stress (for review see(Lahey, 2009)). An important aspect of neuroticism is that 
individual differences in the trait are moderately to highly stable over many years 
(Conley, 1985; Gale et al., 2010) and thus might be useful as a patient level predictor 
for future self-harm risk. However, the link between neuroticism and self-harm is not 
wholly consistent and one large study did not find an association between neuroticism 
and lifetime history of prior suicide attempts (Cox et al., 2004).  
 
Neuroticism is also highly correlated with affective disorder and both conditions show 
evidence of substantially overlapping genetic architecture (Navrady et al., 2017a; 
Kendler et al., 1993; Jardine et al., 1984). There is uncertainty about whether 
neuroticism is a significant predictor of self-harm irrespective of depressive disorder 
history (Farmer et al., 2001; Rappaport et al., 2017) or whether it is insignificant when 
comorbid depression is controlled for (Batterham and Christensen, 2012; Bi et al., 
2012). A recent study (Rappaport et al., 2017) in Chinese females concluded that 
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neuroticism was significantly associated with suicide attempts even after controlling 
for comorbid depression and also stressful life events. Stressful life events are an 
additional posited factor in suicidal behaviour and it is hypothesised that neuroticism 
may serve to increase negative perceptions of these events (Kendler et al., 2003; 
Pickles et al., 2010).  
 
6.4.4 Protective Factors and Coping Styles  
  
While considerable work has been undertaken at elucidating risk factors for self-harm 
and suicidal ideation, less is known about protective factors, which are not merely the 
absence of risk (Skegg, 2005). One component of managing adversity is coping 
styles, the behavioural and cognitive strategies adopted in response to stressful life 
events. These are not only situational but may be environmentally and genetically 
conditioned (Folkman and Moskowitz, 2004). They are of particular interest because 
they are potentially modifiable and might be impacted by treatment (Chou, 2017; 
Eggert et al., 1995).  
 
Coping strategies are elicited by questionnaires like the Coping Inventory for Stressful 
Situations (Endler, 1990) which yields three main groups of coping strategies. The 
first is a “task-“ or problem-oriented coping style (ToC), which is characterised by 
purposeful efforts aimed at problem solving. “Avoidance-orientated” (AoC) coping, by 
contrast, is defined by behaviours aimed at avoiding difficult circumstances (Cosway, 
2000). Finally, “emotion-orientated” coping (EoC) is characterised by attempts to 
regulate difficult emotions as a means of coping.   
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While ToC is generally seen as positively related to health and psychological 
adaptation, AoC and EoC are generally seen as less psychologically adaptive, and 
have been associated with negative mental health outcomes(Higgins, 1995). Task-
oriented coping is thought to be negatively correlated with neuroticism (Connor-Smith 
and Flachsbart, 2007) while emotion-oriented coping is positively correlated (Endler 
and Parker, 1990).  Moreover, emotion- and avoidance- oriented coping are thought 
to be associated with greater risk of suicidal ideation, while  task-oriented coping is 
associated with lower risk (Chou, 2017).  
 
6.4.5 Outline of Study  
 
In the first part of the study, we aimed to investigate the relationship between 
neuroticism and hospital-treated self-harm. We employed two large UK population-
based cohorts with neuroticism quantified by the same Eysenck Personality 
Questionnaire-Revised Short Form (EPQ-SF) scale. In one cohort, Generation 
Scotland (GS:SFHS), we used record-linkage to administrative health data to identify 
individuals with previous hospital-treated self-harm (generally defined and including 
all types of intentional self-injury requiring admission to medical or psychiatric 
hospital, N=15,798; self-harm cases=339). In the second cohort, UK Biobank (UKB), 
we used self-reported intentional self-harm (whether or not with intention to end life) 
requiring hospital treatment (including emergency department) and/or review by 
psychiatric services (N=35,227; self-harm cases=772). We hypothesised that 
neuroticism would be positively associated with self-harm, even after adjustment for 
depressive disorder and other significant sociodemographic factors.  
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In the second part of the study, we employed a follow-up sample of GS:SFHS with 
contemporaneous self-reported measures of suicidal ideation (n=3356, suicidal 
ideation cases=161). This follow-up group also had self-reported questionnaire data 
on significant life events and coping styles in response to stress. We hypothesised 
that neuroticism would also be independently predictive of suicidal ideation in this 
group, when adjusted for depressive disorder, significant life events and other 
significant demographic factors. We also aimed to ascertain the relationships on 







Generation Scotland:Scottish Family Health Study (GS:SFHS) was a population- and 
family-based epidemiological adult (age 18+) cohort recruited February 2006-March 
2011, which has been described elsewhere (Smith et al., 2006; Smith et al., 2013a). 
GS:SFHS had a higher proportion of females (59%) and was of older age (mean 49 
males, 49 females) compared to the Scottish population (mean 37 males, 39 females, 
2001 census) (Smith et al., 2013a). GS:SFHS participants were typically healthier 
and more affluent than the general Scottish population, nevertheless 32.9% of 
individuals lived in areas with worse than average socioeconomic deprivation (Smith 
et al., 2013a). 99% of the study group was of white ethnicity (Scottish population 
98%). Sociodemographic information on age, sex, educational attainment and 
relationship status were collected by questionnaire on enrolment.  
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Neuroticism was measured using the Eysenck Personality Questionnaire-Revised 
Short Form (EPQ-SF) (Eysenck, 1985). The neuroticism subsection of the EPQ-SF 
consists of 12 ‘Yes/No’ questions (e.g. ‘Are you a worrier?’). Scores range from 0 to 
12, with higher scores indicating greater neuroticism. This scale has been 
concurrently validated with other quantitative measures of neuroticism (Gow, 2005) 
and has high reported reliability (a-coefficients 0.85-0.88) (Eysenck, 1985).  
 
Trained researchers elicited lifetime history of major depressive disorder (MDD) by 
using the screening questions from the Structured Clinical Interview for DSM-IV 
Disorders (Smith et al., 2013a) and, if either screening question was positive, going 
on to administer the mood sections of the SCID. The screening questions were: “Have 
you ever seen anyone for emotional or psychiatric problems?” and “Was there ever a 
time when you, or someone else, thought you should see someone because of the 
way you were feeling or acting?”. A diagnosis of MDD was made according to DSM-
IV criteria and all interviews were conducted by a trained researcher (2011 cases 
identified, 12.7% of cohort). Individuals with a history of bipolar disorder were 
excluded.  
 
Cognitive testing included the digit symbol substitution test from the Wechsler Adult 
Intelligence Scale III (Wechsler D, 1998a), logical memory from the Wechsler Memory 
Scale III (Wechsler D, 1998b) and verbal fluency (Lezak MD, 1995). From these tests, 
a measure of cognitive function (g)  was derived as the first unrotated principal 
component, explaining 44% of the variance in scores (Marioni et al., 2014). Loadings 
for processing speed, vocabulary, verbal declarative memory and executive function 
were 0.43, 0.53, 0.49 and 0.54 respectively. The range of g was -4.48 to 8.96, mean 
0.00, one standard deviation 1.3. Socioeconomic deprivation was determined using 
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the Scottish Index of Multiple Deprivation 2009 (SIMD) (Scottish Government, 2009). 
This measure employs 6976 geographical area-based data-zones across Scotland 
which are then ranked in order of deprivation, ascertained through weighted scores 
in seven domains including employment, education, health, housing and crime, with 
data-zone 1 the most deprived and 6976 the least deprived.  
 
6.5.2 Identification of Self-Harm in GS:SFHS 
 
All Scottish citizens registered with a General Practitioner are assigned an unique 
identifier, the Community Health Index (CHI). This was used to deterministically 
record-link GS:SFHS participants to the Scottish Morbidity Records to obtain 
information about hospital admissions (SMR01) and psychiatric hospital admissions 
(SMR04) associated with self-harm. Written informed consent was obtained from 
98% of GS:SFHS and only those who consented were linked. Self-harm cases were 
identified by matching to admissions codes with E950-E959 (ICD-9) or X60-X84, 
Z915, E98 and Y1-Y3 (ICD-10) (Batty et al., 2010). Scottish NHS data on mortality 
was also linked, to exclude any GS:SFHS participants who died during follow-up.  
 
6.5.3 Recontact Group and Identification of Suicidal Ideation in GS:SFHS 
 
In 2014, GS:SFHS participants were re-contacted for a follow up assessment of 
mental health (Navrady et al., 2018). Suicidal Ideation was elicited using two 
questions from the General Health Questionnaire-28 (Goldberg and Hillier, 1979). 
Participants were asked “During the past few weeks…Have you thought of the 
possibility you might make away with yourself?” and “Have you found the idea of 
taking your own life kept coming into your mind?”. Participants who answered 
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‘Definitely have’ or ‘Has crossed my mind’ to either question were defined as suicidal 
ideation cases (n=3503, cases=158 (4.7%)).  
 
Stressful life events were ascertained using the List of Threatening Experiences 
(LTE), whereby respondents self-reported their experiences from a list of 12 common 
threatening life events, occurring in the preceding six months (Brugha et al., 1985; 
Brugha and Cragg, 1990). Examples of LTE include “Serious injury or assault to 
yourself”, “Made redundant or sacked from job” and “marital difficulties or break off of 
a steady relationship” (for full list see Figure 6.1 below).  For each event endorsed, 
contextual threat was rated on a scale from 3 (“very bad”) to 1 (“not too bad”). The 
LTE has demonstrated high test-retest reliability and good agreement with informant 
information (Cohen’s k 0.63-0.90) (Brugha and Cragg, 1990).  
 
Figure 6.1  - The List of Threatening Experiences  
 
List of Threatening Experiences (LTE) 
 
1. Serious injury or assault to yourself 
2. Serious injury or assault to a close relative 
3. Death of a parent, spouse, child or sibling  
4. Death of a close family friend or other relative  
5. Separation due to marital difficulties or break up of a steady relationship 
6. Serious problem(s) with close friend, neighbour or relative  
7. Made redundant or sacked from job 
8. Seeking work unsuccessfully for more than one month  
9. Major financial crisis (such as losing three month’s income) 
10. Problems with the police involving court appearance  
11. Something of value lost or stolen  
12. Yourself or your partner give birth 
 
Source: Brugha, T., Bebbington, P., Tennant, C., & Hurry, J. (1985). The List of Threatening Experiences: a subset of 12 life 





Coping styles were elicited using the Coping Inventory for Stressful Situations (CISS) 
(Endler, 1990; Cosway, 2000), a 48 item self-report questionnaire enabling 
responders to rate on a 5-point scale their engagement in coping styles in response 
to stress, including task-, avoidance- and emotion-oriented coping. The CISS shows 
robust validity and reliability (alpha reliability coefficients (Cronbach’s alpha) of 0.82-
0.90 for the main factors) (Cosway, 2000).  History of MDD was re-ascertained using 
the Composite International Diagnostic Interview – Short Form (CIDI-SF) self-report 
questionnaire (Kessler, 1998), with 605 cases identified (18.1% of sample). Bipolar 
disorder cases were excluded. Unlike the main GS:SFHS cohort, only one member 
from each family was analysed (i.e. unrelated sample). 
 
6.5.4 Identification of Self-Harm in UK Biobank 
 
UK Biobank is a population-based cohort of adults aged 40-69 recruited across the 
UK from 2006-2010, which has been described elsewhere (Sudlow et al., 2015). 
During baseline assessment (Smith et al., 2013b) participants provided socio-
demographic information via a touch-screen questionnaire, including educational 
attainment and whether they lived as a singleton or couple. This study included a 
subset of 35227 (7.0%) of UKB with complete case information for the variables of 
interest. Individuals in UKB who were also present in GS:SFHS (n=201) were 
excluded. 
 
Self-harm was ascertained through the touch-screen questionnaire. Participants were 
asked “Have you deliberately harmed yourself, whether or not you meant to end your 
life?”. A follow-up question enquired “Following any time when you took an overdose 
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or deliberately tried to harm yourself did you (tick all that apply)”. Participants who 
ticked “see anyone from psychiatric or mental health services, including liaison 
services” and/or “need hospital treatment (e.g. A&E)” were included as cases in this 
study (772 cases, 2.2% of sample). The other answers, which were not included as 
cases, were “use a helpline”, “see own GP”, “receive help from friends/family” and 
“prefer not to answer”.  
 
Neuroticism was assessed using the EPQ-SF(Eysenck, 1985), administered via the 
touch-screen questionnaire. Lifetime history of depression was ascertained by touch 
screen questionnaire relating to lifetime experience of depressive symptoms and 
contact with mental health services (Smith et al., 2013b).  
 
Cognitive testing was administered via three touch-screen tests: (1) a symbol 
matching task over 12 trials (reaction time)  (2) 13 logic/reasoning questions over two 
minutes (verbal-numerical reasoning) (3) card pair matching task (visuo-spatial 
memory). From these tests a single measure of cognitive ability (g) was extracted as 
the first unrotated principal component, explaining 42% of the variance. Loadings for 
visuo-spatial memory, verbal-numerical reasoning and reaction time were 0.58, -0.62 
and 0.53 respectively. The range of g was -4.35 to 5.6, with a mean of 0.0 and one 
standard deviation equating to 1.12. 
 
Socio-economic deprivation was measured via the Townsend Deprivation Index, a 
census-based measure incorporating unemployment, non-home ownership, 
household overcrowding and non-car ownership (Jarman et al., 1991). Each small 
postcode-based geographical area is assigned a Townsend Score, with zero 
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indicating mean deprivation, negative scores indicating relative affluence, and 




6.5.5 Statistical Analysis 
 
All analyses were carried out using R version 3.2.3 (R Core Team, 2015). Complete 
case analysis was employed in both cohorts (see Table 6.1 for analysis of complete 
case versus whole-cohort variables). Generalised linear models with logit-link 
function (logistic regression) were used to identify predictors of self-harm in UK 
Biobank. In the GS:SFHS self-harm study, additional adjustment for inter-relatedness 
of the family-based cohort was performed using a Bayesian mixed model approach, 
with pedigree fitted as a random effect, using an inverse pedigree matrix within the R 
package MCMCglmm.  This implements a Markov Chain Monto Carlo estimator, with 
a “threshold” family probit link function which produces similar results to a logit 
function, optimised to pedigree based mixed effects models.  
 
In the GS:SFHS and UKB multivariable analyses of hospital-treated self-harm, 










TABLE 6.1.A  -  Complete Case versus Whole Sample Proportions and Missing Data for GS:SFHS and UKB Analysis of 
Predictors of History of Self-harm requiring Hospital Attendance  











Cohort % p 
Effect 
size 
Male 6544 41.4 8489 41.0 0.46 Male 16092 45.7 22498 46.2 0.11  
Female 9254 58.6 12196 59.0  Female 19135 54.3 26164 53.8   
18-24 1506 9.5 1963 9.5 0.89 18-24 N/A  N/A    
25-34 2115 13.4 2711 13.1 0.43 25-34 N/A  N/A    
35-44 2965 18.8 3836 18.5 0.59 35-44 3328 9.4 4601 9.5 0.97  
45-54 3448 21.8 4603 22.3 0.33 45-54 9899 28.1 13623 28.0 0.74  
55-64 4184 26.5 5313 25.7 0.09 55-64 16325 46.3 22972 47.2 0.013 0.02 
65-74 1255 7.9 1713 8.3 0.24 65-74 5675 16.1 7466 15.3 0.0026 0.02 
75+ 325 2.1 546 2.6 0.0003 75+   0    
No MDD 13787 87.3 17998 87.0 0.46 No MDD 23054 65.4 30840 63.4    
History MDD 2011 12.7 2687 13.0  History MDD 12173 34.6 17822 36.6 6.5x10-
10 0.04 
             
             
Missing Data      Missing Data       
SIMD/Townsend   1208 5.8  SIMD/Townsend   66 0.1   
EPQ 
Neuroticism    1758 8.5  
EPQ 
Neuroticism    0 0.0   
Living as couple   839 4.1  Living as couple   0 0.0   
Education   2097 10.1  Education   101 0.2   
Cognitive 
ability(g)   475 2.3  
Cognitive 
ability(g)   6086 12.5   





TABLE 6.1.B – Analysis of Complete Case versus Whole Sample proportions and missing data for GS:SFHS follow-up 
analysis of predictors of suicidal ideation  
Follow up study on suicidal ideation    c2 test 
 Complete Cases % Whole Cohort % p value 
Male 1399 39.9 1534 38.7 0.27 
Female 2104 60.1 2432 61.3   
18-24 23 0.7 23 0.6 0.67 
25-34 232 6.6 247 6.2 0.49 
35-44 355 10.1 385 9.7 0.54 
45-54 785 22.4 871 22.0 0.64 
55-64 1221 34.9 1391 35.1 0.84 
65-74 780 22.3 913 23.0 0.44 
75+ 107 3.1 136 3.4 0.36 
No MDD 2829 80.8 3200 80.7 0.94 
History MDD 674 19.2 766 19.3  
No SH 3410 97.3 3842 96.9 0.23 
History SH 93 2.7 124 3.1  
      
      
Missing Data    %  
SIMD/Townsend   0 0.0  
EPQ 
Neuroticism    0 0.0  
List of threatening experiences  10 0.3  
CISS Emotion oriented coping  144 3.6  
CISS Task oriented coping  204 5.1  
CISS Avoidance oriented coping  172 4.3  
Abbreviations:  c2 = Chi-squared test  p = p-value MDD = Major Depressive Disorder   SIMD = Scottish Index of Multiple Deprivation  EPQ = Eysenck Personality Questionnaire  
SH = Self-harm   CISS = Coping Inventory for Stressful Situations  
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In the GS:SFHS suicidal ideation follow-up study, an unrelated sample was used and 
multivariable logistic regression was employed. In this analysis, continuous  variables 
were scaled to have a mean of zero and standard deviation of one, to facilitate 
interpretation of the CISS and LTE predictor variables. During fitting of models, 
interaction terms for neuroticism and depression, and neuroticism and coping styles, 
were tested to investigate potential moderation on neuroticism.  
 
Coefficients were expressed as odds ratios with 95% credible intervals and 95% 
confidence intervals as applicable. P values were reported after False Discovery Rate 
adjustment (Benjamini, 1995). Group differences between numeric variables were 
ascertained using Cohen’s t-test and Cohen’s d measure of effect size, and 
differences between proportions were assessed using z-test and Cohen’s h. For all 
analyses, we have reported all measures, conditions, data exclusions and the 








6.6.1 GS:SFHS  
 
As presented in Table 6.2, there were 339 (2.1%) GS:SFHS individuals identified with 
previous self-harm requiring hospital admission. Self-harm cases were slightly  
younger (mean age 44.7 versus 47.1, p=<0.001, Cohen’s d=0.16 ), predominantly 
female (66.7% versus 58.4%, p0.002, Cohen’s h=0.17), with lower mean cognitive 
ability scores, greater prevalence of depression history (47.5% versus 12%, p<0.001, 
h=0.81)and with higher mean neuroticism (mean 6.4 versus 3.7, p<0.001, d=0.89).  
 
Self-harm cases were more likely to be from more deprived areas as measured by 
SIMD (mean 1964 versus 1823, p<0.001, d=0.58). The proportion of graduates was 
lower in self-harm cases (17.1% versus 33.9%, p<0.001, h=0.39).  
 
A greater proportion of self-harm cases reporting being single (51.9% versus 31.7%, 























Table 6.2: Socio-demographic, clinical and cognitive characteristics of 
GS:SFHS (N=15798) and UK Biobank (N=35227) cohorts used in this study 
 GS:SFHS   (N=15798) 
 

























Female 226(66.7) 9028(58.4) 
0.002 
(0.17) 544(70.5) 18591(54.0) 
<0.001 (0.34) 
Age 44.7 (12.3) 47.1(15.0) 
 
0.0005 
(0.16) 53.3(7.6) 56.6(7.7) 
 
<0.001(0.43) 
      Age  
     categories :      
     18-24 18(5.3) 1488(9.6) 
 
    
 
      25-34 57(16.8) 2058(13.3) 
 
    
 
      35-44 
(GS:SFHS) / 
















     75+ 2(0.6) 323(2.1) 
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scores (mean):   
 
    
 
     Verbal Declarative 15.5(4.4) 16.3(3.9) 
 
0.003 
(0.19)   
 
      Vocabulary 28.4(4.8) 30.3(4.7) 
 
<0.001 
(0.40)   
 
     Processing Speed 67.3(16.9) 73.1(16.9) 
 
<0.001 
(0.34)   
 
     Executive 










     Verbal-Numerical  











SIMD rank (mean, 
most deprived rank 
1, least deprived 







(0.58)   
 
Townsend score 






Education : No 














     A-levels or  








     Other  




     College or  






Living as single 176(51.9) 4906(31.7) 
<0.001 
(0.31) 




Percentages are shown in brackets for categorical variables and standard deviations for continuous variables. Probability (p) values are derived from Cohen’s t-tests for continuous 
variables and z-tests for proportions. Effect sizes are derived from Cohen’s d for numeric variables and Cohen’s h for categorical variables. Townsend scores are standardised – positive 
values of the index indicate areas of high material deprivation, negative values indicate relative affluences, and score 0 indicates mean values. Abbreviations: GS:SFHS = Generation 
Scotland, UKB = UK Biobank, SIMD = Scottish Index of Multiple Deprivation; s.d. = standard deviation. O-levels/GCSEs = ordinary level (Year 11) school certificate. CSE=Certificate of 
Secondary Education (Year 11). A-levels = Advanced level (Year 13) school certificate.  
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The most predictive factor for previous self-harm (Table 5.3) was history of major 
depressive disorder (OR 5.6 95% Credible Interval (CI) 3.5-8.9, pFDR 0.0004). 
Neuroticism was positively associated with self-harm risk by an odds ratio of 1.2 
(95%CI 1.1-1.2, pFDR=0.0003) per EPQ-SF unit. No significant interaction terms were 
found during model fitting.  
 
The significant effects of neuroticism were found in both male-only and female-only 
combined models (see Table 6.4). Figure 6.2 displays the increased risk of self-harm 
per unit of EPQ-SF neuroticism score predicted by our model for both cohorts.   
 
The age groups 25-34, 35-44 and 45-54 were positively associated with self-harm 
whereas age groups 64-74 and 75+ were negatively associated, compared to the 
reference category of 55-64. Gender did not show a significant association in the 
combined model. Having a higher SIMD score (less deprived) was associated with 
decreased risk of self-harm (per quintile unit OR 0.8 95%CI 0.7-0.9, pFDR=0.0004). 
Having no qualifications and being single increased risk. Cognitive ability showed an 
inverse association with self-harm (per unit OR 0.8; 95%CI 0.7-0.9, pFDR =0.0005). 
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Table 6.3: Multivariable analysis of predictors of history of self-harm involving 
hospital/psychiatric treatment in GS:SFHS and UKB (comparison made to any 












Cases (%)  339(2.1%)  772(2.2%)  1578(4.4%)   





Gender : Male Ref  Ref  Ref  
Female 1.1(0.8-1.4) 0.67 1.3(1.1-1.5) 0.005(*) 1.3(1.1-1.4) 0.0001(***) 
Age : 18-24 0.5(0.3-1.0) 0.07(.) - - - - 
     25-34 2.0(1.2-3.3) 0.01(*) - - - - 
     35-44 2.2(1.4-3.5) <0.001 (**) 1.4(1.1-1.7) 0.03(*) 2.1(1.8-2.4) <0.001(***) 
     45-54 1.6(1.1-2.5) 0.03(*) 1.4(1.2-1.7) <0.001 (**) 1.7(1.5-1.9) <0.001(***) 
     55-64 Ref   Ref  Ref  
     64-74 0.4(0.2-0.8) 0.02(*) 0.6(0.5-0.9) 0.01(*) 0.7(0.5-0.8) <0.001 (**) 
     75+ 
0.2(0.04-
0.97) 0.04(*) - - - - 
No history of 
depression Ref  Ref  Ref  
History of 
Depression 5.6(3.5-8.9) <0.001 (**) 
12.7(9.9-
16.4) <0.001 (***) 6.4(5.5-7.3) <0.001(***) 
EPQ Neuroticism 1.2(1.1-1.2) <0.001 (**) 1.1(1.1-1.2) <0.001(***) 1.1(1.1-1.2) <0.0011(***) 
Cognitive function 
(g) 0.8(0.7-0.9) <0.001 (**) 1.1(1.0-1.2) 0.051(.) 1.1(1.0-1.1) 0.004(*) 
Education : No 
qualification or 
other 2.2(1.2-4.1) 0.02(*) 1.0(0.6-1.4) 0.96 0.9(0.6-1.2) 0.47 
     O levels 1.1(0.7-2.1) 0.67 1.0(0.8-1.3) 0.97 1.0(0.8-1.2) 0.94 
     CSE or 
equivalent    1.0(0.7-1.5) 0.98 0.9(0.7-1.2) 0.56 
     A-levels or 
equivalent Ref  Ref  Ref  
     NVQ or 
equivalent  1.4(0.8-2.4) 0.23 1.1(0.8-1.6) 0.77 1.0(0.7-1.3) 0.99 
     Other 
professional    0.9(0.6-1.4) 0.96 1.0(0.8-1.4) 0.94 
     College or 





deprived) 0.8(0.7-0.9) <0.001 (**)       
Townsend score 
(increased score,   
more 
socioeconomically 
deprived)   1.1(1.1-1.1) <0.001 (***) 1.1(1.1-1.1) <0.001 (***) 
Living as couple  Ref  Ref  Ref  
Living as single  2.0(1.5-2.8) <0.001 (**) 1.3(1.1-1.5) 0.005(*) 1.3(1.1-1.4) <0.001 (***) 
95% credible (GS:SFHS) and confidence (UKB) intervals are shown in brackets for odds ratios. Significance 
indicators are * = p<0.05, **=p<0.001, ***=p<0.0001. Abbreviations: GS:SFHS = Generation Scotland cohort; UKB = 
UK Biobank cohort; pFDR = p value using False Discovery Rate method; EPQ = Eysenck Personality Questionnaire; 
SIMD=Scottish Index of Multiple Deprivation; NVQ = National Vocational Qualification; Ref= reference category. O-
levels/GCSEs = ordinary level (Year 11) school certificate. CSE=Certificate of Secondary Education (Year 11). A-








Table 6.4: Male and Female Models from GS:SFHS and UKB 
GS:SFHS 




CI)  pFDR UKB 
Odds Ratios 




Age 18-24 0.05(0.01-0.4) <0.001 (**) 0.9(0.3-2.7) 0.94      
Age 25-34 1.4(0.5-3.6) 0.63 3.1(1.3-7.9) 0.01(*)      
Age 35-44 1.1(0.5-3.0) 0.77 4.3(2.0-10.0) <0.001 (**) Age 35-44 1.4(0.9-2.2) 0.15 1.3(0.98-1.7) 0.15 
Age 45-54 1.2(0.5-2.9) 0.72 2.4(1.2-5.1) 0.02(*) Age 45-54 1.7(1.3-2.4) 0.002(*) 1.3(1.1-1.6) 0.04(*) 
Age 55-64 Ref    Age 55-64 Ref    
Age 65-74 0.5(0.1-2.0) 0.46 0.2(0.03-0.7) 0.01(*) Age 65-74 0.6(0.3-1.0) 0.10(.) 0.7(0.5-1.0) 0.13 
Age 75+ 0.03(0.001-1.6) 0.13 0.2(0.02-1.8) 0.22      
No history of depression Ref    No history of depression Ref    
History of depression 
(SCID) 8.2(3.0-25.9) <0.001 (**) 9.8(4.3-26.6) <0.001 (**) 
History of depression (self-
report) 
15.2(10.0-
24.0) 2.9x10-33(***) 11.3(8.4-15.6) <0.001 (***) 
EPQ-SF Neuroticism 1.3(1.1-1.5) <0.001 (**) 1.2(1.1-1.4) <0.001 (**) EPQ-SF Neuroticism 1.1(1.1-1.2) 6.8x10-07(***) 1.1(1.1-1.1) <0.001 (***) 
Cognitive function (g) 0.8(0.6-1.0) 0.17 0.7(0.5-0.9) 0.001(*) Cognitive function(g) 1.1(1.0-1.3) 0.08(.) 1.1(1.0-1.2) 0.37 
Socioeconomic deprivation 
quintile (SIMD) 0.7(0.5-0.9) 0.01(*) 0.8(0.6-0.9) 0.003(*)      
     
Socioeconomic deprivation 














Table 6.4 cont.  
GS:SFHS 




CI)  pFDR UKB 
Odds Ratios 




Educational attainment  : 
No Qualification 2.0(0.5-8.9) 0.49 2.9(1.0-7.6) 0.049(*) 
Educational attainment : 
None of the above 0.7(0.4-1.4) 0.41 1.1(0.6-1.8)) 0.72 
O Levels/GCSEs or 
equivalent 1.5(0.4-5.0) 0.63 1.0(0.4-2.5) 0.93 
O levels/GCSEs or 
equivalent 0.7(0.4-1.1) 0.16 1.1(0.9-1.6) 0.47 
     CSEs or equivalent 0.8(0.4-1.6) 0.62 1.1(0.7-1.8) 0.72 
A Levels or equivalent  Ref    A Levels Ref    
NVQ or equivalent 1.3(0.5-3.9) 0.68 1.4(0.6-3.3) 0.42 NVQ or equivalent 0.7(0.4-1.3) 0.35 1.5(0.9-2.4) 0.22 
College or University 
Degree 0.4(0.1-1.5) 0.32 0.6(0.2-1.4) 0.31 
College or University 
degree 0.6(0.4-0.9) 0.02(*) 1.2(0.9-1.6) 0.24 
     
Other professional 
qualifications e.g. : nursing, 
teaching 0.9(0.4-1.8) 0.73 1.0(0.6-1.6) 0.93 
Household relationship 
status: Couple Ref    
Household relationship 
status: Couple Ref    
Household relationship 
status :Single 3.2(1.5-7.0) 0.001(**) 2.1(1.3-3.7) 0.004(*) 
Household relationship 
















6.6.2 UK Biobank 
 
There were 772 (2.2%) individuals self-reporting self-harm requiring hospital or 
psychiatrist review in UKB (Table 6.2). Self-harm cases were slightly younger (UKB’s 
minimum age is 40), predominantly female (70.5% versus 54.0%, p<0.001, h=0.34), 
and with higher mean neuroticism (mean 5.6 versus 3.3, p <0.001,d=0.83) and higher 
prevalence of history of depression (90.5% versus 33.3%, p<0.001
-18
, h=1.3). 
Cognitive ability scores were not significantly different for any of the tests.  
 
Self-harm cases were more likely to be from deprived areas (more positive scores) 
as measured by the Townsend index (mean -0.5 versus -1.7, p <0.001,d=0.44). 
Educational attainment was not significantly different between the two groups 
(c=7.43, p-value 0.28). The proportion of the self-harm group living as single was 
39.6% versus 22.5% for those reporting no history of self-harm.  
 
The most predictive factor in the multivariable logistic model was self-reported history 
of depression (Table 6.3, OR 12.7 95% Confidence Interval (CI) 9.9-16.4, pFDR 
<0.001). The odds of self-harm were significantly positively associated with 
increasing neuroticism scores, OR 1.1 95%CI 1.1-1.2, pFDR <0.001 per EPQ-SF unit.  
No significant interactions were found during model fitting.  The significant effects of 
neuroticism were found in both the male-only and female-only models (Table 6.4).  
 
Being female was also associated with somewhat higher risk (OR 1.3 95% CI 1.1-
1.5, pFDR 0.005), as was being in the 35-44 and 45-54 age groups, whereas the 65-
74 age group was protective. No educational factors were significant in the 
multivariable analysis. Being single and higher Townsend scores (more deprived) 
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were associated with higher odds of self-harm. Cognitive ability (g) was not significant 
(pFDR = 0.051, OR 1.1, 95%CI 1.0-1.2). 
 
In Table 6.3, comparison is also made to UKB participants who self-reported any self-
harm, irrespective of whether hospital attention was sought (1578 cases, 4.4%). In 
this group self-harm was also positively associated with neuroticism scores (OR 1.1, 
95%CI 1.1-1.2, pFDR <0.001 per EPQ-SF unit). Positive association was also found 
for history of depression, being female, younger age group, increasing Townsend 
deprivation score and being single. However, in this group increasing cognitive 
function score increased odds of self-harm (OR 1.1, 95%CI 1.0-1.1, pFDR 0.004 per 
unit g).  
 
 
6.6.3 GS:SFHS Suicidal Ideation Re-Contact Study 
 
In the GS:SFHS re-contact study (N=3342) there were 158 individuals with self-
reported suicidal ideation (4.7%) (Table 5.3). Of these 21 (13.3%) had a record-
linkage based history of self-harm compared to 1.9% in the control group. History of 
self-harm was the most predictive factor for suicidal ideation in the multivariable 
model (OR 3.5, 95%CI 1.9-6.2, pFDR<0.001) followed by history of depression (OR 
3.2, 2.3-4.7, pFDR<0.001). Scores in the List of Threatening Experiences increased 






Table 6.5: Multivariable analysis of predictors of history of suicidal ideation in 
GS:SFHS Re-Contact Study (N=3342) 
 










OR(95%CI, pFDR value) 
Multivariable model 
including coping styles 
OR(95%CI, pFDR value) 










































deprivation (SIMD)  















List of Threatening 









oriented coping *  
2.9(2.4-3.5)  




CISS Task oriented  
coping * 
0.6(0.5-0.7)  










* = Continuous variables have been scaled to have a mean of zero and standard deviation of one.  
95% confidence intervals are shown in brackets for odds ratios. Abbreviations: OR = Odds Ratio. 95%CI = 95% Confidence 
Interval. EPQ = Eysenck Personality Questionnaire-revised Short Form. SIMD = Scottish Index of Multiple Deprivation.  
CISS = Coping Inventory for Stressful Situations CIDI = Composite International Diagnostic Interview 
 
Neuroticism was positively associated with suicidal ideation in the multivariable model 
(OR 1.6, 1.3-1.8, pFDR<0.001 per standard deviation unit). However, this association 
attenuated to non-significant OR 1.1 (0.9-1.4, p=0.44) when coping styles were added 
to the model (Table 6.5). In the full multivariable model including coping styles, EoC 
was positively associated with suicidal ideation (OR 2.4, 1.9-3.0, pFDR<0.001) and 
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ToC was negatively associated (OR 0.8, 0.8-0.9, pFDR=0.03), while AoC was not 
significantly associated.    The correlation matrix revealed that EoC and neuroticism 
were significantly correlated, r=0.50 p <0.001
 
and task-oriented coping were 
moderately negatively correlated (r=-0.18 p <0.001, Table 6.6). In moderation 
analysis no significant (p £ 0.05) interaction terms were found for neuroticism*ToC, 
neuroticism*AoC or neuroticism*EoC on suicidal ideation, controlled for age, sex and 
depression status.  
 
 
Table 6.6 : Correlation Matrix of Variables in Re-Contact Study  
 
Correlation Matrix      
 
 Neuroticism AoC EoC ToC BLEQ Total 
Neuroticism       
AoC 0.13      
EoC 0.50 0.02     
ToC -0.18 0.20 -0.18    
LTE Total 0.12 0.03 0.08 -0.02   
Abbreviations :  AoC = Avoidance Oriented Coping.   EoC = Emotion Oriented Coping.  ToC = Task Oriented Coping. 









Table 6.7: Multivariable analysis of predictors of history of suicidal ideation in 
GS Re-Contact Study (N=3342)  
 
History of suicidal 





(%/s.d.) p value (Effect size) 
    
Female gender   n (%) 84(53.2) 1913(60.1) 0.08 
Age      mean(s.d.) 53.6(12.7) 56.2(12.1) 0.02 (0.21) 
 
History of depression(CIDI)     n (%) 76(48.1) 529(16.6) <0.001  (0.69) 
 
EPQ Neuroticism score     mean(s.d.) 5.7(3.4) 3.3(3.0) <0.001 (0.80) 
 
Cognitive ability(g)     mean(s.d.) 0.13(1.3) 0.42(1.2) 0.005 (0.25) 
 
Socioeconomic deprivation (SIMD) rank       
mean(s.d.) 3664(1975) 42198(1743) 0.0007 (0.32) 
History of self-harm     n (%) 21 (13.3) 59 (1.9) <0.001  (0.47) 
 
List of Threatening Experiences total     
mean(s.d.) 1.6(1.6) 0.9(1.3) <0.001  (0.55) 
 
CISS Emotion oriented coping   mean(s.d.) 49.5(12.3) 36.6(11.9) <0.001 (1.0) 
 
CISS Task oriented coping   mean(s.d.) 48.5(12.9) 55.5(11.4) <0.001 (0.61) 
 
CISS Avoidance oriented coping   mean(s.d.) 38.6(9.2) 39.4(10.3) 0.28 
Effect sizes are shown using Cohen’s d (quantitative) and Cohen’s h (categorical). Abbreviations : OR = Odds Ratio. 95%CI = 95% 
Confidence Interval. EPQ = Eysenck Personality Questionnaire-revised Short Form. SIMD = Scottish Index of Multiple 





Here we report a significant independent association between neuroticism and history 
of self-harm requiring medical attention in two large population-based cohorts, using 
both self-reported and record-linkage derived measures of self-harm. This finding 
remained significant when controlling for history of depression, socioeconomic 
deprivation, educational attainment and relationship status.  
 
In both UKB and GS:SFHS we found that history of depression was the predictor with 
largest effect size on hospital-treated self-harm risk. In our multivariable models, 
predicted self-harm risk (Figure 6.2) was relatively low in UKB in non-depressed 
individuals even at higher neuroticism scores, whereas in GS:SFHS more neurotic 
non-depressed cases also had significant overall risk. This disparity may be explained 
by the use of self-reported depression in UKB, with broader inclusion criteria than 
GS:SFHS (which employed the objectively assessed SCID). Thus 90.5% of self-harm 
cases reported history of depression in UKB, versus 47.5% in GS:SFHS (Table 6.2).  
 
We found a significant protective relationship for higher cognitive scores against self-
harm in GS:SFHS, but not in UKB. Previous studies have found that cognitive 
impairment is associated with suicide and self-harm (Sorberg et al., 2013; Jiang et 
al., 1999; Batty et al., 2010; Gunnell et al., 2005; Alati et al., 2009) . However, other 
studies have found increased cognitive scores may increase self-harm risk (Apter et 
al., 1993; Chang et al., 2014). One explanation for the discrepancy in our results is 
that different measures of cognitive ability were used in the two cohorts (Table 6.2). 
Moreover, previous research on depression and cognitive ability in GS:SFHS and 
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UKB (Navrady et al., 2017b) has been similarly inconclusive, with an association 
between g and depression being identified in GS:SFHS but not UKB.  
 
For education attainment, we found fewer graduates and more individuals without 
qualifications in self-harm cases in GS:SFHS, but this difference was not significant 
in UKB. This might be accounted for in population sampling differences between 
GS:SFHS and UKB, with the latter having more graduates among controls also (Table 
6.2).  
 
We found socioeconomic deprivation was significantly associated with self-harm 
history in both cohorts, as was living as a singleton. Female gender was not predictive 
of self-harm in GS:SFHS but was significantly associated in UKB, albeit with modest 
effect size (Table 6.3). Previous multi-centre studies have shown female rates of self-
harm to be significantly higher than male (Schmidtke et al., 1996). However, our 
GS:SFHS analysis was for hospital inpatient admitted self-harm and it may be that in 
this subgroup female gender is less predictive of risk, given that hospital-treated self-
harm arguably lies on a spectrum between non-serious self-harm and suicide, the 
latter of which is four times more common in males (Maris, 2002). 
 
In our follow-up analysis of suicidal ideation, we found an independent association 
between neuroticism and self-reported suicidal ideation, which remained significant 
when controlled for history of depression, socioeconomic deprivation and significant 
life events. When coping styles were added to the model, the association with suicidal 
ideation was no longer significant, implying that neuroticism’s effect is not 
independent of coping style. We showed that emotion-orientated coping is highly 
positively correlated with neuroticism (r=0.50) and task-orientated coping negatively 
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correlated (r=-0.18). In addition, we found that emotion-oriented coping was positively 
associated with suicidal ideation whereas task-oriented coping was negatively 
associated.  This relationship was also found in a study of suicidal ideation in middle-
aged workers in Japan, albeit without employing a validated coping style instrument 
(Sugawara et al., 2012). A further study found emotion-focused coping, but not 
problem-focused coping, was associated with suicidal ideation in adolescents 
(Horwitz et al., 2011). “Active” (task-oriented) coping and positive reinterpretation 
were also associated with lower suicidality, adjusted for depression, in a study of 500 
college students (Chou, 2017).  
 
6.7.1 Study Strengths and Limitations 
 
This study had a number of strengths for establishing the association of neuroticism 
to hospital-treated self-harm. We have employed two large, population-based cohorts 
which both have phenotypic information for major covariates of self-harm, allowing 
comparison between the groups while both using the same EPQ-SF measure of 
neuroticism. By utilising self-report in one cohort, and health-data record-linkage in 
the other, our study design obviates some of the biases which can arise from utilising 
either method alone. GS:SFHS encompasses the range of adult age groups, and 
UKB focuses on middle-age to older adults, thus our findings are a significant 
contribution to self-harm research where many of the available studies are for 
teenagers or young adults. By extending our analysis to suicidal ideation, we were 
also able to demonstrate an association with neuroticism and correlated coping styles 
(emotion- and task-oriented coping), the latter of which are potentially modifiable by 
clinical intervention.  
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There are also some important limitations to our work. The cohorts we use are 
population-based but are not fully representative, as UKB includes adults of ages 40-
69 and GS:SFHS has an older mean age that the Scottish population. Additionally, 
the use of GP registration as an inclusion criteria for our GS:SFHS study (by enabling 
record-linkage via CHI number) leads to potential selection bias in our identification 
of self-harming individuals, although in the UK 96% of individuals are registered with 
a GP (Smith et al., 2013a) indicating that such biases are likely to be small. The 
prevalence of self-harm we record should thus be used with caution and should not 
be taken as a reliable population estimate. Nevertheless, it is sobering that 
prevalence of hospital-treated self-harm was relatively high (2.1% for GS:SFHS and 
2.2% for UKB). Since self-harm is more common in younger people, the true 
population prevalence is likely to be greater still. We have also adopted a cross-
sectional design and thus causality between factors such as neuroticism and self-
harm; and neuroticism, coping style and suicidal ideation; is suggested rather than 
conclusively demonstrated by our models.  
 
The type of self-harm we have studied is self-harm involving hospital care. We used 
a general definition of self-harm as the data available to us did not allow distinction 
between non-suicidal self-injury and suicide attempts, as this information is not 
available in the routinely collected administrative hospital data linked to in GS:SFHS 
(and was not part of the self-report question in UKB). This could limit the transferability 
of our results to other studies, although as discussed, the extent to which such 
distinctions of suicidal intent can be accurately made in practice is controversial.   
 
In GS:SFHS we defined self-harm cases via  admission to medical or psychiatric 
hospital, as ascertained by record-linkage. We therefore have not included a number 
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of self-harm cases that were managed in the Emergency Department, where 
available data is incomplete (Marrs, 2016). This represents approximately 50% of 
self-harm cases presenting to hospital, although there are wide variations between 
hospitals (Cooper et al., 2013). A recent study has found that routine hospital data 
underestimates rates of self-harm by approximately 60% compared to combined 
survey-hospital database methods (Clements et al., 2016), as – for example – self-
harm which is assessed in the Emergency Department, but which does not lead to 
hospital admission, may not be included.  
 
However, hospital-admission self-harm is itself an important variable, as cases that 
are admitted are likely to be more serious and can therefore be expected to be of 
greater risk of further self-harm and completed suicide (Gibb et al., 2005). The UKB 
self-report variable was for self-harm requiring any hospital or psychiatric 
management (including Emergency Department) and therefore, while highly 
correlated with the GS:SFHS variable, was more general in its scope. The overall 
prevalence of self-harm in GS:SFHS and UKB was similar (2.1% and 2.2% 
respectively). This might seem surprising as one might expect the more general self-
harm definition in UKB to return a higher prevalence. This could be explained by the 
fact that the UKB cohort had no individuals younger than 40 and this has decreased 
the overall self-harm prevalence, since younger age groups are at relatively higher 
risk.  
 
We employed a complete-case design in our multivariable analyses in GS:SFHS and 
UKB. Potentially, this could have biased our results compared to the whole samples, 
although comparison (Table 6.1) indicated that there were no significant and large-
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effect differences in major variables studied through the complete-case approach. 
Nevertheless, this method could have introduced biases in ways we did not measure.  
 
In summary, our findings must be seen in the context of self-harm with a high 
propensity to cause physical harm warranting medical attention. However, the UKB 
cohort did include a variable for any self-harm regardless of hospital attendance and 
we also included this multivariable analysis (Table 6.3). Neuroticism was found to be 
associated in this group also, with similar effect size (OR 1.1, 95CI 1.1-1.2, p        
=3.4x10
-41
 per EPQ-SF unit).  
 
With regard to our analysis of suicidal ideation and coping-style, neuroticism as a trait 
was measured during GS:SFHS enrolment, which was some years before the 
recontact when coping style and suicidal ideation were measured. However, as 
discussed, neuroticism is considered to be a relatively stable trait and would not be 
expected to change significantly over this time period. We also controlled neuroticism 
by age at enrolment rather than age at recontact within the models.   
 
Our assumption that neuroticism is a stable trait should be weighed against the 
possibility that neuroticism is itself affected by a history of self-harm (i.e. that an 
episode of self-harm increases neuroticism score). This is an area that is relatively 
under-researched. There is some evidence that environmental influences, including 
trauma, are associated with increased neuroticism scores but this has only been 
demonstrated for episodes that occurred in childhood and adolescence(Lahey, 2009). 
Indeed, studies that have investigated the impact of traumatic events in middle 
adulthood on neuroticism have found that it does not reliably change(Ogle et al., 
2014).  As discussed, studies on self-harm have generally concluded that the causal 
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relationship, such as it exists, is between neuroticism as a risk factor and self-harm 
as an outcome. Neuroticism is generally understood as a stable trait although 
neuroticism scores peak in late adolescence and decline moderately through 
adulthood(Lahey, 2009).  
 
Another important consideration is the extent to which neuroticism and emotion-
oriented coping are separate constructs or both emanant from innate responses to 
stress. While we found the correlation of neuroticism and EoC to be significant (0.5), 
it was evidently not complete.  There is also evidence that coping style is amenable 
to clinical treatment in prevention of suicide (Ghahramanlou-Holloway et al., 2012), 






6.7.2 Conclusions and Implications For Practice 
 
We have found that a questionnaire which is relatively quick to administer in a clinical 
setting, the EPQ-SF, is significantly independently predictive of self-harm and suicidal 
ideation when adjusted for multiple other significant factors, including history of 
depression. Neuroticism is therefore an important factor which should be included in 
future studies of self-harm and suicidality risk.  
 
Self-harm is just one of the potential outcomes of high neuroticism. Indeed, there is 
growing evidence that neuroticism is a psychological trait of profound public health 
significance(Lahey, 2009). Neuroticism is associated with mental health outcomes 
including major depressive disorder, anxiety disorders/PTSD and schizophrenia(Gale 
et al., 2016).  It is also associated with physical health outcomes include coronary 
artery disease, eczema, asthma, smoking, irritable bowel syndrome and elevated 
body mass index(Gale et al., 2016; Lahey, 2009). Measurement of neuroticism in 
clinical risk models, particularly given neuroticism’s predictive ability in identifying 
those who will develop disease(Lahey, 2009), arguably has important public health 
potential in preventative medicine, especially for individuals with high neuroticism who 
request intervention.   
 
Our research also implies a potential role for cognitive-behavioural therapies focused 
on decreasing emotion-oriented coping and increasing adaptive task-oriented coping 
in individuals with suicidal ideation. There is current limited research in this area, 
although previous studies are encouraging (Eggert et al., 1995; Eggert et al., 2002). 
The coping styles questionnaires are also relatively straightforward to administer 
clinically and our study suggests that greater attention to reducing emotion-orientated 
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coping, and reinforcing task-oriented coping strategies, in individuals presenting with 
suicidal ideation is likely to have a beneficial effect in protecting against self-harm.  
 
We also demonstrate the utility of record-linkage to health data for examining 
research variables such as self-harm, where there may be an unwillingness to self-
report caseness but a willingness to provide consent for anonymised data linkage. 
Such record-linked cohort studies provide an important new avenue for future 





6.8  Concluding Remarks 
 
In this chapter I have shown that neuroticism is independently predictive of hospital-
associated self-harm even when controlling for MDD status. Adding to the information 
in Chapter 5, the research presented here provides further evidence that neuroticism 
is a significant predictor variable in studies of MDD-associated outcomes.  
 
As argued in Chapter 1, future studies of self-harm that combine self-report with other 
sources of data, including linkage to administrative health data, will demonstrate 
improved ability to correctly identify cases and enable large-scale studies which can 
also incorporate genetic, epigenetic and imaging data contained within applicable 
cohort studies.  
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The ability to link GS:SFHS to Scottish Morbidity Records and the self-harm data 
within them has enabled one of the largest studies of self-harm and its psychological 
predisposing factors yet undertaken. As I have argued throughout this thesis, such 
work has important public health implications in its own right, but also illuminates the 
potential of linked data to reinvigorate existing psychiatric cohort (and other) studies 







Chapter 7: General Discussion and Conclusions  
 
 
7.1 Main Findings  
 
  
This thesis sets out to quantify psychotropic treatment (especially antidepressant 
exposure) and illness outcome (especially self-harm) in a population- and family-
based cohort featuring a well-defined phenotype of Major Depressive Disorder. 
Record-linkage to administrative health and prescribing data was employed which – 
as discussed within this thesis – enabled some of the difficulties and potential biases 
inherent in classical, self-report based, psychiatric studies of these topics to be 
overcome. 
 
The introductory chapters provided a review of depressive illness, antidepressant 
treatment and the aetiology of self-harm. The evolution of record-linkage as a 
discipline within psychiatric research was also described. The comprehensive 
psychological and sociodemographic data contained within the Generation Scotland 
study (and also UK Biobank) was also detailed.  
 
The overall objectives of this thesis were identified in Chapter 1 and considered 
throughout. These were to address the following questions:  
1. Are users of psychiatric medications less likely to accurately self-report their 
usage in research studies compared to users of other medications?  
2. Has exposure to antidepressant medications significantly increased in recent 
years and, if so, is this due to a change in how antidepressants are used ?  
3. Is the psychological trait of neuroticism an independent risk factor for the 




I will discuss the applicable research findings of this thesis for each objective in turn.  
 
7.1.1 Are users of psychiatric medications less likely to accurately self-
report their usage in research studies compared to users of other 
medications?  
 
In Chapter 4, the self-reported medication use of a relevant subset of participants in 
GS:SFHS was validated against Scottish NHS prescriptions data as a gold standard. 
The hypothesis of this study was that psychiatric medications would be relatively 
under-reported compared to other medications such as antihypertensives, due to 
patient-level factors like self-stigma.  
 
What was found was a more complex and nuanced picture. Antidepressant 
medication self-report was found to demonstrate very good agreement with the 
prescribing data gold standard, indeed comparable to that found for antihypertensives 
and cholesterol-lowering medications.  
 
However, the other psychiatric medication type studied, mood stabilizers, showed 
moderate-poor agreement. While self-stigma could potentially be a factor for mood 
stabilizers, I considered that a potentially greater causal explanation was the use of 
the confusing term ‘mood stabilizer’ (which is misunderstood among healthcare 
professionals as well as the general public), especially given that no representative 
examples had been provided to users.  
 
In summary, my analysis did not support the hypothesis that there was a simple 
relationship between psychiatric medication and under-reporting in cohort studies, 
 221 
but the work justified the use of data-linkage (where possible) to provide greater 
granularity of medication use, particularly for medication classes that may be less 
widely recognised by the general public. I found that a relevant past medical history 
was the strongest predictor for self-report sensitivity, regardless of whether the 
medication was psychiatric or non-psychiatric.  
 
7.1.2 Has exposure to antidepressant medications significantly increased in 
recent years and, if so, is this due to a change in how antidepressants are 
used?  
 
In Chapter 5, the cross-sectional phenotypic data of GS:SFHS was combined with 
seven years-worth of longitudinal national prescribing data to obtain new and robust 
estimates of antidepressant exposure prevalence, incidence, adherence and 
predictors of use. I hypothesised that antidepressant prevalence would have 
increased, given the recent findings in multiple research studies and national 
summaries of prescribing data.  
 
However, the levels of increase I found were striking – a prevalence of almost one 
third of the adults in our sample in the five-year period 2012-16 (over one fifth if 
amitriptyline is excluded), representing an increase in prevalence of more than 36%. 
Nevertheless, my analysis found that antidepressant incidence remained stable and 
that the majority of antidepressant treatment episodes were of long (>9 months) 
duration. This implies that the significant increase in antidepressant exposure is 
mainly explained by longer treatment cycles, wider range of indications, and returns 
to usage by previous users.  
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I was also able to demonstrate that antidepressant adherence (measured using the 
Proportion of Days Covered (PDC) system) remained generally high, which is an 
important finding as psychiatric medication is often associated with poor 
concordance.  
 
The choice of a 90 day maximum gap in prescribing events between respective 
prescribing episodes deserves mention. As discussed in Chapter 5, it is based on 
NHS prescribing practices of a maximum drug dispensation cycle of 3 months. The 
90-day standard employed here has since been adopted by the Scottish Government 
when measuring treatment course from PIS prescribing data(Scottish Government, 
2021). Table 5.3 shows the sensitivity analysis performed with different gap lengths 
between prescribing episodes of between 60 and 360 days. At 60 days MPR was 
100% and PDC 87.4% with a mean treatment episode duration of 526 days. At 120 
days MPR was 98.1% and PDC 82.7% with a mean duration of 777 days.  A 90 day 
treatment episode length, as ultimately selected for this analysis, gave a mean 
treatment duration of 679 days (or approximately two years) and a MPR of 99.1% and 
PDC of 84.9%. It can be seen that, as expected, PDC is the more discriminating 
measure of adherence in this context and it was thus preferred.  
 
Another consideration is the extent to which adherence to medication can be gleaned 
from prescribing data. Adherence can be measured by directly observed therapy or 
measurement of concentrations of a drug or metabolite in blood or urine. These direct 
approaches are, however, expensive, burdensome to the health provider, and 
susceptible to distortion by the patient(Osterberg and Blaschke, 2005). Ascertaining 
the rate of refilling prescriptions is an established indirect method of measuring 
adherence, especially in - as discussed in Chapter 5 - a ‘closed’ pharmacy system 
 223 
such as PIS. However, as discussed in Chapter 5, such measures of adherence as 
can be made from prescribing data are not able to account for primary or secondary 
noncompliance. In the case of psychiatric medications a number of interventions have 
been tried to improve compliance to medication. These include education 
interventions, cognitive-supportive interventions and the periodic use of 
reinforcement techniques such as personalised reminders and healthcare worker 
visits(Osterberg and Blaschke, 2005). However, even these measures cannot sustain 
adherence unless they are repeated at intervals.    
 
7.1.3 Is the psychological trait of neuroticism an independent risk factor for 
the MDD-associated outcomes of antidepressant use and self-harm ? 
 
In Chapter 5, my analysis of the predictors of antidepressant use also demonstrated 
that psychological factors, including higher neuroticism scores (and also lower 
cognitive function scores), were also evidently associated with antidepressant use, 
even when controlled for major depression and other major potential confounders. 
 
In Chapter 6, prior history of hospital-treated self-harm was obtained for participants 
of GS:SFHS using record linkage to the Scottish Morbidity Records. This, combined 
with a replication sample drawn from UK Biobank, enabled the largest study yet 
performed on the relationship between neuroticism and self-harm and an additional 
study of suicidal ideation, neuroticism and coping styles against adversity.  
 
The study hypothesised that neuroticism was independently associated with self-
harm, when controlling for major depression and other significant potential 
confounders. The positive association between neuroticism and self-harm was 
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demonstrated in both the GS:SFHS and UKB cohorts. The study also demonstrated 
that the Emotion-oriented Coping style (EoC), itself correlated with neuroticism, was 
an independent predictor of suicidal ideation risk in multivariable models.  
 
7.2 Implications of Findings  
 
 
This thesis has investigated psychotropic treatment (especially antidepressants) and 
illness outcome (especially self-harm) in a population- and family-based cohort where 
Major Depressive Disorder was well phenotyped. By employing a record-linkage 
based design in investigating antidepressant exposure and hospital-associated self-
harm the work contained here has been able to overcome some of the problems of 
more classically designed psychiatric studies, such as those based on self-report 
alone.  
 
The work contained here also provides further evidence for the transformational 
potential of record-linkage based studies in mental health research. In Chapter 2, I 
have previously identified four major areas where psychiatric data science, based on 
record-linkage, can enhance longitudinal cohort studies.  
 
Firstly, by improved signal and power for discoveries and the reduction of false 
associations. As well as being evidenced in all three research Chapters 4-6, this is 
discussed in Chapter 2 referencing the genetic studies of MDD in GS:SFHS, where 
the case and control arms were validated using record-linked data as part of this 
research project(Howard et al., 2017).  
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Secondly, by validation of research data and the identification of inaccuracies, which 
is specifically addressed in Chapter 4. Thirdly, the transformation of cross-sectional 
studies into longitudinal studies, which is demonstrated in Chapter 5 in the 
longitudinal study of antidepressant exposure.  
 
Finally, the identification of new phenotypes for study, which is particularly 
demonstrated in Chapter 6, where record-linked data allows GS:SFHS to be used to 
study self-harm and suicidal ideation, despite these behaviours not being specifically 
phenotyped during GS:SFHS enrolment.  
 
Taken together, these findings provide new insights into mental illness and major 
depression-related research, but also clearly demonstrate the utility of record-linkage 
to administrative health data for addressing modern mental health research 
questions. Excitingly, the record-linkage studies presented here provide answers to 
research questions that were potentially unforeseen at the time of GS:SFHS 
recruitment or that were too difficult to study at scale using conventional population-
based cohort phenotyping methods.  
 
7.3 Methodological Considerations and Limitations 
 
 
The specific limitations associated with each individual study within this thesis have 
been appropriately addressed within their respective Chapter. Here I shall look at the 





7.3.1 Study design 
 
Subjects included in this work were drawn from the Generation Scotland cohort (and 
UK Biobank in Chapter 6). The first limitation that any study employing a population-
based (and family-based) cohort must consider is the appropriateness and 
representativeness of that population for the research questions addressed. 
GS:SFHS was recruited initially from lists provided by General Practices in Scotland 
and there was potential for selection bias in that the participants were generally 
healthier, wealthier, better educated and potentially more likely to be engaged with 
healthcare services. Also, there was further potential for selection bias given that the 
population being studied was based in Scotland and this could potentially make 
conclusions unrepresentative for the UK as a whole. Ethnic minorities, in particular, 
are relatively less a proportion of population in Scotland compared to the rest of the 
UK (some 98% of the Scottish population and 99% of the Generation Scotland 
population are white)(Smith et al., 2013a). However, on the point of 
representativeness, it can be said that comparison with UKB – a more diversely 
recruited sample across the UK - as the replication sample in Chapter 6 did not 
indicate that a Scotland-related selection bias was in evidence, at least for that study.  
 
Regarding further potential selection biases, it is possible that those agreeing to be 
recruited to GS:SFHS, and/or remaining in the cohort for the follow-up STRADL 
recontact study, had particular health concerns, or were more health conscious, than 
the general population. Furthermore, it is possible that those refusing permission for 
record-linkage were more likely to have significant psychiatric illness or significant 
self-harm history (thereby refusing permission due to factors such as self-stigma). 
The number involved in refusing permission for linkage was small (less than 2% of 
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the Generation Scotland) but still potentially significant. Nevertheless, the 
prevalences of psychiatric illness and self-harm found in this research is comparable 
with other large published studies, as discussed in Chapters 5 and 6.  
 
A further major limitation for studies using administrative health data, as discussed 
throughout this thesis, is that the data was not originally recorded or stored for 
research purposes. This inevitably means that significant variables, that would almost 
certainly have been collected in a research study, are missing. For example, the 
prescribing data had no information on indication of medication use, or any precise 
information about when (or whether) the medication was taken. Furthermore, in the 
determination of history of self-harm, I relied on ICD coding which may have been 
erroneous and did not contain further clinical information I could use to cross-validate 
diagnoses.  
 
Not having access to primary healthcare records was a potentially significant 
omission in the administrative dataset available to this study. Primary care/GP data 
could have provided additional information about diagnoses, indications for treatment, 
self-harm not presenting to hospital, and also medications not listed in PIS (such as 
medications dispensed in hospitals). However, primary care data is – at least at 
present – notoriously unstructured and requires highly sophisticated data mining 
techniques to extract useful research data from, so it is not certain that having access 
to primary care data would have realistically improved the methodologies of the 
included studies.  
 
The studies presented here are, for the research questions undertaken, among the 
largest yet attempted. Nevertheless, greater sample sizes would improve predictive 
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power, particularly for large multivariable analyses, and provide further opportunity 
for replication of the results found.  
 
7.3.2 Statistical analyses 
 
As ever with research studies, it is important to remember that correlation does not 
equal causation. This study has been able to demonstrate that (1) self-report of mood 
stabilisers is significantly less accurate than antidepressants and antihypertensives, 
when validated with prescribing data; and that (2) antidepressant prevalence has 
significantly increased while incidence has remained stable; and that (3) neuroticism 
is significantly associated with self-harm presenting to hospitals and with 
antidepressant use. Our inferences about why this may be the case, presented within 
the research Chapters, while evidence-based, are far more speculative and provide 
motivation for further research studies rather than being themselves conclusive.  
 
It is also important to remember that phenotypes derived by record-linkage studies 
often differ in significant ways from related phenotypes commonly studied in other 
psychiatric research. Thus, within this thesis I have studied individuals exposed to 
antidepressants (or at least dispensed medication), rather than individuals with 
depression taking antidepressants. Similarly, I have analysed individuals presenting 
to hospital with self-harm, rather than all types of self-harm. It is very important, when 
assessing the implications and quality of record-linkage based science, to remember 
that the phenotypes under study often emanate from what is possible to define using 




7.3.3 Methodological Considerations for Future Studies  
 
The studies presented here provide a foundation upon which further research can be 
built. For example, through identifying within GS:SFHS those exposed to 
antidepressants (or other medications) and those with a history of hospital-associated 
self-harm, these newly defined phenotypes can be further studied using the wealth of 
sociodemographic, psychological, genetic, epigenetic and imaging data contained 
within GS:SFHS. A considerable proportion of the variance in the outcomes of 
antidepressant exposure and self-harm remain unexplained by the multivariable 
models employed in this study. As more data becomes available, the incorporation of 
the dataset defined here with further genetic data (such as single nucleotide 
polymorphisms (SNPs), epigenetic methylation patterns, and whole-genome 
sequencing); and with additional clinical data (such as from primary care records); 
and additional sociodemographic data (such as educational and social service data), 
will improve the predictive and explanatory power of the models.  
 
Furthermore, as UK Biobank (and other large biobanks) continue to improve the 
quality of their linkage to prescribing, morbidity and general practice related data, the 
research chapters presented here can be used as a basis for further replication, 
validation, prevalence and association studies of psychiatric medication and self-
harm, taking advantage of even greater statistical power and potentially even more 
diverse multivariable methodologies.  
 
Future studies may also benefit from a more simplified approval process to gain 
access to regular updates of administrative data. In particular, future researchers 
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using Generation Scotland data will benefit from more regular updates of SMR and 





7.4 Future Directions and Strategic Vision  
 
 
Interest in data science and record-linkage continues to grow apace within psychiatric 
research and medical research more generally. Future studies of psychiatric 
pharmaco-epidemiology and self-harm will benefit from ongoing improvements to 
available datasets and methodologies in the near future. A number of potential future 
directions for the research work outlined here can be envisaged.  
 
7.4.1 Antidepressant Exposure Studies  
 
With the increased availability of prescribing data and primary care data within UK 
Biobank over the next few years, it will be possible to replicate the prevalence and 
adherence measures utilised in this study on a larger population. A critical variable to 
be defined (most probably using data mining techniques in primary care data) will be 
the indication of use for medication. It would also be advised for the research 
community to lobby the administrators of prescribing data in Scotland and the UK to 
add this variable to future iterations of prescribing data so that within a few years it 




It is important to remember that an antidepressant user phenotype, derived from 
linked data as described in this thesis, indicates antidepressant exposure, rather than 
antidepressant response. The definition and identification of outcome variables which 
measure antidepressant response (made possible for example through data mining 
of primary healthcare records) will enable more sophisticated studies. Surrogate 
measures have been utilised to date in other published studies, such as inferring 
antidepressant treatment resistance in those individuals who have switched 
medication multiple times(Wigmore et al., 2019).  In future, with more robust linkage-
derived measures of treatment response, it should be possible to develop highly 
powered real-world studies of medication response and resistance, medication 
switching and medication dropout, which have similarities to clinical trials but which 
employ record-linkage to administrative data.  
 
The antidepressant exposure phenotype defined in this thesis offers interesting 
potential avenues for genetic studies aimed at understanding medication response 
and the development of tailored, precision medicine. Given the numerous adverse 
effects that are associated with antidepressant discontinuation, the epigenetic and 
genetic attributes of long-term antidepressant users compared to short-term 
antidepressant users, and controls, is an intriguing research area. It may for example 
be possible to use machine-learning techniques to identify SNPs or epigenetic 
methylation patterns which are associated with antidepressant exposure and/or 
discontinuation. Study of the epigenetic disparities of those exposed to 
antidepressants may offer clues to antidepressant mechanism of action, the 
mechanisms underlying adverse effects and discontinuation, and potentially enabling 
a clinically usable test for medication usage.  
 
 232 
7.4.2 Self-Harm Studies  
 
With regard to the self-harm phenotype derived in this study, it is fairly easy to 
envision how a relatively simple data mining exercise utilising primary care records 
and hospital electronic health records could help improve and validate both the case 
and control groups of the study. With a larger powered study over an even longer 
time course than has been possible here, it should also be possible to identify 
dynamic risk factors associated with self-harm and potentially those that are related 
to completed suicide. Another advantage of more regular uploads of healthcare data, 
particularly if it is possible to measure suicidal ideation and self-harm at multiple 
timepoints, is that it will become possible to further investigate the causal processes 
that may underlie the relationship between self-harming behaviour, neuroticism and 
coping styles using mediation analysis and structural equation modelling.  
 
 
7.4.3 Advances in Psychiatric Data Science 
 
I have commented on the absence of General Practice linked data in GS:SFHS at the 
time of the present study. Efforts are underway to provide such linkage in future, for 
both GS:SFHS and UKB. Despite the highly unstructured nature of much primary care 
data, improved data mining techniques should make such data more tractable in 
future. There is good evidence that diagnostic accuracy derived from codified data in 
electronic health records can be improved by access to unstructured data of this kind 
(Ford et al., 2016; McIntosh et al., 2019). However, one of the potential pitfalls of data 
mining in primary health records is that the clinical information is missing from the 
unstructured data (i.e. it was never inputted in the first place) or that it is inputted in 
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such an inconsistent or idiosyncratic manner among GPs as to be inadequate for 
diagnostic purposes when compiled. Once again, we return to the theme of the 
potential disconnect between what a data source was designed for (in this case, brief 
clinical notes) and what we might be intending to use it for (research-grade objective 
diagnosis and treatment).  
 
In addition to primary care records, it is envisioned that future data linkage exercises 
will be able to add non-health datasets to mental health cohort studies. As discussed 
in Chapter 2, the Secure Anonymised Information Linkage (SAIL) project in Wales is 
already making progress in combining health and other social administrative data. 
Future access to educational, social service, police, judicial and employment data, to 
name some examples, could significantly improve the ability of the multivariable 
models employed in this thesis to more appropriately factor the biopsychosocial basis 
of mental illness. Such work shows great potential for an improved understanding of 
the aetiology of conditions such as major depression and self-harm, as well as 
pharmaco-epidemiology and the study of psychological traits such as neuroticism.  
 
Looking further to the future, it is possible that repositories of personal (and 
increasingly biosensor- and health-related) data collected by commercial companies 
such as Amazon, Google and Apple may be available for linkage to health datasets. 
Tentative steps towards this have been made through collaborations between the 
NHS, university researchers and enterprises such as Google DeepMind, but the 
ethical and governance frameworks that must be in place to make such collaborations 
successful are considerable.  
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Indeed, the use of commercial databases for these purposes raises several ethical 
and risk-related concerns(Mittelstadt and Floridi, 2016), most importantly:  (1) the risk 
that consent to use of data was not sufficiently informed; (2) that data privacy is not 
reliable, such that anonymisation and data protection is incomplete; (3) who has 
ultimate ownership of the data, and is there a right to be forgotten  (4) the so-called 
‘Big Data divide’ between those who can access sophisticated data mining 
technology and commercial databases, and those who cannot;  (5) the monetisation 
of data provided by patients for altruistic reasons. Greater clarification on these issues 
is required before commercial databases can be widely utilised for health related 
research. 
 
One of the constraints of the use of administrative health data commented on in this 
thesis is precisely that it is collated for administrative purposes rather than the 
interests of research. In the future, it is hoped that there will be more collaboration 
between healthcare organisations and the research community so that the 
information obtained during patient contacts is more useful for the needs of both. One 
of the benefits of initiatives like the Clinical Record Interactive Search (CRIS) 
discussed in Chapter 2 is that by its nature it involves the collaboration between NHS 
Hospital Trusts and the university research community. Increasingly, NHS Trusts are 
adding research directors and informatics directors to their management teams and 
it can be envisioned that this will increase the availability of high-quality research data 
from administrative output. Essential to this process will be the continued consultation 




Many of the techniques utilised in this thesis, such as the derivation of antidepressant 
episodes and the measurement of adherence, required custom computer coding and 
testing. Such work is useful, but potentially limits replicability and accessibility of 
results. Over time, it is envisioned that many processes of data mining, machine 
learning, Bayesian analysis and pharmaco-epidemiological measurement can be 
standardised by the widespread adoption of statistical computing packages 
customised for healthcare use. The widespread adoption of particular software 
approaches in genetics (such as GCTA, Plink, LD Hub and polygenic risk scoring) 
and in data science (such as the use of dplyr, ggplot2 and tidyr within the R language) 
demonstrates the utility to the research community of widespread adoption of 
standardised approaches. It is hoped that over time similar systems will be available 
for the record-linkage and pharmaco-epidemiological techniques discussed in this 
thesis.  
 
7.5 Translation to Improve Clinical Insight and Patient Care  
 
This thesis has emphasised the importance of the personality trait of neuroticism, 
which is relatively easy to measure using a simple questionnaire (which can be 
performed online or on a touchscreen) and which is a significant risk factor in 
antidepressant usage and self-harm, as well as a variety of other psychiatric and 
medical morbidities. As clinical care becomes further data driven, including more 
comprehensive EHR systems accessible to patients and clinicians, the quantitative 
measure of a patient’s neuroticism should be seen as a potentially important variable 
to include.  
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As has been discussed above, the identification of an antidepressant user phenotype 
within Generation Scotland allows the development of genetic and epigenetic models 
which may enable clinical tests of antidepressant usage and/or adverse effect 
susceptibility. The research within Chapter 5 also has important implications for 
current clinical practice, including providing evidence supporting the need for more 
regular review of antidepressant usage at the primary care level (where the vast 
majority of prescribing is occurring) and the review of medications which appear to 
be widely also prescribed with antidepressants, including opiate analgesics, 
anxiolytics and pregabalin/gabapentin. This research provides an evidence base for 
future clinical guidelines on medication review.  
 
In order to measure adherence in Chapter 5, this thesis involved the generation of 
computing code that formatted administrative prescribing data into discrete 
prescribing episodes in which adherence could be analysed using the MPR and PDC 
methodologies. As prescribing and dispensing becomes increasingly computerised, 
such a tool more widely applied would be useful to prescribers in both the primary 
and secondary healthcare sectors in providing an indication as to whether medication 
concordance was being achieved (at least prompting timely medication review if 
these simple analytic indicators suggested that it was not).   
 
 
Finally, this thesis provides evidence of the potential for discovery science emanating 
from secure, anonymised data linkage of administrative collected healthcare data. 
Alongside other initiatives discussed here like the CRIS data pipeline, this research 
can be used in the education of both patients and clinicians about the benefits of 
enabling anonymised access to their healthcare data, for the improvement of their 
own clinical care and that of society.   
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7.6 General Conclusions 
 
 
This thesis has demonstrated the potential of record-linkage to administrative data for 
mental health research but also to an extent its current limitations. As with other forms 
of research, the questions which can be addressed are to a large extent determined 
by the data which is available for analysis. The availability of large quantities of well-
structured data in morbidity and prescribing records has enabled transformative 
analyses of antidepressant usage and hospital-associated self-harm, which can be 
relatively well defined with the methods available. However, the potential of record-
linkage for more complex questions such as the aetiology of major depression and 
self-harm, or the basis of antidepressant treatment response and precision medicine, 
remains more elusive.  
 
As discussed in this chapter, future developments in joint working between 
academics and healthcare administrators in database design, wider linkage to 
datasets in primary care and also beyond healthcare, and the adoption of 
standardised new technologies for data mining and analysis, will progress the data 
science revolution in psychiatric research which has begun. We can anticipate with 
confidence the future tangible benefits to sufferers of mental illness which such data-
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